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“Under normal conditions the research scientist is not an innovator but a solver of 
puzzles, and the puzzles upon which he concentrates are just those which he believes 
can be both stated and solved within the existing scientific tradition.” 
Thomas Kuhn 
 
“Vigyázz arra, hogy ne mulaszd el a pillanatot, amely csak a te pillanatod, műved 
kivitelének végzetszerűen kijelölt időszaka. Kényelem, szöszmötölés, gyávaság, 
lustaság néha késleltetik feladatod kivitelét, noha szíved mélyén tudod jól, hogy az 
idő telítve van azzal, amit rajtad keresztül el akar mondani, s egy pillanatot sem 
mulaszthatsz, mert elmondja más helyetted, s nem úgy mondja el, ahogyan te jónak 
és igaznak hiszed. Tudományban, művészetben, irodalomban, közéletben vannak 
ilyen sürgető pillanatok, mikor egy igazság megérett és ki kell mondani. S ha úgy 
érzed, végzetesen éppen téged jelölt ki e feladatra a sors, ne késlekedj, mint a rossz 
színész, aki elmulasztja a jelenet végszavát. 
Nemcsak műved van, az idő is van. S az időn belül meg van a te pillanatod, melyet 
nem szabad elmulasztani.”  
Márai Sándor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated to my mother  
ii 
 
CONTENTS 
 
LIST OF FIGURES ...................................................................................... vi 
LIST OF TABLES .................................................................................... xiii 
ACKNOWLEDGEMENTS ........................................................................... xv 
DECLARATION ...................................................................................... xvii 
SUMMARY ............................................................................................ xviii 
ABBREVIATIONS ..................................................................................... xix 
CHAPTER 1: INTRODUCTION ................................................................. 1 
1.1 Instrumentation ............................................................................. 2 
1.1.1 What is a mass spectrometer? ...................................................................... 2 
1.1.2 Ionisation methods ....................................................................................... 3 
1.1.2.1 Electrospray ionisation (ESI) ............................................................... 4 
1.1.2.2 Matrix assisted-laser desorption ionisation (MALDI) ......................... 6 
1.1.3 Mass analysers ............................................................................................. 7 
1.1.3.1 Quadrupole mass analyser (Q) ............................................................. 8 
1.1.3.2 Time-of-flight mass analyser (TOF) .................................................... 9 
1.1.3.3 Ion traps (IT) ...................................................................................... 11 
1.1.3.4 Fourier transform mass analysers ...................................................... 13 
1.1.4 Detectors in mass spectrometers ................................................................ 14 
1.1.5 Tandem mass spectrometry (MS/MS) ....................................................... 17 
1.1.6 Liquid chromatography .............................................................................. 24 
1.2 Clinical applications of mass spectrometry .............................. 28 
1.2.1 Analysis requirements: sample preparation, instrumentation and costs .... 29 
1.2.2 Current clinical MS applications ................................................................ 30 
1.3 Hemoglobinopathies and their analytical detection ................ 33 
1.3.1 Biological background ............................................................................... 33 
1.3.2 Incidence of hemoglobinopathies .............................................................. 42 
1.3.3 Hemoglobinopathy screening in the clinical lab ........................................ 46 
1.3.4 Mass spectrometry-based identification of hemoglobinopathies and future 
directions of screening ........................................................................................... 50 
1.4 Project aims ................................................................................. 61 
iii 
 
1.5 Research and Conference Papers .............................................. 63 
CHAPTER 2:  METHOD DEVELOPMENT FOR MASS SPECTROMETRY-
BASED DIAGNOSIS OF HEMOGLOBINOPATHIES ........................... 64 
2.1 Introduction ................................................................................. 65 
Aims and objectives ............................................................................................... 66 
2.2 Materials and methods ............................................................... 68 
2.2.1 Sample preparation..................................................................................... 69 
2.2.1.1 Intact globin chain analysis ................................................................ 69 
2.2.1.2 Peptide analysis .................................................................................. 70 
2.2.2 Mass spectrometry and data processing methods ...................................... 71 
Intact globin chain analysis and multistep hemoglobin variant identification ... 71 
MS/MS strategy for MRM method development for clinically significant 
variants and HbA2 quantitation .......................................................................... 77 
MRM 1 method using Waters Acquity TQD system ......................................... 80 
MRM 2 method using Waters Xevo TQ ............................................................ 84 
2.3 Results and Discussion ................................................................ 87 
2.3.1 HbA2 and Glycated hemoglobin level determination analysing intact 
globin chains .......................................................................................................... 87 
Method optimisation on clinical samples ........................................................... 89 
2.3.2 Targeted peptide analysis ........................................................................... 98 
2.3.2.1 Initial method developed for delta chain quantitation on a Waters 
TQD system – MRM method 1 .......................................................................... 98 
2.3.2.2 Optimized Method for Clinical Sample Analysis on a Waters Xevo 
system – MRM method 2 ................................................................................. 101 
2.3.3 Identification of Hemoglobin variants ..................................................... 110 
2.3.3.1 Case study A: Identification of the +44 Da alpha chain variant – Hb J-
Nyanza.............................................................................................................. 110 
2.3.3.1 Case study B: Identification of the +14 Da alpha chain variant – HbG 
Philadelphia ...................................................................................................... 113 
2.4 Conclusion.................................................................................. 117 
CHAPTER 3: APPLICATION OF MASS SPECTROMETRY-BASED 
APPROACHES IN A CLINICAL TRIAL .......................................... 119 
3.1 Introduction ............................................................................... 120 
Aims and Objectives ............................................................................................ 133 
3.2 Materials and methods ............................................................. 135 
3.2.1  Materials for analyses performed on the XEVO mass spectrometer ....... 135 
Sample preparation............................................................................................... 136 
iv 
 
3.2.2 Materials for experiments performed on the amaZon speed ETD mass 
spectrometer ......................................................................................................... 137 
Sample preparation........................................................................................... 138 
3.2.3  Intact globin chain analysis combined with full scan tryptic digest mixture 
analysis ................................................................................................................. 138 
3.2.4 LC-MRM-based mass spectrometry analysis .......................................... 138 
3.2.5 Top down ETD Method ........................................................................... 139 
3.2.6 Statistical analysis .................................................................................... 142 
3.3 Results and discussion .............................................................. 144 
Part I: Results obtained on the full sample set using the XEVO TQ 
mass spectrometer ..................................................................... 144 
3.3.1 Determination of HbA2 levels .................................................................. 144 
3.3.1.1 Intact globin chain analysis .............................................................. 144 
3.3.1.2 LC-MRM analysis ............................................................................ 151 
3.3.2 Clinically significant variant detection .................................................... 158 
3.3.2.1 Intact globin chain analysis .............................................................. 158 
3.3.2.2 LC-MRM analysis and full scan peptide mixture analysis .............. 169 
3.3.3 Identification of rare variants ................................................................... 178 
3.3.4 Determination of Glycated Hemoglobin levels........................................ 189 
3.3.5 Detection of elevated HbF levels ............................................................. 192 
3.3.6 Summary of the results from Part I .......................................................... 195 
Part II: Results of the pilot study of the top down MS method, on 
the partial sample set of the clinical trial using the amaZon 
speed ETD mass spectrometer ................................................. 200 
3.3.7  Preliminary experiments ......................................................................... 200 
3.3.7.1 Sequence coverage studies for normal samples ............................... 200 
3.3.7.2 HbA2 and HbA1c quantitation .......................................................... 202 
3.3.7.3 Mass accuracy of intact measurement.............................................. 204 
3.3.7.4 Clinically significant variants .......................................................... 205 
3.3.8 Analysis of clinical samples ..................................................................... 213 
3.3.8.1 Screening for clinically significant variants. .................................... 213 
3.3.8.2 Analysis of rare hemoglobin variants .............................................. 216 
3.4 Conclusion.................................................................................. 222 
3.4.1 Clinical trial with previously developed methods .................................... 222 
v 
 
3.4.2  Pilot study using the top-down ETD method .......................................... 224 
CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS ..................... 227 
4.1 Evaluation of the combination of two MS-based approaches using a triple 
quadrupole mass spectrometer ............................................................................. 229 
4.2 Evaluation of top-down ETD-based MS approach on an iontrap system 231 
Concluding remarks ............................................................................................. 232 
REFERENCES ......................................................................................... 233 
APPENDICES .......................................................................................... 251 
Appendix 1 ........................................................................................... 252 
Figures for Batch B .............................................................................................. 252 
Figures for Batch C .............................................................................................. 255 
Figures for Batch D .............................................................................................. 258 
Figures for Batch E .............................................................................................. 261 
Figures for Batch F .............................................................................................. 264 
Figures for Batch G .............................................................................................. 267 
Figures for Batch H .............................................................................................. 270 
Figures for Batch I ............................................................................................... 273 
Figures for Batch J ............................................................................................... 276 
Figures for Batch K .............................................................................................. 279 
Figures for Batch L .............................................................................................. 282 
Figures for Batch M ............................................................................................. 285 
Appendix 2 ........................................................................................... 288 
Appendix 3 ........................................................................................... 292 
Appendix 4 ........................................................................................... 294 
   
vi 
 
LIST OF FIGURES  
Figure 1.1. Schematic representation of a mass spectrometer .................................... 3 
Figure 1.2. Electrospray ionisation mechanism presented by both theories ............... 5 
Figure 1.3. Schematic representation of a quadrupole mass analyser. ........................ 9 
Figure 1.4. Schematic of time-of-flight (TOF) ......................................................... 11 
Figure 1.5. Schematic of quadrupole ion trap ........................................................... 12 
Figure 1.6. Schematic of a single continuous dynode. .............................................. 15 
Figure 1.7. Schematic representation of a microchannel plate and the electron 
multiplication within one of the channels. ................................................................. 16 
Figure 1.8. Principle of MS/MS experiment ............................................................. 17 
Figure 1.9. Scanning and detection modes in tandem mass spectrometry on a QqQ 
instrument ................................................................................................................... 19 
Figure 1.10. Peptide fragmentation nomenclature .................................................... 22 
Figure 1.11. Schematic of a HPLC system ............................................................... 24 
Figure 1.12. Schematic of reversed phase liquid chromatography under gradient 
conditions ................................................................................................................... 27 
Figure 1.13. Diagrammatic representation of average percentages of the different 
types of hemoglobin chains synthesized during the different developmental periods 
and infancy. ................................................................................................................ 34 
Figure 1.14. Structure of hemoglobin ....................................................................... 35 
Figure 1.15. The α- and β-globin gene clusters and the corresponding hemoglobins 
produced. .................................................................................................................... 35 
Figure 1.16. The carrier rate chart for significant Hb variants per 1,000 babies for 
years 2010/2011 ......................................................................................................... 46 
Figure 1.17. Chromatogram from TOSOH HLC-723 HbG7 analyser (Tosoh 
Bioscience Ltd., Redditch, UK) from normal adult. .................................................. 49 
Figure 1.18. Schematic of the MRM transitions used for detection of sickle cell 
mutation. .................................................................................................................... 58 
Figure 2.1. Schematic of the direct infusion method for glycated hemoglobin level 
quantitation ................................................................................................................. 74 
vii 
 
Figure 2.2. Schematic of the direct infusion method for delta chain quantitation .... 75 
Figure 2.3. Illustration of the direct infusion method for the intact globin chain 
analysis and hemoglobin variant identification.......................................................... 76 
Figure 2.4. Differences in amino acid sequences between beta and delta globin 
chains.......................................................................................................................... 78 
Figure 2.5. Chromatogram of the MRM channels, integrated for T3 (a) and T5 
peptides (b) ................................................................................................................. 82 
Figure 2.6. Scheme of the MRM 1 approach for specific peptide pair relative 
quantification to obtain estimation of the HbA2 levels .............................................. 83 
Figure 2.7. Deconvoluted mass spectrum of intact globin chain analysis of 
international reference reagent for HbA2 level determination ................................... 87 
Figure 2.8. Deconvoluted mass spectrum of intact globin chain analysis of reference 
standard with known level of HbA1c .......................................................................... 88 
Figure 2.9. Results of 15 samples analysed with (blue dots) and without (red dots) 
desalting prior to analysis (a) and showing the correlation calculations by plotting the 
results of different sample preparation methods against each other (b)..................... 90 
Figure 2.10. Results of 10 samples analysed investigating the effects of centrifuging 
prior to analysis plotted against HPLC determined HbA2 values (a) and showing the 
correlation calculations by plotting the results against each other (b) ....................... 91 
Figure 2.11. Results of 92 samples - intact globin chain analysis determined HbA2 
values plotted against HPLC values ........................................................................... 91 
Figure 2.12. (a) Mass errors of different globin-chains resulted from the analysis of 
96 samples in three replicates, and (b) corrected mass errors of beta globin-chain... 93 
Figure 2.13. Mass error distribution of the globin chains separately and adjusted 
beta-chain errors. ........................................................................................................ 95 
Figure 2.14. Calculated glycation levels for separate globin chains and based on the 
average glycation originated from both chains (average of 3 replicates) .................. 96 
Figure 2.15. Correlation analysis between calculated glycation levels of the different 
globin chains .............................................................................................................. 97 
Figure 2.16. HbA2 calculated levels based on T3 peptide ratios - average from 3 
replicates .................................................................................................................... 99 
Figure 2.17. HbA2 calculated levels based on T5 peptide ratios - average from 3 
replicates .................................................................................................................... 99 
viii 
 
Figure 2.18. Calculated percentages for the 60 clinical samples based on T3 (a) and 
T5 (b) peptide ratios ................................................................................................. 100 
Figure 2.19. Calculated percentages based on T2, T3 and T5 peptide ratios shown 
against the theoretically expected HbA2 level ......................................................... 102 
Figure 2.20. Calculated δ-chain % (HbA2 levels) for 20 clinical samples as results of 
a preliminary testing calculated based on three different peptide ratios .................. 103 
Figure 2.21. Calculated percentages of δ-chain based on T3 (a) and T5 (b) peptide 
ratios for 96 samples ................................................................................................ 104 
Figure 2.22. Calculated percentages of δ-chain based on T2 peptide ratios for 96 
samples ..................................................................................................................... 104 
Figure 2.23. Intact globin-chain analysis (a) and MRM tryptic digest analysis (b) of 
a patient sample with heterozygote HbS .................................................................. 106 
Figure 2.24. Intact globin-chain analysis (a) and MRM tryptic digest analysis (b) of 
a patient sample with HbC or HbE .......................................................................... 107 
Figure 2.25. High resolution tryptic digest mass spectra of patient sample with HbD-
Punjab and a control tryptic digest ........................................................................... 108 
Figure 2.26. Intact globin-chain analysis (a) and MRM tryptic digest analysis (b) of 
a patient sample with HbG-Philadelphia.................................................................. 109 
Figure 2.27. Mass spectrum of the intact blood sample showing +44 Da variant. . 111 
Figure 2.28. Deconvoluted mass spectrum of sample with +44 Da α-chain variant
 .................................................................................................................................. 111 
Figure 2.29. Spectra of the tryptic digested +44 Da variant sample and a control 
blood sample ............................................................................................................ 112 
Figure 2.30. Product ion spectra of variant and control peptides ............................ 113 
Figure 2.31. Intact mass spectrum of sample with +14 Da α-chain variant ............ 114 
Figure 2.32. a) MS analysis of tryptic digest mixture of sample with variant and 
control sample b) MS analysis of α-chymotryptic digest mixtures of variant and 
control sample .......................................................................................................... 115 
Figure 2.33. αT9 peptide and the theoretical new peptides resulted by the amino acid 
substitution of Asn→Lys ......................................................................................... 115 
Figure 3.1. Schematic of acquisition for hemoglobin variant diagnosis using the 
Bruker amaZon speed ETD mass spectrometer ....................................................... 140 
ix 
 
Figure 3.2. Histogram for the distribution of coefficient of variation of the HbA2 
quantitation by the intact globin chain analysis ....................................................... 144 
Figure 3.3. Calculated HbA2 values determined by intact globin chain analysis 
plotted against values provided by the ce-HPLC method for the samples in Batch M
 .................................................................................................................................. 145 
Figure 3.4. Distribution of measured values for the HbA2 quantitation by the HPLC 
method and by the intact globin chain analysis. ...................................................... 146 
Figure 3.5. Difference plot for the comparison of values from HPLC and intact MS 
methods using the values from batch M .................................................................. 147 
Figure 3.6. Passing-Bablok regression analysis for the intact MS results for batch M
 .................................................................................................................................. 148 
Figure 3.7. Distribution of the determined HbA2 values by the hospital laboratory 
using the ce-HPLC method (a) and by the intact globin chain analysis (b) ............. 150 
Figure 3.8. Calculated HbA2 values determined by the MRM plotted against the 
values provided by the ce-HPLC method for the samples analysed in Batch M. For 
T2 peptide ratios (a), for T3 peptide ratios (b) and for T5 peptide ratios (c) ........... 151 
Figure 3.9. Distribution of measured values for the HbA2 quantitation by the MRM 
method for different the peptide ratios monitored ................................................... 153 
Figure 3.10. Histogram for the distribution of coefficient of variation of the HbA2 
quantitation by the MRM method a) T2 peptides, b) T3 peptide and c) T5 peptides
 .................................................................................................................................. 154 
Figure 3.11. Distribution of the determined HbA2 values by the MRM method 
calculating T5 peptide ratios .................................................................................... 156 
Figure 3.12. HbA2 values for the reference standard measured by the intact globin 
chain analysis and by the MRM method based on the T5 peptide ratios ................. 157 
Figure 3.13. Calculated βSICKLE-chain levels for the samples classed as heterozygous 
sickle carriers by the hospital laboratory ................................................................. 159 
Figure 3.14. Calculated βSICKLE-chain levels for the samples classed as compound 
heterozygotes for HbS and HbC (green) or homozygous sickle patients (blue), or 
transfused homozygous patients (purple)................................................................. 160 
Figure 3.15. Calculated δ-chain levels using the results of the intact-globin chain 
analysis for the samples classed as homozygous or heterozygous sickle carriers by 
the hospital laboratory .............................................................................................. 161 
x 
 
Figure 3.16. Calculated mass errors for the β-chain after corrected by the mass error 
of the α-chain for Batch E (a), Batch H (b) and Batch J (c) ..................................... 164 
Figure 3.17. Boxplots of error measurement of the β-chain corrected by the α-chain 
mass error. ................................................................................................................ 168 
Figure 3.18. Calculated βSICKLE-chain levels based on the results from the MRM 
method for the samples classed as heterozygous sickle carriers by the hospital 
laboratory ................................................................................................................. 169 
Figure 3.19. Calculated βSICKLE-chain levels based on results from the MRM method 
for the samples classed as compound heterozygotes for HbS and HbC (recalculated 
to HbC peptide in green) or homozygous sickle patients (blue), or transfused 
homozygous patients (purple) .................................................................................. 170 
Figure 3.20. Calculated levels of HbS determined by both MS methods for all 
samples diagnosed with some type of sickle disorder and HbC .............................. 172 
Figure 3.21. Sequence homology between β-chain (MW 15867.24) δ-chain (MW 
15924.32) and Lepore Boston Washington- (LBW, MW 15865.23), Lepore 
Baltimore- (LB, MW 15822.20) and Lepore Hollandia- (LH, MW 15836.23) fusion 
chains........................................................................................................................ 177 
Figure 3.22. Deconvoluted mass spectrum of sample E61 from the intact globin 
chain analysis (a) and mass spectrum of tryptic digest peptide mixture compared to 
control (b) ................................................................................................................. 179 
Figure 3.23. Schematic of T1 tryptic peptide of the β-chain and possible amino acid 
substitution resulting in -10 Da mass shift. .............................................................. 179 
Figure 3.24. Deconvoluted mass spectrum of sample E187 from the intact globin 
chain analysis (a) and mass spectrum of tryptic digest peptide mixture compared to 
control (b) ................................................................................................................. 180 
Figure 3.25. Schematic of (T2-T3) tryptic peptide of the β-chain and possible amino 
acid substitutions resulting in +58 Da mass shift. .................................................... 181 
Figure 3.26. Deconvoluted mass spectrum of sample F127 from the intact globin 
chain analysis (a) and tryptic digest peptide mixture compared to control (b) ........ 182 
Figure 3.27. Schematic of (T9-T10) tryptic peptide of the α-chain and possible 
amino acid substitutions resulting in -14 Da mass shift. .......................................... 182 
Figure 3.28. Deconvoluted mass spectrum of sample H47 from the intact globin 
chain analysis (a) and tryptic digest peptide mixture compared to control (b) ........ 184 
Figure 3.29. Schematic of T2 tryptic peptide of the β-chain and possible amino acid 
substitutions resulting in +28 Da mass shift. ........................................................... 184 
xi 
 
Figure 3.30. Deconvoluted mass spectrum of sample H141 from the intact globin 
chain analysis (a) and tryptic digest peptide mixture compared to control (b) ........ 185 
Figure 3.31. Schematic of T4 tryptic peptide of the β-chain and possible amino acid 
substitutions resulting in -28 Da mass shift. ............................................................ 186 
Figure 3.32. Deconvoluted mass spectrum of sample M75 from the intact globin 
chain analysis (a) and tryptic digest peptide mixture compared to control (b) ........ 187 
Figure 3.33. Schematic of T12 tryptic peptide of the β-chain and possible amino 
acid substitutions resulting in +18 Da mass shift. .................................................... 187 
Figure 3.34. Deconvoluted mass spectrum of sample M136 from the intact globin 
chain analysis (a) and tryptic digest peptide mixture compared to control (b) ........ 188 
Figure 3.35. Schematic of T2 tryptic peptide of the β-chain and possible amino acid 
substitutions resulting in +14 Da mass shift. ........................................................... 189 
Figure 3.36. Histogram of calculated cv% values for the measurement of beta-chain 
glycation levels......................................................................................................... 191 
Figure 3.37. Distribution of measured beta glycated values for the different sample 
batches analysed. ...................................................................................................... 192 
Figure 3.38. Calculated HbF% levels based on intact globin chain analysis plotted 
against ce-HPLC values ........................................................................................... 193 
Figure 3.39. Histogram of the calculated coefficient of variation values for the 
quantitation of the different fetal chains, for (a) γ1
G
 and for (b) γ2
A
 ........................ 193 
Figure 3.40. Pie-charts showing the proportion of the hemoglobinopathies in the 
whole set of samples (a) and the proportion of different hemoglobin disorders (b) 198 
Figure 3.41. Pie-charts showing the proportion of the hemoglobinopathies within 
different ethnic groups (a) and the proportion of Sickle carriers within different 
ethnic groups (b) ...................................................................................................... 199 
Figure 3.42. Sequence coverage for beta-chain ...................................................... 200 
Figure 3.43. Sequence coverage for alpha-chain. ................................................... 201 
Figure 3.44. Mass error calculated for the Beta-chain using the Alpha-chain as 
internal standard. ...................................................................................................... 204 
Figure 3.45. Fragment ions observed for sickle β-chain (Black spectra represent the 
control sample while red spectra are obtained from HbS sample) ........................... 207 
Figure 3.46. Fragment ions observed for HbC β-chain (Black spectra represent the 
control sample while green spectra are obtained from HbC sample) ...................... 209 
xii 
 
Figure 3.47. Fragment ions observed for HbE β-chain (Black spectra represent the 
control sample while blue spectra are obtained from HbE sample) ........................ 210 
Figure 3.48. Fragment ions observed for HbD-Punjab variant β-chain .................. 211 
Figure 3.49. Example of the variant diagnostic section of the generated report for a 
control sample .......................................................................................................... 213 
Figure 3.50. Example of the variant diagnostic section of the generated report for a 
sample compound heterozygous of HbS and HbC .................................................. 214 
Figure 3.51. Additional fragment ions observed for sample E61, carrier of Hb Tyne 
variant ....................................................................................................................... 218 
Figure 3.52. Additional fragment ions observed for sample M136 ........................ 219 
Figure 3.53. Additional fragments observed for sample H47 ................................. 220 
Figure 3.54. Fragment ions observed for sample E187 variant β-chain ................. 221 
Figure A.1. Predicted fragments for the HbJ Baltimore βT2-T3 peptide ............... 292 
Figure A.2. MS/MS spectrum of the HbJ Baltimore βT2-T3 peptide m/z 100-670 292 
Figure A.3. MS/MS spectrum of the HbJ Baltimore βT2-T3 peptide m/z 710-1240
 .................................................................................................................................. 292 
Figure A.4. MS/MS spectrum of the HbJ Baltimore βT2-T3 peptide m/z 1260-1640
 .................................................................................................................................. 293 
Figure A.5. MS/MS spectrum of the HbJ Baltimore βT2-T3 peptide m/z 1620-1870
 .................................................................................................................................. 293 
  
xiii 
 
LIST OF TABLES 
Table 1.1. Common clinically significant variants .................................................... 38 
Table 1.2. Masses of human globin chains (α, β, γA, γG), glycated forms of major 
globin chains (αG, βG) and variant globin chains (βSICKLE, βD-Punjab, βC, βE, βO-Arab) .. 51 
Table 2.1. Summary of samples used for different applications during method 
development ............................................................................................................... 68 
Table 2.2. Tryptic peptides affected in clinically significant variant chains and the 
mass shift associated with the mutations. .................................................................. 78 
Table 2.3. List of tryptic peptides and variant tryptic peptides and expected mass to 
charge ratios. (Corresponding peptides are clustered based on what part of the amino 
acid sequence they comprise, first the wild-type peptide present in normal adult 
hemoglobin) ............................................................................................................... 80 
Table 2.4. The developed MRM transitions for T3 and T5 peptides in the beta and 
delta chains of hemoglobin on a Waters TQD . ......................................................... 81 
Table 2.5. Tryptic peptide ions and targeted fragment ions on the Xevo TQ 
instrument used for MRM transitions. ....................................................................... 85 
Table 3.1. Analysed samples for a period of 12 weeks used for comparative study to 
current methods ........................................................................................................ 135 
Table 3.2. Clinical samples analysed using the developed top-down ETD method 137 
Table 3.3. Results of the correlation analysis for all analysed sample batches by the 
intact globin chain analysis ...................................................................................... 146 
Table 3.4. Results of the Bland-Altman statistical analysis for all analysed sample 
batches by the intact globin chain analysis .............................................................. 148 
Table 3.5. Results of the Passing & Bablok Statistical analysis for all analysed 
sample batches by the intact globin chain analysis .................................................. 149 
Table 3.6. Results of the correlation analysis for all analysed sample batches by the 
different peptide ratio analysis using the MRM method .......................................... 152 
Table 3.7. Results of the Bland Altman statistical analysis for all analysed sample 
batches by the MRM analysis for the T5 peptide ratios........................................... 155 
Table 3.8. Results of Passing-Bablok Statistical analysis for all analysed sample 
batches by the MRM analysis for the T5 peptide ratios........................................... 156 
xiv 
 
Table 3.9. Summary of sickle conditions among all batches analysed in the clinical 
trial. .......................................................................................................................... 158 
Table 3.10. Summary of the occurrence of -1 Da variants in the 12 batches analysed.
 .................................................................................................................................. 162 
Table 3.11. Summary of -1 Da variants grouped based on the specific mutation 
conditions (shadings represent different mutations, purple for HbO-Arab, green for 
HbC, blue for HbE and orange for HbD-Punjab) .................................................... 167 
Table 3.12. Detection of -1 Da clinically significant variants by the MRM method.
 .................................................................................................................................. 173 
Table 3.13. Confirmation of HbD-Punjab variant by the analysis of tryptically 
digested peptide mixture in full scan mode ............................................................. 175 
Table 3.14. Summary of identified rare variants found during the clinical trial ..... 178 
Table 3.15. Table to summarise abnormal samples analysed in the clinical trial ... 195 
Table 3.16. Summary of different conditions, numbers and proportions of clinically 
significant variants ................................................................................................... 197 
Table 3.17. Results of HbA2 quantitation for a clinical sample and the reference 
standard .................................................................................................................... 202 
Table 3.18. Results of HbA1c quantitation for a clinical sample and the reference 
standard .................................................................................................................... 203 
Table 3.19. Summary of hemoglobin variants and chosen reporter fragment ions for 
the detection of different conditions ........................................................................ 212 
Table 3.20. Summary of analysed samples with different conditions and successful 
confirmation by the ETD approach .......................................................................... 215 
Table 3.21. List of rare Hemoglobin variants analysed with the top-down ETD-
method ...................................................................................................................... 217 
Table A.1. Calculated sickle β-chain percentages for the samples classed as 
heterozygous sickle carriers. .................................................................................... 288 
Table A.2. Calculated sickle β-chain percentages for the samples classed as 
heterozygous sickle carriers. .................................................................................... 289 
Table A.3. Calculated sickle β-chain percentages for the samples classed as 
heterozygous sickle carriers based on MRM method results. .................................. 290 
Table A.4. Calculated sickle β-chain percentages for the samples classed as 
heterozygous sickle carriers. .................................................................................... 291  
xv 
 
ACKNOWLEDGEMENTS 
 
At the end of this long journey, I realise that it’s not the length of the road, the 
difficulties alongside it and the never-ending challenges that were important, but the 
people who shared all this with me, who supported me, who listened to me, gave 
advice, or an occasional hug when it was most needed. Their belief in me and my 
ability to walk, or intermittently run, to the very end of this road have given me the 
strength to keep going and finally arrive at my destination.  
I would like to begin by thanking my acedemic supervisor Prof. Jim Scrivens for 
giving me the opportunity to undertake this PhD. His support, advice and continoual 
encouragement have been invaluable over the last three years. I would like to thank 
Waters Corporation for all the financial support.  
I would like to thank Charlie Scarff for guiding me on this new field in my first 
years, her advice and help was invaluable. Special thanks to Baharak who was the 
best post-doc I could ask for; creative in problem solving and fun to work with. 
Without her all this could not have happened.  
I am grateful for Dr Nicholas Jackson and Jane Newbold our collaborators at UHCW 
for their contributions and help.  
I would like to say thank you for all the help and support from Bruker; to Ian 
Saunders for the opportunity to be part of an exciting project, to Julia for her 
constant help and always being there when I needed to discuss the work and to 
Martyn for his constant efforts in fixing the LC whilst answering my never-ending 
questions. I would also like to thank Ralf Hartmer for method development, and 
Zoltan Czentar for his data processing script which made life easier.  
 
I am very grateful to Nisha and I consider myself a lucky person to have her 
friendship. Thanks to all past and current members of the Scrivens’ group: Fran, 
Elle, George, Kostas, Gill and special thanks to Matt and Sue, who supported me and 
kept my blood pressure fairly low in the last three months.  
Thanks to all my friends Bori, Agika, Kati, Balazs. Csaba for believing me while 
supervising me for my MSc thesis. Thanks to all my Warwick friends: Dani, Mike, 
Matei, Adrienne, Pete and Nick.  
I am always going to be grateful for Tamas for his support, love and faith in me, 
even being thousands of kilometres away being the person closest to me.  
xvi 
 
Special thanks to my two fellow Hungarians Mate and Viki who handled my 
stressful periods with huge patience. 
 
Végül, de nem utolsó sorban szeretnék köszönetet mondani a családomnak: az 
édesanyámnak, aki akkor is hitt bennem, amikor én magam nem, minden amit 
elértem neki köszönhető és a nővéremnek. Remélem mindketten büszkék rám, és 
tudják én felnézek rájuk, mégha mindketten alacsonyabbak is egy ici-picit.  
 
 
  
xvii 
 
DECLARATION 
 
I hereby declare that this thesis, submitted in partial fulfilment of the requirements 
for the degree of Doctor of Philosophy and entitled “The Development of Mass 
Spectrometry-Based Approaches for the Diagnosis of Hemoglobinopathies”, 
represents my own work and has not been previously submitted to this or any other 
institution for any degree, diploma or other qualification. Work undertaken by my 
colleagues or collaborators is explicitly stated where appropriate. 
 
 
 
Krisztina Radi 
May 2013 
 
  
xviii 
 
SUMMARY 
 
Hemoglobinopathies are disorders of the protein hemoglobin (Hb), one of the most 
common inherited disorders, and pose an increasing healthcare problem. Worldwide, 
approximately 200 million people have hemoglobinopathies (Hartwell et al. 2005), 
and whilst the majority of them are clinically silent, some are life-threatening. 
Screening programs for hemoglobinopathies traditionally employ chromatography 
and electrophoretic techniques, which only provide presumptive identification of 
clinically important hemoglobin disorders. The definitive characterisation of these 
disorders requires protein sequence elucidation or DNA analysis. The development 
of a rapid population screening method for hemoglobinopathies, which could also 
provide definitive diagnosis of a disorder, is of significant interest to the healthcare 
profession. Mass spectrometry (MS) is currently used to routinely characterise 
variants but not as a validated clinical diagnostic tool.  
 
The work undertaken addresses the increasing demand for population screening. 
Different mass spectrometry-based approaches to hemoglobinopathy detection have 
been developed based on previously described procedures found in literature. The 
methods, for intact globin chain analysis and targeted variant specific peptide 
analysis, have been optimised and evaluated using clinical blood samples on a triple 
quadrupole system.  
 
Intact globin chain analysis and targeted tryptic peptide screening methods have 
been evaluated in a clinical trial analysing 2017 blood samples to identify clinically 
significant variants routinely screened as a requirement by the NHS Screening 
programme and to quantify minor globin chains (HbA2 and HbF) suitable for the 
diagnosis of thalassemic and other disorders. This work was carried out in a three 
month mirrored testing experiment against existing clinical laboratory methods. The 
results obtained showed an excellent correlation to values from current clinical 
methods, as all clinically significant variants were detectable by MS methods. In 
addition, MS was able to detect Hb variants undetected by electrophoretic or 
chromatographic methods and highlighted some issues with the current phenotypic 
methods which can lead to misdiagnosis.  
 
A top-down ETD method utilising an iontrap mass spectrometer has been developed 
and applied to provide fragmentation for positive identification of known 
hemoglobin variants. This method was evaluated by analysing 1000 samples in a 
pilot study as a sideproject to the clinical trial. The generation of an automated report 
with the detection of clinically significant variants and minimal sample preparation 
are some of the benefits associated with this approach. This method has been shown 
to meet the majority of requirements for a rapid diagnostic screening method and has 
the potential to become a validated tool in the clinical laboratory screening in the 
near future.   
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1.1 Instrumentation 
 
Mass spectrometry is a versatile analytical technique originally used in physical and 
chemical analysis. It has become a method of choice in characterising biological 
systems. Complex biological problems increasingly rely on mass spectrometry data. 
The underlying fundamentals and technical details of the mass spectrometry-based 
analysis of biological samples are presented in this section.  
 
1.1.1 What is a mass spectrometer? 
 
The mass of a molecule is a fundamental characteristic, and the possibility of 
determining the molecular mass provides a powerful tool for identifying compounds 
in complex mixtures. Mass spectrometry is an analytical technique which is capable 
of measuring mass-to-charge ratios (m/z) of ionised molecules in the gas phase.  
The origin of mass spectrometry may be placed in the early 20
th
 century when J.J. 
Thomson was  working on the transmission of electricity through gases and cathode 
rays. This led him to find an extremely useful application of his research in chemical 
analysis (Thomson 1913). After this, mass spectrometry became a physicist’s tool 
with increasing usage in chemical analyses after the 1940s. It remained that for four 
more decades, until the invention of soft ionisation techniques in the late 1980s as 
reviewed by (Cristoni and Bernardi 2003) (Karas et al. 1987, Karas and Hillenkamp 
1988, Fenn et al. 1989). 
The main components of a mass spectrometer are the ion source, the analyser(s) and 
the detector. A simplified block diagram can be seen in Figure 1.1. In the ionisation 
source molecules become charged, the ions are then resolved based on their mass-to-
charge ratios in the mass analyser(s). Following this separation, ions are detected and 
with the help of a computer system the acquired data is presented in an accessible 
format.  
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Figure 1.1. Schematic representation of a mass spectrometer 
Elements in blue are used by tandem in space instruments. 
 
1.1.2 Ionisation methods  
 
In the ion source of a mass spectrometer the sample of interest is ionised prior to 
mass analysis. During this process neutral molecules become charged, and they are 
transferred into the gas phase if they have not been evaporated previously. Early 
ionisation techniques required the sample to be vaporised prior to ionisation. These 
methods included electron impact ionisation, chemical ionisation and field 
ionisation, and their use was limited to analytes which were volatile and thermally 
stable. Electron impact ionisation is still widely used for the analysis of small 
organic molecules. This requires the sample to be in the gas phase and so is 
unsuitable for the study of large biomolecules. 
Biological samples such as proteins are usually large, polar and thermally labile and 
cannot be easily transferred into the gas phase without extensive decomposition. 
Field Desorption ionisation was introduced for analysis of non-volatile compounds 
in the late 1970s (Beckey 1969b) , and with the invention of fast atom bombardment 
(FAB) it became possible to produce ions from liquid or solid surfaces overcoming 
the need for volatilization prior to ionisation (Barber et al. 1981, Morris et al. 1981). 
This allowed the routine analysis of thermally liable and non-volatile molecules, 
proteins and peptides up to a few thousand Daltons in mass and the mass 
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spectrometric analysis of biomolecules started a new era in the history of the 
technique.  
The development of soft ionisation techniques such as matrix-assisted laser 
desorption/ionisation (MALDI) and electrospray ionisation (ESI), in the 1980s 
significantly increased the role of MS in biomolecule analysis, dominating the field 
with application areas are still growing (Karas et al. 1987, Karas and Hillenkamp 
1988, Fenn et al. 1989). ESI can be coupled with separation techniques making it a 
predominant ionisation technique for research purposes in the life sciences. A 
potential advantage of MALDI over ESI is the predominant production of singly 
charged ions of peptides and proteins, which can be helpful for instances where 
decreasing spectral complexity is required (El-Aneed et al. 2009). The theories 
underlying these two ionisation methods are presented below.  
 
1.1.2.1 Electrospray ionisation (ESI) 
 
The first electrospray ionisation experiments were conducted in Malcolm Dole’s 
laboratory in the late 1960s. This involved the successful introduction of a polymer 
into the gas phase (Dole et al. 1968). This technique was then optimised and 
improved by Fenn and co-workers (Yamashita and Fenn 1984) and emerged at the 
end of the 1980s as a powerful technique to produce intact ions from large and 
complex molecules in solution (Fenn et al. 1989).  
In ESI the analyte molecules present in solution are introduced into a strong electric 
field through a capillary under atmospheric pressure. The electrospray itself is 
formed as a result of the electrostatic potential difference between the capillary and 
the counter electrode (cone). A fine spray is ejected from the capillary in a form 
commonly known as the Taylor cone. The solution at the end of the needle is 
polarised and torn away from the needle (Wilm and Mann 1994). A spray is 
comprised of droplets containing charged analyte molecules and depending on the 
applied potential on the tip of capillary, these droplets are positively or negatively 
formed. Due to solvent evaporation the size of the droplets decreases while the 
surface tension increases up to a point when the columbic repulsion overcomes this 
tension and reaches the Rayleigh limit, whereby the droplet undergoes fission and 
new smaller droplets are formed. Further evaporation of the parent droplet leads to 
repeated coulombic fissions. The progeny droplets also evaporate and undergo the 
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same fission, resulting in small charged droplets which ultimately leads to gas-phase 
ions (Kebarle and Verkerk 2009). How the actual ions are formed from the small 
droplets is still under debate. A schematic of the two major models proposed is 
shown in Figure 1.2. 
 
 
 
Figure 1.2. Electrospray ionisation mechanism presented by both theories 
Adapted from (Nguyen and Fenn 2007) 
 
The ion desorption mechanism (IEM) was first proposed by Iribarne and Thomson 
(Iribarne and Thomson 1976), while the charge residue model (CRM) was 
previously presented by Dole and co-workers (Dole et al. 1968).  
The IEM proposes that after a number of evaporation and fission events, and before 
a charged droplet becomes small enough to further reduce some of the analyte ions 
from the surface of the droplet are pushed into the gas phase since the electric field 
present is sufficiently intense to make that happen. According to CRM the solvent 
evaporation and subdivision proceeds until small droplets are formed that contain 
one analyte molecule. The final evaporation of the remaining solvent from this 
ultimate droplet leaves the residual analyte molecule with the charge previously 
carried by the droplet.  
Despite work on the mechanisms by a number of research groups in the last four 
decades it has not been fully elucidated and remains a subject of investigation 
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(Abonnenc et al. 2010, Hogan et al. 2009). There is some agreement in that low 
molecular weight analytes are proposed to follow the ion evaporation model (IEM), 
while the charged residue model (CRM) applies to large globular species. A chain 
ejection model (CEM) has also been proposed recently for disordered polymers 
(Konermann et al. 2012).  
One of the key characteristics of ESI is the formation of multiply charged ions. 
Analytes need to be solubilised in a preferably polar/aqueous solvent, often with the 
presence of organic solvents (acetonitrile and methanol) which is supportive of the 
desolvation process, but in case of proteins also makes the analyte more amenable to 
protonation by facilitating denaturation. One of the disadvantages of ESI is that the 
technique is very sensitive to small amounts of salts present in the solution, which 
are likely to compete successfully in the ionisation process at the expense of the 
analyte (Lubec and Afjehi-Sadat 2007). 
For smaller scale and nanoflow applications nano-electrospray was developed, which 
generally follows the same principles as standard electrospray. A chip-based nano-
electrospray technique has been developed for direct sample injection (Covey, 
Thomas et al. 2009, Wilm and Mann 1996, Van Berkel 2003). 
 
1.1.2.2 Matrix assisted-laser desorption ionisation (MALDI) 
 
The other leading ionisation technique for biological molecules is matrix assisted-
laser desorption ionisation (MALDI). The technique was introduced and made 
applicable for mass spectrometric analysis by Karas and Hillenkamp in 1987 (Karas 
et al. 1987, Karas and Hillenkamp 1988). They realised that applying a matrix 
significantly improves the ionisation efficiency. The Nobel prize was however given 
to Tanaka based on his earlier presented less practically applicable work on laser 
desorption (Tanaka et al. 1988).  
MALDI analysis requires that the analyte is co-crystallised with a matrix, the most 
common of which are nicotinic acid, benzoic acid and cinnamic acid derivatives. The 
matrix molecules need to be in excess to the analyte molecules, and they are excited 
by the application of a pulsed laser beam, most commonly a N2 laser (frequency in 
the UV region with 337nm) but IR lasers have been also used. The energy provided 
by the laser is absorbed by the matrix and transferred into vibrational energy. 
Choosing the right matrix for mass spectroscopic analysis is crucial, as it is 
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important that it has absorption at the wavelength of the laser (Batoy et al. 2008). 
The absorbed energy from the laser then causes the matrix to vaporise and the 
analyte to be transferred into the gas phase and ionised.  
The ion formation process is currently thought to follow a two-step mechanism. In 
the first step the formation of primary ions takes place, which then undergo reactions 
forming secondary ions. The secondary ions are produced in proton transfer 
reactions between the matrix and analyte molecules (Knochenmuss 2006). 
Similarly to ESI the processes of ion formation are still under investigation. It has 
been debated whether ionisation takes place in the solid phase prior to desorption or 
in the gas phase. Conventional models assume chemical equilibrium in the gas 
phase, while Lai and co-workers has showed a quantitative interpretation assuming 
chemical and thermal equilibrium in the solid state prior to desorption (Lai et al. 
2010). 
In most cases ions produced by MALDI are singly charged resulting from the 
attachment of a single proton. The result of this is less complex mass spectra and the 
requirement of a mass analyser capable of measuring over a broad m/z range, such as 
a time of flight (TOF) analyser.  
 
Both ESI and MALDI are very sensitive analytical techniques utilizing picomolar  
analyte concentrations. The fact that ESI can be easily coupled to LC makes it 
suitable for quantitative measurements, and ESI has been shown to be more 
reproducible than MALDI. There were some attempts to interface MALDI with LC, 
mainly because of the robustness of the technique to the presence of salts, but due to 
the heterogeneity of a MALDI crystal sample the quality of MALDI spectra can be 
significantly influenced by the position of the laser beam, which is not ideal for 
quantitative applications (El-Aneed et al. 2009). 
 
1.1.3 Mass analysers 
 
The mass analyser is an important part of the mass spectrometer, where the produced 
ions are separated according to their m/z ratios. Instruments are often named after the 
analyser. The most appropriate analyser to achieve the best results is usually 
dependent on the hypothesis or application. Analysers can be classified based on 
different properties but most commonly they are grouped into analysers which scan 
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and  can successively detect ions of different m/z over a period of time or those 
which allow simultaneous transmission of ions of all m/z at the same time (de 
Hoffmann and Stroobant 2009). Scanning analysers are quadrupole (Q) and 
magnetic sector , while the second  group includes the time of flight analyser (TOF) 
and trapping analysers such as ion trap (quadruploe ion trap, QIT, linear iontrap LIT) 
Fourier transform ion cyclotron resonance (FTICR) and the Orbitrap. For 
biochemical research a broad variety of analysers have been used to date and the five 
dominant techniques which have been developed are presented below.  
All mass analysers can be described using some key characteristics: upper mass 
limit, transmission efficiency and resolving power. The most important one is the 
resolving power, which can have a significant influence in the analysis of complex 
mixtures. The resolution is related to the ability of the analyser to distinguish 
between two ions that are of similar m/z. It is a ratio calculated between the 
measured mass and the smallest mass difference (m/Δm) to the neighbouring mass 
peak at a certain m/z ratio with the difference calculated at full-width half-height 
maximum (FWHM) of the peak.  
The highest m/z value that can be measured with the application of a certain analyser 
is the upper mass limit. The transmission efficiency is defined by the ratio of the 
number of ions detected to the number of ions that are produced in the ion source.  
Hybrid instruments have been developed to support tandem mass spectrometric 
experiments. These are further discussed in section 1.1.5.  
 
1.1.3.1 Quadrupole mass analyser (Q) 
 
The quadrupole analyser introduced by Paul in 1953 was a breakthrough which 
provided an alternative to large magnetic field analysers (Paul and Steinwedel 1953). 
The quadrupole is a scanning mass analyser consisting of four parallel conductive 
circular or hyperbolic rods arranged in pairs which are electrically connected. Direct 
current (DC) and alternating radio frequency (RF) potentials are applied to the rods 
in a way that the two opposite rods have the same voltages. When an ion with a 
certain m/z enters the quadrupole, depending on the produced electromagnetic field 
between the rods the ion can either have a stable trajectory and pass through the 
quadrupole or have an unstable trajectory and collide into the rods or be lost at the 
walls of the analyser, and not reach the detector. This is illustrated in Figure 1.3.  
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Figure 1.3. Schematic representation of a quadrupole mass analyser.  
A stable ion trajectory (shown in red)  gets through the quadrupole to the detector whilst 
the unstable ion trajectory (shown in green) is repelled 
 
By changing the electric field that the ions are exposed to different ranges of m/z 
ratios may be scanned and ions allowed to pass through the quadrupole. When the 
quadrupole is operating in scanning mode, a constant ratio of the voltages (particular 
value of DC and RF voltages) is applied to the pair of rods, and only ions of a 
specific m/z will have a stable trajectory. 
In the RF-only operation mode the quadrupole can also act as an ion guide. In this 
mode RF voltages are applied to the rods making it possible for all ions to pass 
through the analyser with a stable trajectory.  
Quadrupole analysers do not require very high vacuum and they are relatively fast. 
This supports high throughput analyses, but their upper mass limit (around 2000 m/z) 
and resolution (unit resolution) is relatively low compared to other analysers. There 
have been some new developments to provide quadrupole mass filters with higher 
mass ranges with the quadrupole operating at different frequencies (Douglas 2009). 
 
1.1.3.2 Time-of-flight mass analyser (TOF) 
 
The linear time-of-flight analyser was first described by Wiley and McLaren (Wiley 
and McLaren 1955). The time-of-flight (TOF) mass analyser separates ions 
according to their velocities. Mass-to-charge ratios can be related to the time it takes 
an ion to pass through a field-free region called a flight tube. The ions enter the analyser 
+
+
-
-
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and are accelerated with the use of a kinetic energy pulse in the electrostatic field. As all 
ions acquire the same kinetic energy, their velocities and therefore their flight times 
depend on their masses and charges. Ions travel at a velocity inversely proportional to 
the square root of their mass. In general, the larger the ion, the longer it takes to travel 
through the tube.  
In principle the upper mass range of this type of analyser has no limits, but there are 
limiting factors in resolution. The length of the ion formation pulse, the volume of the 
space where the ions are formed and the differences in initial kinetic energy between 
ions all affect the resolution. Ions of the same m/z but with slightly different kinetic 
energy will reach the detector at slightly different times, resulting in peak broadening 
and reduced resolution. This variation in kinetic energy can be compensated by the 
application of delayed pulse extraction (Vestal et al. 1995). The time delay between 
ion formation and extraction allows ions to separate according to their kinetic energy 
in the field free region. The ions with more energy move further away from the 
source towards the detector, and when the pulse applied more energy is transmitted 
to ions which remained for a longer time in the source (de Hoffmann and Stroobant 
2009). 
As mass resolution is proportional to flight time, higher resolution can be achieved 
by increasing the length of the flight tube. Reflectron instruments achieve this by 
reflecting ions back down the flight tube using a series of electrodes which act as an 
ion mirror, as shown in Figure 1.4. Ions with higher initial kinetic energies travel 
further into the reflectron compared to those with less initial kinetic energy. The 
addition of an extra mirror (also known as W optics) can further improve resolution, 
the flight distance is increased by a factor of four compared to the original length of 
the flight tube.  
Delayed extraction compensates for the spatial distribution, while the reflectron 
reduces the kinetic energy variation. By the time they have reached the detector the 
faster moving ions catch up with the slower ions (Somogyi 2008). 
TOF analysers were originally directly compatible with pulsed laser ion sources like 
MALDI, but orthogonal acceleration TOF (oa-TOF) provides fast, sensitive mass 
analysis for continuous ion sources, where ions are sampled orthogonally from the 
ion beam to transform a continuous ion flow into a pulsed one (Mirgorodskaya et al. 
1994, Coles and Guilhaus 1993, Guilhaus et al. 2000). 
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The TOF analyser benefits from highly efficient ion transmission, good sensitivity, 
the ability to measure over a wide mass range, and the capability of achieving a 
relatively high mass resolution. To date high-end TOF instruments can have a 
resolution up to ca 40,000–50,000 and mass accuracy in the parts per million (ppm) 
range. Routine instruments have a resolution up to 10,000–20,000 and mass 
accuracy of below 5 ppm (Jiwan et al. 2011). 
 
 
 
Figure 1.4. Schematic of time-of-flight (TOF) 
 
1.1.3.3 Ion traps (IT) 
 
Ion trap mass analysers operate on the principle of trapping by using an electric field 
to store ions. The ions are trapped in two or three dimensions by using an RF 
quadrupolar field (de Hoffmann and Stroobant 2009).  
 
The quadrupole or 3D ion trap (QIT) 
 
The first ion traps were three dimensional traps. The principle of the ion trap 
originated from Paul and Steinwedel, but it was modified to provide a useful mass 
spectrometer by Stafford (Stafford et al. 1984). 
It consists of a circular electrode and two ellipsoid caps at the ends of the 3D 
quadrupolar field (de Hoffmann and Stroobant 2009). One endcap is the entrance 
through which ions enter the trap and the other is the exit electrode through which 
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ions are transferred to the detector. The ring electrode has an internal hyperboloidal 
shape (March 2009), schematic is shown in Figure 1.5.  
 
 
Figure 1.5. Schematic of quadrupole ion trap 
End cap electrodes in blue, and ring electrode in the middle in orange with the characteristic details 
describing the distance from the center to the endcaps and the ring, U0 is the applied voltage. 
 
Similarly to the quadrupole analyser direct and alternating potentials are applied. The 
overlapping potentials give a kind of 3D quadrupole, in which all the ions ar trapped 
on a 3D trajectory. Commercial ion traps are operated in a way that a fundamental 
RF voltage is applied to the ring electrode, that voltage has a constant frequency, but 
its amplitude can be varied, while additional voltages of selected frequencies can be 
applied on the end caps. As all the ions are trapped simultaneously, they repel each 
other and their trajectories expand as a function of the time. To reduce the expansion 
a certain level of gas pressure is maintained withing the trap with Helium, which 
collides with the ions and removes their excess energy.  
Early ion traps employed mass-selective detection based on recording the oscillating 
ion motions to analyse ions. This was followed by mass-selective storage but the 
mass-selective axial ejection was the real breakthrough which made it the mass 
analyser we use today. Ions with different m/z are present in the trap simultaneously, 
and they are sequentially expelled out of the trap. The mass spectrum is acquired 
while ions are systematically scanned out with the application of a linear gradient of 
RF voltages.  
In the 3D ion trap tandem mass spectrometry can be performed in a time-dependent 
rather than a space-dependent manner. The precursor ion is selected by expelling all 
other ions from the ion trap, fragmentation energy is provided by collisions with the 
helium gas and with resonant excitation. The produced fragment ions are analysed 
CHAPTER 1 – INTRODUCTION 
13 
 
with the described scanning method, which also allows another selection and further 
fragmentation of the selected product ion.  
 
The Linear or 2D ion trap (LIT) 
 
The linear ion trap or 2D ion trap (LIT) has a similar build to the quadrupole. Ions 
are restrained radially in a two-dimensional RF field and axially by applying 
additional stopping DC potentials to the end electrodes. Ions can be ejected either 
radially or axially. Hager revolutionised the technique by describing how ions can be 
ejected axially from a LIT in a mass selective manner (Hager 2002). Compared to 
3D traps, linear traps have higher injection efficiencies and greater ion trapping 
volumes. Based on the structure of LIT use is not limited to storage of the ions, it can 
also act as an ion guide, an m/z selector or a collision cell. As a consequence LIT is 
often used with other mass analyzers in hybrid instruments for the isolation of ions 
with selected m/z to perform tandem mass spectrometry experiments (Douglas et al. 
2005). 
 
1.1.3.4 Fourier transform mass analysers 
 
Fourier transform ion cyclotron resonance (FT-ICR) 
 
Ion cyclotron resonance was first described by J.A. Hipple in 1949 (Hipple et al. 
1949), but Marshall and Comisarow realized that Fourier transform could be applied 
to ICR to reduce the data acquisition time (Comisarow and Marshall 1974). FTICR 
has become the analyser offering the highest mass accuracy (< 1 ppm) and resolution 
(~ 500,000) to date. 
In FTMS ions are forced to undergo a cyclotron motion by a spatially uniform static 
magnetic induction. The frequency of their oscillation is characteristic of their mass-
to-charge ratio (m/z) (Zhang et al. 2005). Ions with different m/z are present in the 
ICR cell, and they all have different circular motion with different frequencies. The 
detected signal is an extremely complex signal, which needs to be deconvoluted by 
Fourier transformation. FTICR requires ultra-high vacuum and a stabile homogenous 
magnetic field, which is maintained by superconductive magnets. These 
requirements make this technique the most expensive analyser.   
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Orbitrap 
 
A recently developed Fourier transform analyser was invented by Makarov in 2000 
(Makarov 2000). The Orbitrap mass analyser is built up of a spindle-like central 
electrode and a barrel-like outer electrode. An electrostatic potential is produced by 
applying a DC voltage between the two axially symmetric electrodes, which makes 
the ions oscillate around the inner electrode in a stable trajectory with a defined 
frequency. This is responsible for orbital trapping of the ions in the radial direction, 
and a quadrupolar potential traps ions axially while they undergo harmonic 
oscillation in the z-direction (Jiwan et al. 2011, Perry et al. 2008). Since there is no 
need for a superconductive magnet in this analyser, the cost of the Orbitrap is much 
lower than FT-ICR, and this fact makes the Orbitrap an affordable high-resolution 
technique. Specification of the resolving power is 100,000 (FWHM definition) at m/z 
400 (Jiwan et al. 2011). 
 
1.1.4 Detectors in mass spectrometers 
 
After ions have been separated by a mass analyser they need to be detected and 
transformed into an interpretable signal by the detector. Several varieties of detectors 
exist and the choice of detector depends on the instrument design and the analytical 
application. TOF instruments require detectors with a very rapid response. Isotope-
ratio measurements require very stable, intercalibrated detectors, that are capable of 
measuring a number of ion masses at the same time (Koppenaal et al. 2005). 
Detection of ions is based on charge, mass or velocity. Detectors may be classified 
into two major categories. These are direct measurement, such as a Faraday cup, 
which measure the direct charge current when an ion hits a surface, or detectors that 
amplify the intensity of the signal, such as electron- or photon-multipliers and array 
detectors (de Hoffmann and Stroobant 2009). 
The first mass spectrometers used photographic plates. Ions with the same m/z hit the 
plate at a specific place and that position based on a calibration scale could be used 
to determine the particular m/z values. The darkness of the spots enabled an 
approximation of beam intensity. The disadvantages of this type of detector included 
poor sensitivity, short linear dynamic range, the requirement for off-line image 
development and calibration, poor precision and quantitation (Koppenaal et al. 2005). 
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A Faraday cup is also a direct charge measurement detector. It is made of a metal 
cup, ions hit the cylinder wall and they are neutralised while accepting or donating 
electrons (de Hoffmann and Stroobant 2009). These detectors are used for isotope-
ratio MS based on their ability to provide high signal stability (Koppenaal et al. 
2005). 
Electron multiplier detectors are the most common ion detectors used in modern 
mass spectrometers. A schematic of a single continuous dynode, one of the EM 
detectors also known as a channeltron, can be seen in Figure 1.6. In electron 
multipliers, ions which reach the plate cause the emission of secondary electrons. 
The secondary electrons produced are accelerated into a continuous dynode electron 
multiplier, and generate an electron cascade. This can multiply the initial signal by 
10
6
 or more (Koppenaal et al. 2005). 
 
 
 
Figure 1.6. Schematic of a single continuous dynode. 
    Taken from (Parker et al. 2010) 
 
The array plate shown in Figure 1.7 is a variant of the continuous dynode EM, called 
multichannel or microchannel plate. In this configuration, a series of microchannels 
are arranged a few tens of micrometers in diameter and a few millimetres in length in 
a plate or disk. This is an ideal detector for TOF analysers because the short electron 
path supports the very short electron pulse widths (~1 ns) used in this technique. The 
operation method is similar to that of a continuous dynode, in that ions strike the 
surface close to the entrance of the microchannel, generating a cascade of electrons. 
The cloud of ions exiting the microchannel can be directed onto an anode where it 
can be detected and converted into a mass spectrum using either time-to-digital or 
analog-to-digital conversion.  
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Figure 1.7. Schematic representation of a microchannel plate and the electron 
multiplication within one of the channels.  
Adapted from (de Hoffmann and Stroobant 2009) 
 
 
A time-to-digital converter (TDC) is often used with TOF instruments. Due to its 
pulsed nature, a TDC records an arrival time for each mass within a transient (in the 
case of TOF analysers ions resulting from one TOF pulse). A TDC records the 
arrival time for the first ion of a given mass, so it cannot tell the difference between 
one ion at a given mass or several ions at that given mass arriving in a transient. This 
inability to determine how many ions are arriving at a particular time can severely 
limit the instrument’s dynamic range. 
An analog-to-digital converter (ADC) takes the total analogue signal, reduces the 
high frequency background noise and converts it to a digital signal. The total signal 
strength is recorded at very frequent intervals (as often as a billion times per second). 
The ADC can distinguish between one ion of a given mass to many ions of a given 
mass arriving in a single transient. This results in an improved dynamic range 
compared to TDC. TDC detectors have about one or two orders of magnitude 
dynamic range whilst the ADC has a dynamic range of three to four orders of 
magnitude (McIntyre 2004). 
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1.1.5 Tandem mass spectrometry (MS/MS) 
 
The introduction of soft ionisation techniques spurred on the development of tandem 
mass spectrometric (or MS/MS) techniques, which triggered the development of 
hybrid instruments capable of performing various types of MS/MS experiments. Soft 
ionisation techniques produce intact, non-fragmenting ions which make molecular 
mass determination possible, but do not give further information about the structure 
(Somogyi 2008). To obtain structural information the development of tandem mass 
spectrometry was necessary.  
 
 
 
Figure 1.8. Principle of MS/MS experiment 
A precursor ion is isolated by the first mass analyser, fragmented by collision with an inert gas and 
the products ions are analysed by the second mass spectrometer. 
 
Tandem mass spectrometry (MS/MS) involves at least two stages of mass analysis, 
either in conjunction with a dissociation process or in a chemical reaction that causes 
a change in the mass or charge of an ion (de Hoffmann and Stroobant 2009). In a 
tandem mass spectrometry experiment utilising two mass analysers, the precursor 
m/z
m/z
Precursor ion selection 
by MS1 
Fragmentation by 
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fragment ions by MS2
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ion is isolated by a first analyser, undergoes fragmentation, (usually achieved by 
applying an activation method) with the generated product ions and neutral 
fragments analysed using a second mass analyser (Madeira and Florêncio 2012). The 
principle of MS/MS is illustrated in Figure 1.8. 
There are two basic concepts for MS/MS based on instrumental construction. There 
are tandem mass spectrometry in space or in time. In MS/MS in space this is 
accomplished by the physical coupling of two mass analysers. Tandem mass 
spectrometry in time employs a single mass analyser (QIT, LIT, FT-ICR), which is 
operated to allow the steps of ion selection, activation and product ion analysis to 
take place in the same location consecutively in time and also potentially sequentally 
to provide third or further (nth) generations of fragments (MS
n
) (Gross 2011). 
 
In space MS/MS experiments are commonly performed by use of a Q-TOF (a 
quadrupole mass analyser coupled to a TOF instrument), TOF-TOF or triple quadrupole 
(QqQ) instruments. In the latter all four main scan modes may be used: product ion scan, 
precursor ion scan, neutral loss scan and selected/multiple reaction monitoring 
(SRM/MRM). These modes are illustrated in Figure 1.9. Q-TOFs are used largely for 
product ion scanning experiments.  
While performing a product ion scan a precursor ion of a certain m/z is selected in 
the first analyser and all resulting product ion masses are scanned. In precursor ion 
scan mode: a product ion is chosen and the second analyser is focused on the 
corresponding m/z and the associated precursor ions are determined as the first 
analyser scans all the masses.  
In a neutral loss scan mode all fragmentations leading to the loss of a neutral 
fragment of defined mass are determined. Both mass analysers operate in scanning 
mode, but with a constant mass offset. This scanning mode is extremely useful for 
screening specific compound groups with a certain side-chain which is primarily lost 
by fragmentation. It is often used for determination of phosphorylation sites.  
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Figure 1.9. Scanning and detection modes in tandem mass spectrometry on a QqQ 
instrument 
Adapted from (Domon and Aebersold 2006) 
 
Multiple reaction monitoring (MRM) is a very sensitive and specific detection and 
quantification method for targeted molecules. MRM experiments are conducted 
mainly using triple quadrupole instruments. A typical MRM strategy starts by using 
the first quadrupole to select a molecule with a certain m/z value. In the collision cell 
fragmentation of the specific selected ion is facilitated by collisionally induced 
dissociation (CID) when supplied with optimized collision energy. The resulting 
fragment (or product) ions are monitored using the second quadrupole analyser and 
in the monitored MRM channel signals are only recorded when the specific pre-
identified product ion associated with the given precursor is detected in the second 
quadrupole (Zanella-Cleon et al. 2009). A selected fragmentation pathway 
(transition) from a defined precursor to a defined product ion is monitored, and a 
signal is detected in only those cases when that selected transition occurs. For higher 
specificity it is necessary to monitor a number of transitions for the same target 
molecule.  
Tandem in-space experiments set in motion the development of hybrid mass 
spectrometers, which can use different types of analysers for the first and second 
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stages of MS/MS. The main purpose of designing hybrid instruments was to 
combine different performance characteristics (mass resolution, the given ion kinetic 
energy for collision-induced dissociation, and speed of analysis) offered by various 
types of analysers (Glish and Burinsky 2008). One of the most commonly used 
hybrid instruments is the previously mentioned Q-TOF. More recent developments 
include QIT-TOF, LIT-TOF, LIT-Orbitrap, LIT-FT-ICR, etc. A more detailed 
discussion of hybrid instruments can be found in a recent review paper (Glish and 
Burinsky 2008). 
 
Fragmentation methods and tandem mass spectrometry in peptide sequencing 
 
The ion activation process is crucial to the MS/MS experiment and the choice 
determines the nature of the fragment ions. Various ion activation methods have 
been developed. Early experiments studied decomposition of metastable ions (Cooks 
1973). In the 1960s collision-induced dissociation (CID) was introduced by Keith 
Jennings (Jennings 1968) and Fred McLafferty (McLafferty and Bryce 1967). CID is 
still the most common ion activation method used in tandem mass spectrometry 
instruments today (Sleno and Volmer 2004). 
In CID, collisions between the precursor ion and an inert gas are accompanied by an 
increase in internal energy. The translational energy from the collisions is converted 
into internal energy which is distributed throughout the ion. Consecutive collisions 
gradually increase the internal energy to a point which leads to subsequent 
decomposition.  
Low and high energy collisions give different fragmentations which can be 
complementary providing different structural information. Low-energy CID is 
mostly performed in quadrupole instruments (such as triple quadrupoles) and 
trapping instruments (such as ion traps and FT-ICR instruments). During CID in ion 
trap instruments, precursor ions are accelerated by on-resonance excitation causing 
collisions to occur. Product ions are detected by subsequent ejection from the trap 
(Madeira and Florêncio 2012). Collisional activation in the high energy (keV) range 
occurs mainly in TOF instruments, where the precursor ions have high translational 
energies. 
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Electron capture dissociation (ECD) has been developed as an alternative method to 
CID (Zubarev et al. 1998). During ECD, fragment ion production involves the 
capture of low-energy electrons by multiply charged ions, which results in charge 
state reduction and subsequent fragmentation. ECD mechanism was described as 
non-ergodic process in the past (Turecek and McLafferty 1984). In a non-ergodic 
process energy is not redistributed over the whole molecule and fragmentation at 
weaker bonds is not necessarily favoured (Madeira and Florêncio 2012, Turecek and 
McLafferty 1984). Recent publications, however, discuss cleavage mechanisms 
favoured based on lower transition-state energies pointing to a mechanism which is 
not a non-ergodic process (Simons 2010, Moss and Turecek 2012). ECD requires an 
ultra-high vacuum and it is currently limited to use on Fourier transform ion 
cyclotron resonance mass spectrometers (Gross 2011).  
Electron transfer dissociation (ETD) has been developed to overcome the need for 
the use of FT-ICR instruments (Syka et al. 2004). The fragmentation mechanism is 
believed to be analogous to ECD and the two methods result in similar fragment 
ions, although the mechanisms are currently not fully evaluated and well understood.  
In the first ETD experiments, singly charged anthracene anions were obtained from a 
chemical ionisation reaction with methane which were then used to transfer an 
electron to multiply protonated peptides. This electron transfer then induced 
fragmentation of the peptide backbone (Madeira and Florêncio 2012, Syka et al. 
2004). Fluoranthene has become more widely used on commercial mass 
spectrometers (Good et al. 2007). ETD is available on quadrupole ion traps, recent 
Orbitraps and on some Q-TOFs. These analysers are lower cost and more widely-
accessible then FT-ICR. 
ECD and ETD are only applicable to multiply charged cationic species. The 
precursor ion must hold at least two, but preferably three or more, positive charges to 
avoid charge neutralization, which occurs when a singly charged ion undergoes 
electron capture and the resulting neutral is undetectable by mass spectrometer.  
ECD and ETD have been shown in some cases to produce more diagnostic fragment 
ions than CID for large peptides and proteins. In-site specific reaction fragmentation 
occurs along the peptide backbone and leaves little surplus energy for additional 
fragmentation such as losing post translational modifications (PTM). These 
techniques have been widely used to investigate the position of PTMs (Chi et al. 
2007, Stensballe et al. 2000).  
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Tandem mass spectrometry experiments are widely used for obtaining primary 
sequence information from peptide ions. The production of peptide fragment ions by 
means of CID has been well characterised (Jennings 2000). Figure 1.10 shows the 
nomenclature for the possible types of product ions, which was initially proposed by 
Roepstorff, Fohlmann and extended by Biemann (Biemann 1992, Roepstorff and 
Fohlman 1984). 
 
 
 
Figure 1.10. Peptide fragmentation nomenclature  
adapted from (Roepstorff and Fohlman 1984) *note : b1 ion in a non-modified peptide would not be 
observed because of the ring structure, but with derivatization they can be detected. 
 
CID typically produces a series of b and y type ions from the peptide fragmenting at 
the amide bonds of the peptide backbone. The respective ions are formed where the 
b-series ions extend from the N-terminal and the y-series ions extend from the C-
terminal. The CID spectra of typical tryptic peptides with a basic residue at the C-
terminus often contain extended y ion and short b ion series (b2 to b3, b4) excluding 
the b1 ions (Seidler et al. 2010). The calculation of the mass difference between 
consecutive fragment ions belonging to the same ion series (b or y ion-series), allows 
the determination of the amino acid sequence of the peptide (Soares et al. 2012). 
Sequence information from complementary b/y ion pairs also provides molecular 
weight information, the sum of their mass values gives the precursor ion mass, which 
can be useful if a mixture of precursor ions has been isolated for fragmentation 
(Seidler et al. 2010). 
CID can be carried out on a wide range of mass spectrometers, provides reproducible 
fragmentation patterns, and can produce extensive coverage for tryptic peptides. CID 
fragment ion spectra have been shown to differ when obtained using an ion trap 
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compared to a Q-TOF instrument. Ion trap MS/MS spectra are very reproducible and 
dominated by ﬁrst generation fragments, however the low mass cut-off excludes 
fragment ion detection below m/z 200-300 for average sized tryptic peptides (Seidler 
et al. 2010). 
Peptide ions with charge state 2+ and 3+ are preferred precursor ions since the 
resultant fragment ion spectra of these charge states often contain more sequence 
ions. When tryptic digestion efficiency is high, the generated peptides are present 
with 2+ or 3+ charges, because the basic sites or Arg/Lys, N-terminus and His can 
hold charges. Fragmentation of doubly charged peptides usually results in the 
production of complementary b/y ions. The y ion retains a positive charge at its C-
terminus, whilst the b ion retains charge at the N-terminus.  
High energy fragmentation can be used for determining the side-chain of an amino 
acid, which is useful for distinguishing between leucine and isoleucine (Williams et 
al. 2009). MS
n
 in an ion trap can also be useful for this purpose.  
Other activation methods such as ECD and ETD lead to the direct generation of c- 
and z-type fragment ions by breaking the Cα-N bond. ECD and ETD can produce a 
complete or almost complete fragmentation spectrum of peptides leading to more 
information regarding the peptide sequence (Mikesh et al. 2006). 
A large number of publications have compared ETD (or occasionally ECD) to CID 
in terms of accessible information content from peptide fragmentation (Cook et al. 
2012, Creese and Cooper 2007, Hart et al., Molina et al. 2008, Sobott et al. 2009, 
Zubarev et al. 2008), and a number of experiments have been described which 
combine the use of ETD and CID for more comprehensive peptide sequence analysis 
(Han et al. 2008, Hartmer and Lubeck 2005, Kim et al. 2011). 
Since the introduction of CID, tandem mass spectrometry has become the primary 
method of choice for the sequencing of proteins replacing the previously used 
Edman degradation method and it is becoming more and more important in the 
investigation of protein function (Jennings 2000). A summary of wider applications 
of tandem mass spectrometry can be found in the recently published book edited by 
Jeevan K. Prasain (Prasain 2012). 
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1.1.6 Liquid chromatography 
 
In the analysis of complex biological samples there is a requirement for separation 
techniques to simplify mass spectra and enable interpretation. The MS analysis can 
be complicated when there are hundreds of components present, and often ion 
suppression can occur during ionization in the ESI source. With the development of 
ESI it became possible to couple ESI to liquid chromatography allowing separation 
of complex samples before mass spectrometric analysis.  
Chromatography is a separation method in which the components to be separated are 
distributed between two phases called the stationary phase and the mobile phase. As 
the mobile phase moves in a definite direction in contact with the stationary phase, 
the components, depending on their affinity to the stationary phase, are either 
retained on the stationary phase or solubilised in the mobile phase. In a mixture, 
different compounds have different physical/chemical properties and so theoretically 
varying affinity to the stationary phase. This enables elution from the stationary 
phase at different times allowing chromatographic separation to occur. Analytes with 
relatively weak affinities for the stationary phase elute early and so are detected first. 
In high pressure liquid chromatography (HPLC) the mobile phase is liquid delivered 
under high pressure (up to around 400 bar) through a column packed with particles 
covered with a particular compound. When the mobile phase composition is kept 
constant during elution this is referred to as isocratic separation. Gradient elution is 
when the composition is changed gradually. By applying gradient elution generally a 
better separation can be achieved. Physical properties of compounds such as size, 
binding affinities, hydrophobicity, charge and pI have been used to separate 
compounds of interest. 
A schematic of a typical HPLC system, illustrating its major components can be seen 
in Figure 1.11.  
 
 
 
Figure 1.11. Schematic of a HPLC system 
 
High performance liquid chromatography (HPLC) was developed in the 1960s 
(Horvath and Lipsky 1966, Horvath et al. 1967) and there were several efforts to 
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couple it to mass spectrometry with slowly growing success by McLafferty’s group 
in the 1970s (Arpino et al. 1974), and by Fenn’s group together (Whitehouse et al. 
1985), Henion’s lab at Cornell and Andries Bruins developed the most practical 
interface in the 1980s (Bruins et al. 1987, Covey et al. 1986, Henion 2009). 
Historically, the main problem was how to handle high liquid flows while 
maintaining the high vacuum required for the mass spectrometer. This was achieved 
and revolutionised bio analytical research (Abian 1999, Thomson 1998). 
Why was it so beneficial to couple the two techniques? Samples of biological origin 
can contain hundreds to thousands of components present at varying mass and 
concentration. Analysis of these mixtures by mass spectrometry alone is difficult. It 
is beneficial to provide separation of these components prior to MS to allow their 
identification or determine their levels. Chromatography alone as a technique is 
unable to provide unambiguous identification of the separated components. 
Recognition can only be based on the measurement of retention times, often by 
comparison with reference standards, which does not make the identification of 
unknown compounds possible. Even with matching retention times the uncertainty 
of the presence of a different compound other than that identified is high. The mass 
and mass fragmentations of many compounds are sufficiently specific to allow 
identification with a higher degree of confidence. If a single analyte of interest is in a 
mixture the mass spectrum can contain ions from all of the compounds present, and 
the identification is more challenging, in addition accurate quantitation of the 
compound is difficult. By combining HPLC with mass spectrometry a powerful 
analytical technique has become available to provide confident identification and 
reliable quantitative determination of compounds in a complex mixture (Ardrey 
2003). 
Reversed phase-HPLC (RPLC) has emerged as the most commonly used method for 
peptide separation. The separation of non-polar compounds happens on a stationary 
phase containing non-polar functional groups such as long alkyl chains (for example 
C8 and C18), and involves a mobile phase that is significantly more polar than the 
stationary phase which is often water-based with combination of organic solvents 
such as acetonitrile or methanol. The term reversed phase has a historic origin, the 
early liquid chromatography separations were performed using a stationary phase 
with unmodified silica which is hydrophilic and able to bind polar compounds. This 
is today called normal phase chromatography. Employing aqueous solvents and 
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separating non-polar compounds under these conditions was not possible. The 
introduction of alkyl chain coated stationary phases which were hydrophobic and the 
opposite of hydrophilic silica, hence the term reversed, made it possible to routinely 
analyse biological samples and organic non-polar analytes like peptides.  
The peptides bind to the non-polar stationary phase and during the chromatography 
separation the composition of the mobile phase is altered gradually increasing the 
concentration of the organic content over a period of time. The increasing organic 
concentration will disrupt the binding mechanism between the analytes and the 
stationary phase, which assists the elution of the hydrophilic peptides first, followed 
by increasingly hydrophobic peptides during the rest of the gradient. This course of 
action is presented in Figure 1.12. 
The solvents used for mobile phase in RPLC are compatible with ESI, which makes 
coupling this type of separation technique to the mass spectrometer easier.  
The separation efficiency of HPLC is influenced by several factors. It is necessary to 
choose and optimise the content of the mobile phase, the pH and the chemistry of the 
stationary phase. The stationary phase is usually a packed column which can vary in 
its particle size, pore size, column length and column diameter. The operating 
temperature of the column, the length and slope of the applied gradient, and the flow 
rate all affect the chromatographic separation.  
Separation efficiency is measured in theoretical plates. In order to optimize 
separation efficiency, it is necessary to maximize the number of theoretical plates 
and reduce the plate height, which is inversely proportional to the plate number and 
also influenced by the column length. The plate height is related to the flow rate, and 
according to the van Deemter equation separation efficiency can be maximised by 
optimising the flow rate (VanDeemter et al. 1995).  
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Figure 1.12. Schematic of reversed phase liquid chromatography under gradient 
conditions 
Adapted from (McDonald 2009) 
 
Particle size is one of the variables, and the evolution of liquid chromatography 
facilitated the production of smaller particle sizes. Reducing the particle size results 
in higher speed and peak capacity (number of peaks resolved per unit time in 
gradient separation) (Swartz 2005a). Smaller particle size and higher flow rates made 
it necessary to handle much higher operating pressures, which led to the introduction 
of ultra-high pressure liquid chromatography (UPLC). MS detection is significantly 
enhanced by employment of UPLC (Swartz 2005b). The obtained higher 
chromatographic efficiency results in better resolution and higher peak capacity, 
which is particularly important for the analysis of peptides and proteins (Tolley et al. 
2001).  
Faster separations achieved by UPLC are beneficial for high throughput applications, 
where time saving is extremely important while running multiple samples. The 
application of liquid chromatography for the separation of biological mixtures can 
require long and thorough method development and optimisation, which is also 
shortened by the use of UPLC.   
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1.2 Clinical applications of mass 
spectrometry 
 
As routine analysis of biological samples and biomolecules has become possible it is 
inevitable that this powerful technique would become established for biomedical and 
clinical applications. The use of MS in biomedical sciences is rapidly increasing and 
the potential of MS in medical diagnostics grows. To detect physiological disorders, 
molecular disease markers can be monitored. These markers can be found in the 
following systems: the metabolome - the products or substrates of endogenous 
metabolism, the proteome and peptidome - functional/dysfunctional protein and 
peptide products of gene transcription and translation, and the genome and 
transcriptome - disease-related genes and mRNA transcripts (Flad and Tolson 2005). 
The sources of these markers are from biological fluids such as serum, plasma or 
urine, and because of the growing need for non-invasive diagnosis even saliva has 
become a more widely used source recently. For the diagnosis of molecular markers,  
antibody recognition, methods like enzyme linked immunosorbent assays (ELISA) 
or polymerase chain reactions (PCR) for genetic determination have been used. Mass 
spectrometry is a sensitive tool, with high specificity and high-throughput 
capabilities. The ability of MS to screen for multiple molecules in a single run has 
shown promise has already proved to be useful in the diagnostics field and is forseen 
to strengthen its position in the coming years (Petricoin and Liotta 2003). 
Mass spectrometry has long been used in clinical laboratories. In the 1970s gas 
chromatography (GC)-mass spectrometry was used for drug screening and the 
diagnosis of organic acid metabolic disorders as reviewed by Shushan (Shushan 
2010). Since GC requires a certain level of analyte volatility, derivatization needed 
to be applied to those biological molecules that were involatile. After successfully 
coupling HPLC to MS, providing a more appropriate separation technique for polar 
thermolabile molecules, LC-MS was introduced into the field of neonatal screening 
for metabolic disorders and became a widely-accepted method in clinical 
diagnostics. More than 30 different metabolic disorders can now be simultaneously 
and quantitatively screened using tandem MS (Flad and Tolson 2005). MS has been 
shown to be a good alternative to currently used screening methods in many other 
fields. Some examples and importance are discussed below.  
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1.2.1 Analysis requirements: sample preparation, instrumentation and 
costs 
 
The most commonly used MS instruments for clinical purposes are triple quadrupole 
(TQ or QqQ) analyser instruments. Triple quadrupoles achieved this popularity due 
to their high specificity and capability for quantitative measurements for small 
molecules using the selected reaction monitoring mode with frequent usage of 
isotope labelled standards. This type of measurement provides good sensitivity for a 
wide variety of compounds in targeted applications, but other instruments can be 
better for applications where wider screening for unknown components is necessary. 
Ion traps are also relatively popular and are significantly less expensive than TQ 
mass spectrometers. Ion traps are not as suitable for quantitative applications but 
their strengths lie in more qualitative screening applications such as identification 
and structural characterization of unknown metabolites (Vogeser and Seger 2008). 
High resolution mass spectrometry also has a significant role in biomedical research 
but these studies are usually confined to academic laboratories. Orbitrap and TOF 
instruments can provide accurate mass data and potential structural elucidation, 
which can be extremely useful in large scale screening, and with the inevitable 
further improvements in quantification performances these high mass resolution 
instruments will be adapted for use in clinical laboratories (Jiwan et al. 2011) . 
The advantages of LC-MS/MS include high specificity and selectivity, better 
sensitivity for small molecules when compared to immunoassays, the ability to carry 
out multi-analyte screening methods with no additional cost, and rapid method 
development. There are some disadvantages which need to be overcome in the 
following years in order for LC-MS/MS to be more suitable for high-throughput 
medical diagnostic/screening. A significant amount of pre-analytical sample 
treatment can be required producing toxic or clinical waste. An LC-MS/MS system 
is based on technology which can require skilled and trained staff, and the initial 
capital cost of these instruments is relatively high, as are the maintenance service 
costs (Herman and Shushan 2012). Several review papers discuss HPLC-MS/MS, 
and capillary electrophoresis-MS/MS is also becoming more widely used (Kolch et 
al. 2005). 
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Working with MS analysis of biological matrices can be challenging due to matrix 
interferences, ion suppression and sensitivity loss due to contamination. Several 
purification steps may be carried out before HPLC–MS/MS to help alleviate these 
issues. Depending on the concentration range, sample concentration or dilution has 
to be performed. For the analysis of small molecules there is a need to remove as 
much protein and lipid as possible and the most widely applied technique for protein 
precipitation is the addition of organic solvents. There are continuously developing 
methods for automated on-line and or off-line sample preparation prior to HPLC 
separation, otherwise lengthy chromatography must be used to separate the large 
number of compounds what may be present in the biological matrix (Herman and 
Shushan 2012, Vogeser and Kirchhoff 2011). 
To make MS routine in clinical diagnosis, sample pre-treatment, separation, and 
detection must become integrated. This could be achieved by implementing on-line 
multidimensional chromatography to facilitate sample introduction, ease-of-use, and 
speed of analysis (Shushan 2010). An important consideration is the cost of the 
technique. The cost of the mass spectrometer can be a high initial investment, but in 
a long term, using it for the screening of multiple analytes simultaneously, this initial 
high capital cost can be recovered. To achieve this cost-effectiveness many 
applications may need to be implemented into one analytical method to increase 
productivity. Measurement and chromatographic times need to be shortened to make 
the technique more appropriate for high-throughput analysis to cope with the large 
numbers of samples (hundreds of samples per day) required for population screening. 
From a hospital point-of-view the method needs to be automated, easy-to-use and 
rapid with a report readily accessible giving the required answers.  
 
1.2.2 Current clinical MS applications 
 
At present, the most widely performed MS clinical applications are for therapeutic 
drug monitoring (TDM) and metabolic disorder diagnosis.  
Vitamin D deficiency has been linked to skeletal disease conditions, chronic renal 
failure and osteoporosis. Vitamin D analysis is one of the most often used LC-
MS/MS assays in the clinical laboratory today. This technique is widely accepted as 
it is able to distinguish between analogs of vitamin D while making it possible to 
quantify the diagnostically informative 25-hydroxyvitamin D metabolites. There is 
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some debate as to whether immunoassays give accurate results due to potential 
nonspecific binding of different vitamin D metabolites simultaneously, and experts 
consider LC-MS/MS the most accurate assay for vitamin D analysis (Herman and 
Shushan 2012). Recent publications discuss vitamin D analysis in further detail 
(Babic 2012, Higashi et al. 2010). 
Therapeutic drug monitoring (TDM) is one of the most important fields for LC-
MS/MS, especially in supporting therapies involving immunosuppressants. There are 
several other screening methods already implemented for anti-fungal drugs, anti-
viral drugs, anticonvulsants, antidepressants, antibiotics, anticancer drugs and drugs 
affecting the cardiovascular system (Adaway and Keevil 2012). Monitoring of 
immunosuppressants can be critical to achieve optimal patient care after organ 
transplantation. Elevated dosing can result in significant toxicity while too low dose 
of the drug can result in transplant rejection. This provides a narrow therapeutic 
window and requires extreme care to maximize the beneficial therapeutic reaction 
while minimizing undesirable side effects (Herman and Shushan 2012). 
HPLC-MS/MS is considered superior to immunoassays for immunosuppressant 
TDM (Yang and Wang 2008). The most frequently used drugs include cyclosporine 
A, tacrolimus, sirolimus and everolimus, which can be all monitored simultaneously 
with one method (Karapirli et al. 2012).  
 
Newborn screening for inborn errors of metabolism with MS has a large history 
and is a widely accepted method in clinical laboratories. Newborn Screening (NBS) 
for metabolic disorders started with the introduction of Guthrie’s test for 
phenylketonuria (PKU) using bacterial inhibition in the 1960’s (Guthrie 1969, 
Guthrie and Susi 1963). By 2010, every infant in major developed countries could be 
screened for  inherited metabolic disorders using tandem MS (Chace 2009). In the 
UK infants are screened for only certain metabolic disorders, including 
phenylketonuria (PKU), congenital hypothyroidism (CHT), medium-chain acyl-CoA 
dehydrogenase deficiency (MCADD) (http://newbornbloodspot.screening.nhs.uk).  
The most well-known metabolic disorder phenylketonuria results form a deficiency 
in the enzyme phenylalanine hyroxylase, which catalyses the oxidation of 
phenylalanine to tyrosine. When phenylalanine is substantially increased and 
untreated it causes mental retardation (Chace 2003). This can be easily avoided by 
strict dietary treatment.  
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Other metabolite disorder screening involve acylcarnitines, amino acids, fatty acid 
oxidation and organic acid metabolism. These metabolism disorders are individually 
rare but collectively may be as frequent as 1 affected infant in 500 newborns (Vekey 
et al. 2008). It is extremely important to screen for these disorders with the most 
specific technique possible to decrease the numbers of undiagnosed and untreated 
infants.  
 
The list of applications of mass spectrometry in clinical and biomedical labs is 
extensive. Other examples include human serum albumin measurement in urine as a 
biomarker for renal disease, proteins and peptides in blood (Zhu et al. 2010) steroids 
hormones (Kushnir et al. 2009), proteins and proteomics applications to support 
biomarker discovery for different cancer research or other therapeutic purposes 
(Indovina et al. 2012, Matta et al. 2010, Silberring and Ciborowski 2010, Tan et al. 
2012, Zhang, X. et al. 2007), neuroscience and measurement of neurotransmitters, 
neuropeptides, neuroproteomics (Drabik et al. 2007), and clinical and forensic 
toxicology (Peters 2011). One of the most promising fields for biomarker discovery 
is metabolomics (Dettmer et al. 2007). The number of expressible genes is more than 
30,000 and the number of proteins expressed is close to 1,000,000, while the number 
of metabolic products in the human body is estimated to be around 3,000, which 
means less of a challenge to identify, quantify, and validate their potential diagnostic 
usage (Shushan 2010).  
Recently the MALDI Biotyper system from Bruker has become a popular instrument 
in clinical laboratories. The MALDI-TOF mass spectrometry-based identification of 
microorganisms is currently used in over 700 clinical and non-clinical microbiology 
laboratories worldwide (Kliem and Sauer 2012). 
Another opportunity for MS/MS-based methods in population screening (newborn 
and also antenatal) is the diagnosis of hemoglobinopathies, which is discussed in 
Section 1.3.4.  
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1.3 Hemoglobinopathies and their analytical 
detection  
 
1.3.1 Biological background 
 
Hemoglobin (Hb) is the protein in red blood cells that is responsible for the delivery 
of oxygen from the lungs to the tissues and the transport of carbon dioxide from the 
tissues to the lungs (Thein 2011). It is the most abundant protein in mammals, and 
probably the best characterised protein on the planet (Buxbaum 2007). The structural 
changes that occur during binding of O2, CO2 and poisons like CO are also well 
characterised, and the structural alterations of the protein due to mutations have also 
been thoroughly investigated (Buxbaum 2007). 
Human hemoglobins have a tetrameric structure consisting of two α-like (α and ζ) 
and two β-like (ε, γ, δ or β) globin chains, each linked to a heme group (Thein 2011). 
Different types of hemoglobin transfer oxygen at different stages of development. 
During the first 3 months of development, embryonal hemoglobins are developed in 
the yolk sac, these are Hb Portland (ζ2γ2), Hb Gower I (ζ2ε2), and Hb Gower II (α2ε2). 
As the bone marrow of the embryo develops, it starts producing the major fetal 
hemoglobin (HbF) which has the structure of α2γ2 (Buxbaum 2007). 
The switch from embryonic to fetal hemoglobin production begins at around the 5th 
week of gestation and is completed by week 10 (Thein 2011). Normal adult 
hemoglobin is HbA (α2β2) and comprises around 95-97% of the total hemoglobin 
with a minor component of HbA2 (α2δ2) in the red blood cells. β-globin expression 
starts only a couple of weeks later than fetal Hb, at around week 8 but the synthesis 
remains low, increases to approximately 10% at weeks 30–35 of gestation and then 
production jumps radically to higher levels at birth, when the level of fetal Hb is 
around 60-80%, declines to 5% by the age of 6 months slowly reaching the level of 
normal adult around 1% at years 2 (Thein 2011). Normal adult blood contains about 
2-3.5% HbA2. Production starts about 3 months after birth (Wild and Bain 2006). 
The production of the different hemoglobins and their levels during development is 
shown in Figure 1.13.  
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Figure 1.13. Diagrammatic representation of average percentages of the different 
types of hemoglobin chains synthesized during the different developmental periods 
and infancy. 
    Taken from (Thein 2011) 
 
Embryonic and fetal hemoglobins have a higher affinity for oxygen than adult 
hemoglobin, which is necessary for the efficient transfer of oxygen across the 
placenta from maternal to fetal circulation (Thein 2011). 
In the quaternary structure of HbA the α1β1 (and equivalent α2β2) dimer are held 
together tightly by ionic and hydrophobic bonds which involve a number of amino 
acids with interlocking side chains; the contact between α1β2 (and equivalent α2β1) 
involves fewer amino acids and consequently is less strong, the contacts between 
similar chains being relatively weak. A heme group is attached to each. These are 
responsible for the oxygen-carrying capacity of the molecule and also stabilise the 
whole molecule (Bain 2006a, Buxbaum 2007, Wild and Bain 2006). The connecting 
hydrogen bonds allow alteration of the structure to some extent during oxygen 
binding and release. The heme is a porphyrin molecule with an iron bound in its 
centre by complex bonds to the 4 ring nitrogen atoms. The iron is normally in the 
ferrous form (Fe
2+
), which makes it possible for the heme to reversibly bind oxygen 
in order for hemoglobin to function as an oxygen transporting protein. Oxidation of 
iron to the ferric form (Fe
3+
) makes the hemoglobin incapable of binding oxygen 
(methemoglobin) (Bain 2006a).  
The structure of the hemoglobin tetramer is shown in Figure 1.14.  
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Figure 1.14. Structure of hemoglobin 
 
The α-like and β-like globin chains are encoded by genetically distinct gene clusters. 
The α-like cluster is positioned on chromosome 16 with duplicate α genes and the β-
like cluster on chromosome 11, as shown in Figure 1.15. The genes are arranged 
along the chromosome in the same order in which they are expressed during 
development (Thein 2011). Each gene contains 3 coding segments (exons) and 2 
non-coding segments (introns). The latter have to be spliced out of the mRNA prior 
to protein synthesis. Synthesis of the hemoglobin subunits is synchronised to 
produce equal amounts of α- and β-subunits (Buxbaum 2007). 
 
 
Figure 1.15. The α- and β-globin gene clusters and the corresponding hemoglobins 
produced.  
    Taken from (Wild and Bain 2006) 
 
The α and β chains consist of 141 and 146 amino acid residues, respectively. There 
is some sequence homology between them (64 amino acid residues in identical 
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positions). The β chain differs from the δ chain by only 10 amino acids and from γ 
chain by 39 residues (Clarke and Higgins 2000, Shackleton et al. 1991). The γ globin 
genes are duplicated like the α genes in the gene cluster but, while the two α globin 
genes have theoretically the same product, the produced γ globin genes are slightly 
different (
Gγ = γ 136Gly; Aγ = γ 136Ala). In fetal red cells, the ratio of Gγ to Aγ is 
approximately 3:1; in adult red cells, it is approximately 2:3 (Wild and Bain 2006). 
Hemoglobin can undergo post-translational modification. By a spontaneous reaction 
between the N-terminal valine of the β globin and glucose, HbA1c is produced from 
HbA. This reaction is a non-enzymatic glycosylation. The concentration of HbA1c-
formation, based on its accumulation during the 120 days life span of an erythrocyte, 
is related to the average blood glucose concentration (Buxbaum 2007). In normal 
individuals HbA1c is around 4-6%, but in diabetics it can be much higher (Bain 
2006a). Monitoring of HbA1c levels can be used as a marker for long term diabetic 
control.  
 
The DNA of globin genes may be subject to spontaneous mutations. The mutation 
could be a point mutation, affecting a single nucleotide, or a more complicated 
mutation including deletion, insertion or alteration of more than one nucleotide. As a 
result of a point mutation there can be expressed variations on the protein level or no 
effect on the amino acid sequence (Bain 2006a). There are many genetically 
determined variants of human hemoglobin although only a few have serious clinical 
manifestations. The inherited disorders of hemoglobin synthesis are referred to as 
hemoglobinopathies (Bain 2011, Wild and Bain 2006). 
Hemoglobinopathies are categorised into two main disease groups, structural 
variants and thalassemias. These are genetically distinct groups, but the clinical 
manifestations are similar. The hemoglobin variants (also called abnormal 
hemoglobins) arise from an alteration in the globin protein structure with a change in 
type or number of amino acids. Thalassemia results from gene mutations that cause 
production of an insufficient amount of normal structure globin chains (Hartwell et 
al. 2005). To date over 1170 different hemoglobin variants have been described with 
approximately 460 mutations potentially giving rise to thalassemia (based on the 
most recent information of Globin Gene HbVar database August 2013) (Hardison et 
al. 2002, HbVar). Hemoglobin disorders are genetically inherited and it is estimated 
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that ~7% of the world’s population are carriers for one of them, making 
hemoglobinopathies the commonest monogenic diseases (Thein 2011). 
 
Structural variants 
 
Alterations in the structure of hemoglobin usually occur by point mutations affecting 
one or, in less frequent cases, two or more bases, coding for amino acids of the 
globin chains (Wild and Bain 2006). Although there are plenty of potential structural 
variants, based on the calculations by Kleinert et al for α- and β-chains together 1695 
theoretical variants are possible, of which only 43% were detected in 2008, and 69% 
(1170) listed in the HbVar database today, a significant number of the detected 
variants being clinically silent (Kleinert et al. 2008). Additionally, there are also 460 
thalassemia disorders listed in the HbVar database 
(http://globin.bx.psu.edu/hbvar/menu.html). 
The most important structural variants which have potential significant clinical 
manifestation are HbS, C, E, D
Punjab
, O
Arab
. These result from single amino acid 
substitutions in the β-chain. Other mutations include a combination of the sequences 
of β and γ or δ chains resulting in hybrid hemoglobins. The β and δ combinations are 
known as Lepore and are also clinically important (Wild and Bain 2006). These 
mutations and their positions are outlined in Table 1.1. 
Hb S results from a point mutation in the β-globin gene (GAG → GTG in codon 6) 
causing substitution of valine for glutamic acid in position 6 of the β-globin chain 
(β6Glu→Val). The substitution of a charged amino acid by a hydrophobic one 
creates a hydrophobic patch, which is only exposed in deoxy-hemoglobin, and 
hidden when oxygen is bound (Buxbaum 2007). As a consequence the variant 
hemoglobin (Hb S) can polymerize in the deoxygenated state, resulting in the 
characteristic distorted red blood cell shape change, the so-called sickle cell. Clinical 
symptoms occur only with homozygous sickle cell disease. Heterozygotes are said to 
have sickle cell trait and are usually symptom-free (Wild and Bain 2006). 
Heterozygous individuals are resistant to infection with Plasmodium falciparum, the 
causative agent for malaria. This parasite spends part of its life cycle in erythrocytes, 
feeding on hemoglobin. The presence of Hb S decreases the erythrocyte life span (in 
heterozygotes less than in homozygotes), and so the parasite cannot complete its life 
cycle (Buxbaum 2007). 
CHAPTER 1 – INTRODUCTION 
38 
 
 
Name  
Position  
(Tryptic peptide 
affected by the 
mutation) 
Mutation 
(Substitution) 
Mass 
change of 
the β 
chain (Da) 
Clinical manifestation 
Homozygote/Heterozygote 
Hb S 
β 6  (βT1) 
Glu→Val -30 
Sickle cell disease/ no 
symptoms 
Hb C β 6  (βT1) Glu→Lys -1 Mild anemia/no symptoms 
Hb D-Punjab,  β 121  (βT13) Glu→Gln -1 Mild anemia/no symptoms 
Hb E 
β 26  (βT3) 
Glu→Lys -1 
Thalassemia minor/mild 
microcytosis 
Hb O-Arab β 121  (βT13) Glu→Lys -1 Mild anemia/no symptoms 
  
Lepore-Boston-
Washington 
Hybrid: δ 1-87, β 116-146 
-2 
Thalassemia minor 
Lepore-Hollandia Hybrid: δ 1-22, β 50-146 -30 Thalassemia minor 
Lepore-Baltimore Hybrid: δ 1-50, β 86-146 -45 Thalassemia minor 
 
Table 1.1. Common clinically significant variants 
 
The homozygous state or sickle cell anaemia (β genotype SS) causes moderate to 
severe hemolytic anaemia. The main clinical symptoms are repeated vascular 
occlusion by sickled red cells resulting in acute crises and eventually end-organ 
damage. The clinical severity of sickle cell anaemia can be very variable (Wild and 
Bain 2006). 
 
Hb C results from a single base-pair mutation in the β-globin gene similar to Hb S 
but Glu-6 is replaced by Lys rather than Val. A negatively charged amino acid is 
replaced by a positive one, which causes decreased solubility, and tendency to 
crystallise. Hb C does not give a positive sickle solubility test. It causes a moderate 
hemolytic anemia in the homozygous form. Heterozygotes are asymptomatic, 
patients are carriers, but experience no symptoms. Interaction with β0 (the complete 
absence of β-subunits) and β+ (diminished production of the β-subunits) 
thalassaemia trait results in mild or moderate hemolytic anaemia. Hb C is the second 
most common structural hemoglobin variant in people of African descent (Wild and 
Bain 2006).  
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Hemoglobin SC disease is a compound heterozygous state for Hb S and C resulting 
in a milder form of sickle cell disease. Haemolytic crisis may occur in special 
situations (e.g. during child birth or surgery) (Lawrence et al. 1955). 
 
Hb O-Arab and Hb D-Punjab both result from point mutations of the β-globin gene, 
affecting the Glu in position 121, replacing it with Lys and Gln respectively. They 
have clinical significance only in co-inheritance with Hb S and β-thalassemia, and so 
may give rise to severe sickle cell disease.  
Hb E arises from a point mutation resulting from a glutamic acid to lysine change at 
position 26 of the β-chain. Hb Lepore is a hybrid. Both of these have thalassemic 
manifestations that lead to decreased globin chain production with hypochromic 
microcytic anemia, a type of anemia characterized by small red blood cells (for 
microcytic, the measured mean corpuscular volume (MCV) - measure of the average 
red blood cell volume- is <80fL) which are paler than usual (for hypochromic). The 
Lepore globin gene resulted from a crossover between the delta and beta globin gene 
loci (Itano et al. 1954). 
Heterozygotes of these mutations are mainly asymptomatic, although the blood of 
Hb C trait carriers contains target cells, and Hb E carriers may have very mild 
anemia. Even homozygotes for Hb C and Hb E have only mild hematologic 
abnormalities and mild anemia. Compound heterozygotes for Hb E and β-
thalassemia usually have the phenotype of transfusion-dependent β-thalassemia 
(Steinberg 2011). 
Sickle cell diseases (SCD) include sickle cell anemia (SS) and compound 
heterozygous syndromes which have sickling clinical abnormalities such as SC, Sβ 
thalassemia, SD-Punjab, SO-Arab, SLepore (Bain 2011). 
Bone marrow transplantation offers the only hope of a cure for SCD. This is not 
available for many patients. For the majority of SCD patients there are two non-
transplant options for the management of the disease – blood transfusion and 
hydroxyurea therapy (Thein 2011). HbF has been shown to inhibit HbS 
polymerization. Experimental treatments to induce higher levels of HbF are 
undergoing clinical trials (Steinberg 2011). 
 
Some rare hemoglobin variants may have altered affinity for oxygen (hemoglobins 
with increased or decreased oxygen affinity), be susceptible to oxidation, or can have 
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molecular instability (unstable hemoglobins). Amino acid substitutions affecting 
heme-binding residues may lead to irreversible iron oxidation, methemoglobinemia 
(Hb M), and cyanosis. Substitutions involving contacts between globin subunits may 
alter the affinity of hemoglobin for oxygen (Steinberg 2011). 
 
Thalassemias 
 
Thalassemias are also caused by mutations in globin genes, but in thalassemia the 
globin gene expression is affected in a way that the synthesis of a globin chain is 
reduced or absent, but the structures of the globin chains which are produced are 
usually normal (Steinberg 2011). 
The thalassemias are classified into α, β, δβ, γδβ, δ, γ and εγδβ groups according to 
the type of globin chain(s) expression that is reduced. The two major categories are 
the α and β thalassemias while the others are rare. Failure of hemoglobin synthesis is 
a main cause of microcytosis and anemia, which can vary from mild to severe 
(Hartwell et al. 2005). β globin chains are encoded by a single gene; α globin chains 
are encoded by two closely linked genes. In diploid cells there are two loci encoding 
the β chain, and four loci encoding the α chain, which explains why the possibility of 
having β thalassemia is higher. Production of the subunit can be totally absent (α0- 
and β0-thalassaemias) or reduced (α+- and β+-thalassemias). Clinical manifestations 
arise from completely asymptomatic microcytosis to severe anemia (Wild and Bain 
2006). The term thalassemic is often used for certain variants, where the mutant 
globin chain is synthesised at a reduced rate, leading to a thalassemic disorder. An 
example is Hb Constant Spring which causes non-deletional α-thalassemia, or Hb E 
which often evolves into β-thalassemia intermedia or even major in compound 
heterozygotes with β thalassemia (Bain 2011). 
 
Beta-thalassemia 
 
In β-thalassemia the α-subunits are produced at a normal level, but in the absence of 
equivalent amounts of the β-subunits the normal hemoglobin cannot form and the 
excess α-subunits precipitate in the cells. There are only two copies of the β-globin 
gene. Affected individuals either have the thalassemia trait when only one gene is 
affected (β-thalassemia minor, no treatment required) or β-thalassemia major, 
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when both genes are affected. Individuals with thalassemia major appear healthy at 
birth, since fetal hemoglobin is still present, but become rapidly anemic as HbF 
cannot be replaced by HbA. Diminished β-chain production is known as β+-
thalassemia, while the complete absence of β-subunits is referred to as β0-
thalassemia.  
Many different mutations can cause β-thalassemia. This usually results from 
mutations that affect transcription, translation, or RNA stability. More than 300 β- 
thalassemia mutations have been characterized, and probably only 20 β-thalassemia 
alleles account for more than 80% of the β-thalassemia mutations in the whole 
world. Unlike α-thalassemia, where deletions in the α-globin gene cluster cause most 
of the mutations, the molecular defects causing β-thalassemia are usually point 
mutations involving one more nucleotides within the β gene (Thein 2011). 
β-thalassemia major is a severe, transfusion-dependent, inherited anaemia. Excess α-
chains are unstable and precipitate in the red cell precursors forming inclusion 
bodies. If untreated, 80% of children with β-thalassemia major die within the first 5 
years (Wild and Bain 2006). Heterozygotes for β-thalassaemia have either a normal 
hemoglobin with microcytosis or a mild microcytic hypochromic anemia, while 
HbA2 is often elevated and Hb F is sometimes also higher than normal. 
 
Alpha-thalassemia 
 
The severity of thalassemias depends on the number of affected α globin alleles: the 
greater the number, the more severe the manifestations of the disease. 
The genetic information for the α-subunit is coded in four copies (two on each of the 
chromosomes 16), therefore four syndromes of α-thalassemia are possible: 
(1) α+-thalassemia trait occurs when one of the two globin genes on a single 
chromosome fails to function (− α /α α); (2) α0-thalassemia trait occurs when two 
genes on a single chromosome fail to function (− − /α α); (3) Hb H disease is when 
three genes are affected(− − /− α); and (4) Hb Bart’s hydrops fetalis, where all four 
are defective (− − /− −). The clinical severity depends on the number of α-globin 
genes affected. Patients with loss of either one or two α-globin genes on the same 
chromosome, or one on each of the two chromosomes 16 are usually asymptomatic 
(Leung et al. 2008). 
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The excess β chains form tetramers (called Hemoglobin H or HbH of 4 beta chains) 
which are unstable and have abnormal oxygen dissociation curves. The excess γ 
chains form tetramers which are poor carriers of O2. Their affinity for O2 is too high 
and prevent it from dissociating in the organs, where oxygen is needed. Homozygote 
α0-thalassemias, where there are no α-globins at all (called Hb Barts), often cause 
still birth. 
Hb H disease patients rarely require transfusion. α0 -thalassemia trait is characterized 
by microcytic, hypochromic indices and the hemoglobin level is usually normal or 
slightly reduced. α+-thalassemia trait can be completely silent. Both α+- and α0- 
thalassemia trait are more difficult to diagnose than β thalassemia trait since there is 
no characteristic elevation in HbA2, and the Hb H bodies are often not observed. 
Definitive diagnosis of the α-thalassaemia trait can be achieved with the use of DNA 
techniques or globin chain biosynthesis studies (Wild and Bain 2006). 
There are also a group of β-thalassemia-like disorders, referred to as δβ thalassemias 
and hereditary persistence of fetal hemoglobin (HPFH). These are caused by 
mutations that alter the switch from fetal to adult hemoglobin, and can be 
distinguished from β thalassemias by an increase in HbF levels (Thein 2011). 
 
Hb variants detected and identified to date are listed in the online accessible database 
called the Globin gene server (http://globin.cse.psu.edu/globin/hbvar/) where 
information and details regarding the different variants can be found (Hardison et al. 
2002, HbVar). Data regarding the circumstances of their discovery, experimental 
information about currently known Hb variants and thalassemias are provided. 
Results observed by different analytical techniques are included, which can help to 
identify certain variants, or confirm their identification. This database is constantly 
being updated as new Hb variants are discovered.  
 
1.3.2 Incidence of hemoglobinopathies 
 
The disorders of hemoglobin are the most common inherited monogenic diseases 
worldwide. There are many studies and surveys to estimate the incidence and 
possible further distribution of these disorders, emphasising the fact that this is now 
a worldwide health problem, which needs attention, and organised screening for 
prevention or possible genetic counselling.  
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It has been suggested that between 300,000 and 400,000 babies are born with a 
serious hemoglobin disorder each year and up to 90% of these births occur in low- or 
middle-income countries. Based on estimated annual births the most common 
disorder is homozygous HbS (over 200,000), followed by HbS in coinheritance with 
HbC (more than 50,000), with β-thalassemia as the next common (22,000), followed 
by HbE-β-thalassemia, and HbS heterozygous with β-thalassemia. HbH disease and 
Hb Bart’s hydrops incidences are in the low thousands. The distribution is extremely 
heterogeneous within different countries (Williams and Weatherall 2012). 
Sickle cell anemia is mainly present in sub-Saharan Africa and in small areas in the 
Mediterranean region, the Middle East, and the Indian subcontinent (Williams and 
Weatherall 2012). 
Hemoglobin SC disease appears more frequently in parts of west and north Africa 
whereas HbS β-thalassemia occurs in restricted parts of sub-Saharan Africa and 
infrequently all over the Middle East and Indian subcontinent. HbS at some places 
may rise up to 20%– 25% of a particular population.  
Hemoglobin E is also a common structural hemoglobin variant which occurs widely 
across East India, Bangladesh, Myanmar, east and Southeast Asia, the northern parts 
of Thailand and Cambodia. HbE is restricted to populations which have been 
endemic for malaria.  
The mild forms of α-thalassemia are widespread from sub-Saharan Africa through 
the Mediterranean regions and Middle East to the Indian subcontinent and the whole 
of east and Southeast Asia. In these areas the frequency is around 10%–25%. In a 
few smaller populations in north India and Papua New Guinea α-thalassemia 
syndromes can be found in up to 80% of the population. The more severe forms of α-
thalassemia have a much more limited incidence with high frequencies only in 
Southeast Asia and in some of the Mediterranean islands.  
The geographic appearance of HbC is more limited than that of HbS, being common 
in West and North-West Africa (Williams and Weatherall 2012). 
Hemoglobinopathies occur at high frequencies in the tropical regions. They have 
been transported to most countries of the world by population migration. The sickle 
cell gene is exceptionally common in the Caribbean Islands and in areas of North 
America, but is the most common in the majority of countries. All the common 
forms of thalassemia have appeared everywhere in the world. Their frequency is 
often explained by natural selection and the protection of heterozygotes against 
CHAPTER 1 – INTRODUCTION 
44 
 
severe malaria. Hemoglobin AS, CC, and AC genotypes and homozygous and 
heterozygous α-thalassemia give important protection from severe malaria 
syndromes (Taylor et al. 2012). 
Williams and Weatherall have suggested that the high frequency of consanguineous 
marriages in some of the high incidence countries has an important effect on the 
increasing prevalence of these inherited disorder.  
Approximately 5% of the world’s population and over 7% of pregnant women are 
carriers of some kind of hemoglobinopathy, with Hb S trait accounting for 40% of 
all carriers. Over 300,000 babies are born every year with a major hemoglobinopathy 
in the world. Approximately 85% of births affected with SCD occur in Africa 
(Aygun and Odame 2012). A study on the global epidemiology of sickle cell 
estimated an increase in  the global number of newborns affected by HbS in 2010 , 
accounting only for the homozygote SS neonates more than 300,000 (Piel et al. 
2012). Based on the estimations by Vichinsky et al about 900,000 births are 
expected with some form of clinically significant thalassemia disorders in the next 
20 years. Hb E–β-thalassemia and Hb H disease are believed to be responsible for 
much of this increase. Hb E–β-thalassemia is one of the most frequent 
hemoglobinopathies. The incidence of Hb E is nearing 60% of the population in 
some parts of Southeast Asia, and it is also rapidly growing in North America. Some 
of the α-thalassemia syndromes are accepted to be more severe and common than 
originally predicted. Hb H, Hb H–constant spring (CS), and homozygous α-
thalassemia affect a million people worldwide. Homozygous α0-thalassemia, in most 
cases fatal, is also being more frequently detected (Vichinsky 2005). 
A detailed study of European epidemiology of Hb disorders which shows that sickle 
cell disorders are more common than thalassemias can be found in the overview by 
Modell et al (Modell et al. 2007). 
 
The UK is also seriously affected by increase in the frequency of hemoglobin 
disorders. This has been well presented for thalassemias in the study by Henderson et 
al. (Henderson et al. 2009). In a five year period a total of 68 different β-thalassemia 
mutations were identified during screening for antenatal diagnosis, 59 of these 
mutations were found in immigrants to the UK, from all major ethnic groups. A total 
of 40 different α-thalassemia mutations were also characterised. Ten of these were 
deletional mutations including all the Southeast Asian and Mediterranean α0-
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thalassaemia mutations. The thirty non-deletion α+-thalassemia mutations identified 
form 46% of the worldwide currently known non-deletion mutations, which is an 
incredibly high heterogeneity. Based on this study, the UK currently had the largest 
number of different β-thalassemia mutations among the countries involved in the 
comparison. The wide range of mutations found in ethnic groups known to live in 
the UK reflects the ethnic diversity of the UK population. Altogether β-thalassemia 
mutations have been characterised in 1712 individuals, while α-thalassemia 
mutations have occurred in 2500 possible carriers (Henderson et al. 2009). 
In 2001 the results of a 10-year period study analysing 414,801 neonates in the UK 
were evaluated. HbS was found to be the most common variant, followed by Hb C, 
D and E. 250 of the samples screened were homozygotes or compound 
heterozygotes, and 6554 samples were heterozygotes for these common variants. 
From this data the calculated gene frequencies were for Hb S (0.57 %), Hb C 
(0.14%), Hb D-Punjab (Los Angeles) (0.07%), Hb E (0.05%). 16 babies had beta 
thalassemia major and 405 neonates had rare variants, of which six had not been 
previously described (Almeida et al. 2001). 
The most current progress review for the NHS Sickle cell and Thalassemia 
Screening Programme revealed that sickle cell disease is still the most common, 
affecting one in every 2,000 births in England. The estimated numbers for Hb variant 
carriers is as high as 380,000. These are mainly healthy individuals with most of 
them sickle cell carriers (Hb S) with an additional number of carriers of Hb C. The 
highest proportion of the known sickle cell disease incidences in England is 
accounted for by the Black African and Black Caribbean population (NHS 2012a). 
Beta thalassemia major is estimated to affect about 1 baby in every 20–30,000 births. 
There are approximately 300,000 healthy carriers and more than 800 people with 
beta thalassemia major and intermedia (NHS 2012a). 
In the period of 2010-11, 358 out of the 688,314 babies screened had a positive 
result for a clinical significant mutation and 9830 were carriers. In the antenatal 
screening programme from the 723,768 pregnant women tested, 17,354 were 
recognized as carriers, predominantly of the Hb S gene. After screening consenting 
partners of women who were identified as a carrier, 940 high risk couples were 
identified.  
Carrier rates grouped by ethnicity show that sickle cell carriers are common in the 
Caribbean and African populations while thalassemia carriers are common in the 
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Pakistani population. According to reported ratios 1 in every 7 carriers are Black 
African, 1 in every 8 Black Caribbean, and only 1 in every 450 newborn carriers are 
White. For thalassemia 1 in every 7 babies are from Pakistani or Cypriot descent, 1 
in every 30 Indian, Bangladeshi & other Asian, 1 in every 100 Black African and 
Black Caribbean and only 1 in every 10,000 babies are from White British ethnic 
background. The thalassemia data is an estimation from antenatal data (NHS 2012a). 
The carrier rate per 1,000 of the babies screened from different ethnicities can be 
seen in Figure 1.16.  
 
 
Figure 1.16. The carrier rate chart for significant Hb variants per 1,000 babies for 
years 2010/2011 
  Taken from NHS Screening Programme Review 2011/2012 (NHS 2012a) 
 
 
1.3.3 Hemoglobinopathy screening in the clinical lab 
 
Because of the extremely high prevalence of hemoglobinopathies and the continuous 
increase as a result of the population migration these clinical syndromes pose a 
significant burden on the health system in developed and developing countries today.  
In many countries including the UK there is a recognised need for a good screening 
programme which allows for the quick and accurate detection of 
hemoglobinopathies. The timely identification of such genetic disorders make it 
possible to initiate the necessary and appropriate treatment as early as possible. In 
the UK the NHS Sickle cell and thalassemia screening programme has been 
undertaking this role in the last 12 years. The developed program links two screening 
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set-ups, antenatal screening for pregnant women and their partners and 
recommending neonates to be screened for variant hemoglobins (Ryan et al. 2010).  
The aim of the newborn screening programme is to identify infants at risk of sickle 
cell disease within the neonatal period, since early reliable diagnosis is necessary to 
initiate early treatment and to arrange clinical follow up. The analytical methods will 
also detect β-thalassemia major and related conditions in the majority of cases. 
Newborn sickle cell screening is offered to all babies born in England and is also 
being implemented in the other UK countries (NHS 2012b). The screening is offered 
at 5-8 days of age as part of the newborn dried blood spot screening programme 
(Streetly et al. 2009). 
The main aim of newborn screening is to identify affected babies and providing 
treatment to prevent as many deaths as possible from sickle cell disease (NHS 
2012a). 
The objective of antenatal screening is to offer sickle cell and thalassemia screening 
to all pregnant women (and their partners) early in the pregnancy – ideally by 8–10 
weeks of gestation – so they can request counselling about possible options and can 
make an informed decision (NHS 2012a). It is desired to initiate all the tests in the 
first 10 weeks, and finish all necessary additional testing by the 12 weeks of 
gestation, if termination of pregnancy is required it should happen as early as 
possible (Bain 2011). 
It is extremely important to collect information of family origin and ethnic 
background, and investigating this is considered a crucial part of the screening 
process. The screening procedure is dependent on whether the parents are from high 
or low prevalence area for SCD and thalassemia. High prevalence areas are those 
which have fetal prevalence of SCD of 1.5 per 10,000 pregnancies or higher, and 
low prevalence areas are where the incidence is below 1.5. Initial laboratory 
screening involves the use of the Family Origin Questionnaire (FOQ), and based on 
ethnicity a full screen may be performed (Ryan et al. 2010, NHS 2012b). 
The screening procedure involves measurements with several different techniques. 
Initial screening techniques are simple and give an indication for the presence of 
abnormalities but they are not evaluated diagnosis methods. Initial screening 
involves complete blood count measurements (CBC) and the assessment of 
important characteristics. The most important parameters are mean corpuscular 
volume (MCV - measure of the average red blood cell volume) and mean 
CHAPTER 1 – INTRODUCTION 
48 
 
corpuscular hemoglobin (MCH - the average mass of hemoglobin per red blood 
cell). These can indicate the presence of thalassemia when MCV<80 fL and 
MCH<27 pg (Hartwell et al. 2005). 
Hemoglobin variants are routinely screened using electrophoresis and 
chromatography techniques. The most commonly used approaches are ion exchange 
chromatography, and isoelectric focusing (IEF). Electrophoresis has been the method 
of choice for identification and quantification of variant Hbs, but it is slow, labour-
intensive and inaccurate at low concentration range, and it is not suitable for large 
batches of samples (Clarke and Higgins 2000). 
The Hb variants which must be detected under the screening programme are: Sickle 
cell anemia (HbSS), HbS/β-thalassemia, HbS/HPHF, HbSC disease, HbS/DPunjab, 
HbS/E, HbS/O
Arab. It is also considered necessary to detect β-thalassemia major, 
HbE/β-thalssemia, β-thalassemia intermedia and HbH disease (NHS 2012b). The 
employed analytical procedures must be capable of detecting all the common 
clinically significant Hb variants and also to quantify HbA2 and HbF accurately as a 
screening tool for thalassemias (Ryan et al. 2010). 
High performance liquid chromatography (HPLC) separates different hemoglobins 
based on their retention times which depend on their interactions with the stationary 
phase. In cation exchange HPLC (ce-HPLC) the components with a net positive 
charge are separated from their interaction with a negatively charged stationary 
phase, while the mobile phase flows through with an increasing concentration of 
cations (Bain 2006b). Cation-exchange HPLC has been evaluated for presumptive 
identification of hemoglobin variants, giving unambiguous results in 90% of cases 
(Chevenne et al. 1999, Riou et al. 1997). HPLC has many advantages, it can be 
automated and is capable of processing large batches, provides separation of 
clinically significant variants and allows sufficiently accurate quantitation of HbA2 
and HbF (Ryan et al. 2010). It is, however, unable to detect a large number of 
existing hemoglobin variants and cannot fully characterise any novel ones which 
may be present. It only provides an indication that a sample is not normal. The 
obtained retention times are reproducible under specific experimental conditions. 
Different variants, however, can elute at the same retention time, so retention time 
does not provide definitive identification.  
A HPLC chromatogram from a normal blood sample is shown in Figure 1.17. In this 
method peaks correspond to hemoglobin heterodimers (αβ dimers), and elution of 
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HbA2 fully separated from HbA allows the quantitation based on integration of the 
peak. The different retention windows show the expected ranges for different 
clinically significant variants. The HPLC measurement only takes 7.5 minutes and 
sample introduction and report processing is automated.  
 
Figure 1.17. Chromatogram from TOSOH HLC-723 HbG7 analyser (Tosoh 
Bioscience Ltd., Redditch, UK) from normal adult.  
  Retention time windows for Hb F, A, A2, D, S and C are shown. 
 
IEF separates variants based on their isoelectric point, different hemoglobins migrate 
via a pH gradient to the point where the pH corresponds to their pI, and net charges 
are zero (Hartwell et al. 2005). The bands are sharper than in the case of 
electrophoretic techniques (cellulose acetate electrophoresis), and hemoglobins 
which could not be separated by electrophoresis can be distinguished and identified. 
The precision for quantification at low concentrations is poor and this technique has 
not been validated for HbA2 quantitation (Bain 2006b).  
DNA analysis is required for absolute genetic characterization of mutations resulting 
in β-thalassemia and quantitation of the HbA2 is crucial for the routine identification 
of carriers. Guidelines and recommendations for correct HbA2 measurements can be 
found in publications by Stephens et al. Stephens points out a common problem, that 
many Hb variants partially or totally co-elute with HbA2, making the quantification 
in certain circumstances unreliable (Stephens et al. 2011b). The national 
recommended cut-off for HbA2 (3.5%) is the action point which has been established 
for the diagnosis of β-thalassemia carriers (Ryan et al. 2010). 
Hb A
αβ dimer
Hb A2
Hb D Hb S Hb CHb F
Glycated Hb
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Measurement of Hb F is important in the diagnosis of δβ thalassaemia, hereditary 
persistence of fetal haemoglobin (HPFH) and in the diagnosis and management of 
sickle cell disease. As HbF is expected to be present up to 1%, elevated levels of 
HbF are of diagnostic value. In thalassemia trait levels of up to 10% occur, in δβ 
thalassaemia trait levels between 5% and 20%, and in HPFH heterozygotes from 
2.5% up to 30% in the deletional forms are found (Stephens et al. 2011a). Further 
investigation of elevated HbF is initiated at a measured level of 5% or higher (Ryan 
et al. 2010). 
 
Presumptive identification should be based on a minimum of two techniques based 
on different principles (Ryan et al. 2010). The routine techniques are useful in the 
screening of the common clinically significant variants but they are unable to 
identify novel variants and so additional DNA sequencing or tandem mass 
spectrometry (MS/MS) is required for identification of a variant. DNA analysis for 
the diagnosis of every patient is not achievable due to high cost and complexity. The 
use of mass spectrometry has become an alternative for variant identification and has 
potential to become a future tool in everyday screening (Ryan et al. 2010). 
Some lessons and pitfalls about currently used screening methods and algorithms on 
how to get the most appropriate results can be found in recent review by Barbara J. 
Bain (Bain 2011). 
 
1.3.4 Mass spectrometry-based identification of hemoglobinopathies and 
future directions of screening 
 
All molecules have a molecular mass which can be used to help to identify them. 
The different hemoglobin molecules, and their building blocks, the globin chains, 
have molecular masses which can be measured with MS. The molecular masses of 
the fetal (γA and γG) and adult globin chains (α, β, δ) are listed in Table 1.2. Genetic 
mutations resulting in amino acid substitutions in globin chains will cause alterations 
in these masses in most cases and therefore mass spectrometry can provide a 
powerful tool in the detection and identification of such mutations. 
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Globin chain Average molecular mass 
(Da) 
Number of amino 
acids 
Hemoglobins 
α 15,126.38 141 HbA; HbA2; HbF 
β 15,867.24 146 HbA 
γ1
G
  
γ2
A
 
15,995.27 
16,009.30 
146 HbF, Hb Portland
a
 
δ 15,924.32 146 HbA2 
αG 15288.52 141  
βG 16029.38 146 HbA1c 
βSICKLE 15837.25 146 HbS 
βD-Punjab 15866.26 146 Hb D-Punjab 
βC, βE, βO-Arab 15866.30 146 Hb C, Hb E, Hb O-
Arab 
 
Table 1.2. Masses of human globin chains (α, β, γA, γG), glycated forms of major 
globin chains (αG, βG) and variant globin chains (βSICKLE, βD-Punjab, βC, βE, βO-Arab) 
 
Mass spectrometry has been used in the identification of hemoglobinopathies for 
more than 30 years. Investigations have included structural-based studies, 
identification of hemoglobin disorders, quantitation of the minor hemoglobins such 
as HbA2 and HbF and the characterisation of post translational modifications (PTMs) 
such as glycated hemoglobin HbA1c and glutathionylated Hb as reviewed by many 
publications (Kleinert et al. 2008, Wajcman and Riou 2009, Zanella-Cleon et 
al.2009).  
Structural analysis of peptides from human hemoglobin variants was performed and 
demonstrated first by the analysis of tryptic peptide mixtures of abnormal 
hemoglobins by Wada et al. Measurements were performed with instruments using 
field desorption (FD) (Wada et al. 1981). Fast atom bombardment (FAB) (Pucci et 
al. 1989, Wada et al. 1983a) and molecular (or liquid) secondary ion mass 
spectrometry (SIMS) have also been used (Wada et al. 1983b). After the advent of 
electrospray ionisation the ability to obtain multiply charged ion series of biological 
molecules was possible, which allowed the clinical diagnosis of variant hemoglobins 
(Shackleton et al. 1991). Tandem mass spectrometry of variant peptides proved to be 
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the method of choice for peptide sequencing, which allowed the determination of 
positions of amino acid substitutions (Falick et al. 1990).  
There are two main strategies which are employed and often combined by 
researchers for the analysis of hemoglobin disorders. The requirement for these 
methods can be explained by the purpose of the analysis, which is either to undertake 
the identification of unknown variants or to screen for specific known variants. 
Intact globin chain analysis is an obvious first choice of analysis to measure the 
intact mass of hemoglobin chains. Results obtained from this type of analysis may 
indicate abnormalities, but for a comprehensive investigation of disorders smaller 
scale examination is a necessary follow-up method. In an intact analysis, masses of 
globin chains (α, β, δ, γ), their adducts, PTMs including glycation or 
glutathionylation, and additional information can be obtained readily without 
complex sample preparation procedures. Increased complexity arises at the peptide 
level, requiring in-depth data analysis to interpret the results. Globin chains are 
broken down to peptides comprising a maximum of 10-15 amino acids. Analysing 
smaller fragments of the protein can provide sequence information, and may identify 
mutations within the abnormal globin chain sequence, which can also occasionally 
serve as variant specific markers. 
In more details about variant identification: the most widely accepted procedure for 
intact globin chain analysis is predominantly based on the work of Brian Green 
(Green et al. 1990), utilising the protocol developed by Wild et al. (Wild et al. 
2001). This general multi-step approach is the suggested protocol for rapid 
identification of hemoglobin variants first employed the ESI-MS analysis of diluted 
whole blood. Under denaturing conditions the mixture of separate intact globin 
chains and heme groups could be analysed. This step allowed the detection of the 
presence of any abnormal globin chains. In early research publications the  variant 
mass could be resolved on lower resolution instruments and associated with the α 
and β-chain if it differed from the normal globin chain by at least 6 Da, this is not the 
case now when high resolution instruments are more common Based on the 
measured mass difference the possible amino acid substitutions based on single point 
mutations which could be responsible for the mass shift could be determined. A 
second step may involve tandem mass spectrometric analysis of the intact globin 
chains, but generally only when the variant tryptic peptide was not found. A third 
step is the previously mentioned analysis of the peptide mixture produced by 
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enzymatic cleavage with trypsin. Without prior separation observation of an 
additional mass can identify the peptide which contains the variant. Following this in 
a final step the variant peptide can be sequenced by tandem MS to identify and 
confirm the position of the substitution (Wild et al. 2001).  
This multi-step approach requires only a small amount of whole blood (10 µl) and no 
extra pre-analytical steps, such as separation of red cells or chromatographic 
separation of globin chains. The desalting of the samples prior to analysis is advised, 
but not a strict requirement. 95% of the variants in over 250 samples were positively 
identified by this method. The whole process with sample preparation and ESI-MS 
analysis was proposed to require only 1 to 2 hours with minimal reagent costs.  
 
To observe the globin chains as separate entities in the mass spectrum it was reported 
that the mass difference between them would need to be 6 Da or higher (Wild et al. 
2001, Wild et al. 2004). This limitation has been overcome since then with the 
developmemt of high mass resolution instruments and with accurate mass 
measurements. The majority of the clinically significant variants differ by only 1 Da. 
Rai et al has shown that with accurate mass measurement, using the alpha-chain as 
internal mass calibrant the presence of variants differing by 1 Da can be detected 
based on mass shifts caused by the combination of the different mass peaks (Rai et 
al. 2003). The achievable accuracy of the β-globin chain measurement is ±0.1 Da, 
and if a -1 Da β-chain variant is present at 20%, the mass shift caused would be 
expected to be -0.2 Da. An abnormal variant differing by 1 Da from normal should 
be detectable if it is present at >10%. The ESI-MS analysis of intact globin chains 
was proposed to be useful in the newborn screening for the detection of sickle cell 
disease (Wild et al. 2004). Although there is a risk for false positives in cases where 
a variant chain had the same mass as βSICKLE. 
 
A recent review by Zanella-Cleon et al. summarised the different mass spectrometric 
methods which have been used for phenotype determination of hemoglobinopathies 
(Zanella-Cleon et al. 2009). Today 150 variants are listed on the Globin gene server 
for which mass spectrometry provided experimental structural characterisation 
(HbVar, http://globin.bx.psu.edu/hbvar/menu.html).  
Taking only single point mutation leading to single amino acid substitutions into 
account it was shown that only 43.2% of all possible α- and β-chain variants had 
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been detected up to 2007 and 69% up today (Kleinert et al. 2008, HbVar). Kleinert et 
al. predicted that approximately 90% of the possible but up to then undetected 
variants (885 of 962) could potentially be detected by mass spectrometry differing by 
6 Da or more from corresponding wild-type chains. The detection of the resulted 
mass change from mutations like Lys↔Gln or Leu↔Ile is not possible by ESI-MS 
analysis of denatured globin chains. For Lys↔Gln, the mass difference is  only 
0.05Da, which can be identified on peptide or fragmentation level with high 
resolution instruments. The Gln→Lys mutation can be detected on peptide level, as 
the introduction of a Lys creates an additional cleavage site and produces two new 
peptides (Wild et al. 2001).  
Measurement of fusion globin chains like Hb Lepore by mass spectrometry has also 
been shown to be possible. Hb Lepore is a relatively low-expressed variant 
accounting for 5 to 15 % of the total hemoglobin and so it can be challenging to 
detect. De Caterina et al. characterized the different Hb Lepore variants with 
multiple mass spectrometry-based methods analysing the separated hybrid globins 
and their tryptically digested peptide mixture (De Caterina et al. 1992). Rai et al. 
used accurate mass measurement and tandem mass spectrometry of intact globin 
chains to identify the most common Hb Lepore-Boston-Washington variant directly 
from diluted whole blood. This differs by only 2 Da from the normal β-chain variant 
(Rai et al. 2004). They also showed that ESI-MS could be a valuable tool for the 
identification of another fusion variant Hb Kenya (Rai et al. 2002).  
 
Advanced mass spectrometry techniques have proved to be useful in special 
circumstances. Williams et al. showed that the coupling of ion mobility (IM) to MS 
can help in identifying variants present at low abundance (Williams et al. 2008). A 
doubly-charged tryptic peptide from a low abundance variant (4%) was present at the 
same m/z value as a singly- and a doubly-charged interfering ion, and IM was used to 
separate these ions. The approach allowed complete sequencing, and thus the 
characterisation of the variant was possible.  
In another challenging case a variation of ECD (hot ECD) on an FT-ICR was used to 
distinguish between Leu and Ile to identify a novel variant (Williams et al. 2009). 
 
Post translational modifications of hemoglobin result in a certain mass shift, which 
enables them to be studied using mass spectrometry. They often carry diagnostic 
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mass values. The measurement of glycosylated hemoglobin (HbA1c) level has been 
widely used as an indicator for long-term diabetic control for about 30 years 
(Gabbay et al. 1979). There have been attempts in the clinical diagnosis field to 
standardise the analysis of HbA1c as a primary tool for monitoring glycaemic control 
(John and English 2012).  
An ESI-MS procedure has also been developed for the determination of the amount 
of glycated hemoglobin in blood. The relative glycation of the alpha- and beta-globin 
chains was determined (Roberts et al. 1997) and the MS results compared with 
established affinity chromatographic results. A good overall agreement was 
observed. In 2001 Roberts et al. carried out a detailed evaluation of this method over 
a 4 month-period to establish the potential of using ESI-MS as a routine reference 
method for quantification of glycohemoglobin (Roberts et al. 2001). They concluded 
that ESI-MS provided a precise measurement of HbA1c (glycation of the β chain). 
The method has been shown to be robust and could be used as a procedure to 
substantiate HbA1c measurement and/or calibration. 
Nakanishi et al. showed that the presence of a variant can effect routine 
measurement of the glycated Hb, HbA1c. This can lead to an erroneous value 
obtained by HPLC (Nakanishi et al. 2002). Nakanishi et al. analyzed enzyme-
digested peptides and intact globin chains and suggested that MS may offer an 
opportunity to correct these errors. With accurate measurement of the 
glycohemoglobin, MS has the potential to become a routine technique used for 
quantitation of glycated Hb. Kobold et al. developed an approved international 
reference method for quantification (Kobold et al. 1997), based on monitoring 
specific N-terminal peptides of the beta-chain. Investigations were made as to 
whether the glycated and non-glycated beta-N terminal peptides could be analyzed 
instead of measuring the total molecule. They studied the cleavage of the Hb 
molecule with endoproteinase Glu-C, which cleaves the N-terminal portion of the 
beta-chain between two glutamic acid residues. The method specifically measures 
the ratio of the N-terminal hexapeptides of HbA1c and HbA0. The authors found that 
the HbA1c values were lower than those determined with current routine methods, 
and suggested that the ranges normally quoted may have to be revised and adjusted. 
 
There is a growing need for automated screening methods for the detection of 
clinically significant hemoglobin variants. Screening methods and automated variant 
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detection approaches need more definitive identification than determination of 
protein mass shifts on the intact globin chain level, which can lack specificity since a 
certain mass shift could result from the same amino acid substitutions but at different 
positions along the globin chain sequence. A more reliable confirmation can be 
achieved on the peptide level.  
 
An alternative to intact globin chain combined with tryptically digested peptide 
mixture analysis is a targeted method to monitor the presence and level of pre-
specified peptides with a known sequence belonging to specific variants or minor 
globin chains. This targeted method has the potential to be a fully automated mass 
spectrometry-based method that may be incorporated in clinical screening, and is of 
particular interest. Enzymatic cleavage of normal α-globin chain results in 14 tryptic 
peptides (αT1-T14), whilst the β-chain is broken down to 15 peptides (βT1-T15).  
The major disadvantage of this type of experiment is that only known variants and 
their corresponding mutant peptide of interest can be screened for. The advantage is, 
however, that for the presence of those variants which are screened, a definitive 
answer from a single measurement can be obtained.  
Daniel et al. published an approach that demonstrates clear evidence of the rapid and 
specific detection of significant hemoglobinopathies by MS (Daniel et al. 2005). 
They perfomed ESI-MS/MS measurements, and worked in multiple reaction 
monitoring mode on a ESI-triple quadrupole instrument. MRM transitions for 
normal and variant β-chain peptides such as wild-type T1, HbS T1, HbC T1, wild 
type T3, HbE T3, wild type T13, HbO T13 and HbD T13 have been developed. A 
total of 200 blood samples were analysed, comprising of normal hemoglobin 
samples as well as clinically significant variants. All hemoglobin variants were 
correctly identified by MS/MS, in agreement with the existing clinical methods. This 
approach alone provided a simple and rapid solution to high-throughput population 
screening of the clinically significant hemoglobin variants, detected both 
heterozygotes and homozygotes and has the potential to be used in neonatal and 
antenatal screening. In 2007, the method was extended and the authors integrated the 
quantitation of HbA2 (Daniel et al. 2007). The δ:β ratios were measured as potential 
surrogate markers of HbA2, which is used as a biomarker for β-thalassemia. They 
included the δT2, βT2, δT3, βT3, and δT14, βT13 peptides in their previous method. 
Samples were analyzed with normal HbA2 and with elevated HbA2 levels. This 
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method successfully provided reproducible results for differentiating between 
samples with normal HbA2 concentration and those with increased concentrations, in 
excellent agreement with HPLC HbA2 results.  
The developed MRM method outlined by Daniel et al. for detecting a known protein 
variant is based on the following criteria: 
1. The protein needs to be digested to produce a defined series of peptides; 
2. The peptides need to be ionised and an ionised species of known mass-to-charge 
ratio which is indicative of the protein variant is selected by the first quadrupole in 
the mass spectrometer.  
3. The ionised species selected is subjected to collision induced dissociation (in the 
second quadrupole) and one or more of the derived ionised species of known mass-
to-charge ratio measured in the third quadrupole, confirming the presence of the 
protein variant in the sample.  
The peptide containing the variant amino acid is assumed to be indicative of the 
variant protein. If the variant protein differs from the wild-type protein in a way that 
the cleavage site for the used protease changes, one or more new peptides will be 
produced, and those new peptides will be representative of the variant protein. Since, 
in the case of a known variant, the specific ionised peptide to be selected is known, it 
is possible to predict the mass-to-charge ratio of the ionised species to be selected by 
mass spectrometry. The ionised species selected depends on a number of variables, 
including fragmentation efficiency and the ability to distinguish the selected ion 
from those which derived from the non-variant protein. All of these parameters need 
to be considered in order to obtain an optimum level of detection.  
The energy introduced for collision induced dissociation can be varied, thereby 
allowing the degree of dissociation of the selected ionised species to be controlled. 
Low energy fragmentation is preferred since it does not cause substantial 
dissociation of the selected ion. This information can provide further confirmation of 
the presence of the protein variant.  
Multiple reaction monitoring methods allow the accurate and specific detection of a 
protein variant, and so can detect the presence of clinically important hemoglobin 
variants such as Hb S, Hb C, Hb D
Punjab
, Hb O
Arab
, Hb Lepore and HbE, delta/beta 
thalassemia, hereditary persistence of fetal hemoglobin trait (HPFH) and alpha zero 
thalassemia trait.  
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An example of an MRM approach for the confirmation of Sickle cell mutation is 
detailed in the following. The mutation occurs at position 6 of the beta chain and it 
affects the first tryptic peptide βT1; Daniel et al. worked on suitable MRM 
transitions for wild-type and sickle cell beta T1 peptides. They chose the doubly 
charged peptide ions in both cases as precursor ions: for wild-type βT1 peptide the 
[M+2H]
2+
 is m/z 476.8 and for the HbS βT1 is m/z 461.8. The fragment ions which 
are monitored in the third quadrupole are the y4 fragment ions. The y4 fragment ion 
of the control T1 peptide is m/z 502.2, and of the sickle T1 peptide is m/z 472.3 . 
Peaks are detected when the MRM transition of [M+2H]
2+
 = m/z 461.8 ion to the 
singly charged y4 ion at m/z 473.2 occurs; this is used to demonstrate that the blood 
contains the variant sickle cell peptide. A schematic diagram of the MRM approach 
for both peptides can be seen in Figure 1.18. 
 
 
 
Figure 1.18. Schematic of the MRM transitions used for detection of sickle cell 
mutation.  
Adapted from (Zanella-Cleon et al. 2009)  
 
For clinically significant variants the mutation occurs, in most cases, in the T1, T3 
and T13 tryptic peptides. For the determination of delta/beta ratios, we can use those 
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chains (T2, T3, T5, T10, T12, T13). MRM can be applied in all cases when a unique 
transition exists which is characteristic for the variant peptide.  
Another MRM-based method for clinically significant variant detection has been 
developed and proposed for newborn screening by Boemer et al. (Boemer et al. 
2008, Boemer et al. 2009). During a 3-year validating period with the analysis of 
about 44,000 samples they proved this method could provide an efficient alternative 
approach in neonatal screening (Boemer et al. 2011).   
 
Multiple reaction monitoring has also been used for the quantification of 
glycohemoglobin. Unique MRM transitions have been used to characterise the 
glycated and non-glycated hemoglobins present in the sample (Willekens et al. 
2000). β-N-terminal hexapeptides of HbA1c and HbA0 were obtained by enzymatic 
cleavage of the intact hemoglobin molecule with endoproteinase Glu-C and then 
doubly charged precursor and singly charged product ion pairs of m/z 347/237 for 
non-glycated and m/z 428/245 and for glycated hexapeptides. Samples were analysed 
using the LC-ESI-MS (SIR) reference method and by the MRM approach. The 
results of the two methods were found to be comparable.  
 
A single-step approach for the Hb variants has been developed by Basilico et al. 
(Basilico et al. 2007). Their method is a proteomic-like approach, offering data 
dependent MS/MS analysis of tryptically digested peptide mixture of diluted whole 
blood after separation with HPLC. The experimental MS data is compared to 
theoretical mass spectra generated form an in-house built database. The database 
contains variant tryptic peptides of known human variants based on the HbVar 
database (Hardison et al. 2002, HbVar).  
 
In the review by Zanella-Cleaon et al. the potential to use top-down protein 
identification with ETD fragmentation techniques was also mentioned (Zanella-
Cleon et al. 2009). Recent publications have shown that it can indeed provide a 
future direction for Hb variant identification. The combination of direct surface 
sampling of dried blood spots with tandem mass spectrometry has been used for the 
identification of unknown variants on an Orbitrap instrument (Edwards et al. 2011, 
Edwards et al. 2012). This method had the advantage of directly analysing samples 
from newborn blood spots without prior sample preparation. The application of an 
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LC coupled top-down approach on a lower cost 3D ion trap also has been shown to 
give unambiguous identification of clinically significant variants and shows potential 
for future clinical laboratory screening applications (Graca et al. 2012). 
 
The application of MS in combination with other methods such as electrophoresis, 
IEF, and ce-HPLC has been shown to be very powerful, because a wider range of 
variants can be detected and identified (Troxler et al. 2012). 
Although MS has been shown to be capable for high-throughput population 
screening of hemoglobinopathies, and it has been used for the analysis of larger 
clinical sample-sets, it is not yet a validated primary clinical laboratory diagnosis 
tool.  
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1.4 Project aims 
 
The primary aim of the project is to show how mass spectrometry can provide a 
single analytical platform, with the potential to replace the combination of 
techniques currently used in antenatal screening, while saving time and money.  
The objective is to improve existing mass-spectrometry-based methods, develop 
novel approaches and make them as automated and straightforward as possible to 
assess their suitability for high-throughput screening of clinically significant 
hemoglobin variants and offering the option for occasional identification of novel or 
silent variants.  
The combination of developed approaches, or preferably a single method will be 
able to provide a simple and rapid solution to high-throughput population screening 
of structural hemoglobin variants, thalassemias and glycated adducts.  
Primary aim is to develop a mass-spectrometry based approach which is: fast, 
sensitive; accurate, financially competitive with existing approaches; more 
comprehensive than current methods and capable of detecting all known and 
previously unidentified single-point mutation variants.  
This approach is proposed to be easier-to-use and require less interpretation meaning 
that less expert staff are required. If all these expectations are met, the developed 
approach could be routinely applied in the everyday population screening. 
 
 To develop mass spectrometry-based approaches based on previously 
published MRM and full scan mode methods, develop MRM transitions for 
novel peptide pairs, which has not been applied for screening purposes 
before. 
 Assess the suitability of different methods, compare their results to evaluate 
which method is the most appropriate for screening purposes and needs 
further development 
 Test the developed methods on a larger set of clinical samples, assess 
robustness and agreement with current clinical screening methods. Methods 
will be tested on a larger set of antenatal samples, which has not been 
presented in the literature before.  
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 Develop novel tandem mass spectrometry-based method utilising ETD  with 
alternative fundamental aspects to previously published methods, which 
apply chromatographic separation and SIR type detection, while monitoring 
only specific reporter fragment ions for all clinically significant variants 
could provide a less time-consuming screening method.  
 Test the novel ETD method on clinical samples and assess agreement for 
clinically significant variant detection with current clinical method 
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1.5 Research and Conference Papers 
The work has been presented at the following conferences: 
 
Krisztina Radi, Charlotte A. Scarff, James H. Scrivens. A mass spectrometry-based 
approach to hemoglobinopathy detection. BMSS Annual Meeting 2010, Cardiff, UK 
 
Krisztina Radi, Charlotte A. Scarff, Susan E. Slade, Nisha A. Patel, James H. 
Scrivens. The development of rapid diagnostic approaches for the characterisation of 
hemoglobin disorders. Proc. 59
th
 ASMS Conf. on Mass Spectrometry and Allied 
topics, 2011, Denver, USA 
 
Krisztina Radi, Baharak Vafadar-Isfahani, Jane Newbold, Nicholas Jackson and 
James H. Scrivens. Mass spectrometry-based approaches to the diagnosis of 
hemoglobinopathies. Warwick Mass Spectrometry 80/60 Conference, 2012, 
Coventry, UK 
 
Krisztina Radi, Baharak Vafadar-Isfahani, Jane Newbold, Nicholas Jackson and 
James H. Scrivens. Automated quantitative mass spectrometry-based approaches for 
the diagnosis of beta thalassemia in a clinical trial setup. MSACL 2013 - Mass 
Spectrometry Applications to the Clinical Laboratory, San Diego, CA, United States 
 
James Scrivens, Krisztina Radi, Baharak Vafadar-Isfahani, Julia Smith, Jane 
Newbold, Nicholas Jackson. Development of a mass spectrometry based approach 
for the diagnosis of hemoglobinopathies. Proc. 61
st
 ASMS Conf. on Mass 
Spectrometry and Allied topics, 2013, Minneapolis, USA 
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2.1 Introduction 
 
As presented in previous chapter mass spectrometry can provide definitive 
information regarding the masses of the globin chains, location of mutation points 
and confirm the presence of known variants. Current methods based on UV or 
electrophoretic responses are based on pre-identified information, such as retention 
time for UV chromatograms and can only give presumptive diagnosis (Bain 2011). 
Since MS is not a routinely applied screening technique yet, methods need to be 
further developed and evaluated.  
The protocol of variant identification using ESI-MS consists of as detailed by Wild 
et al. needs to be optimized to be applied in an automated manner tobe approved as a 
population screening method(Wild et al. 2001). This is necessary approach for 
identification of unknown variants, therefore it is advised to include it in the 
developmental work. For screening purposes of the clinically significant variants the 
absolute confirmation is also essential and can be performed with further developed 
targeted peptide monitoring achieved by MRM approaches.  
Quantitation of the different minor globin chains is important to monitor healthy 
levels of proteins in blood. The accurate quantification of hemoglobin A2 is essential 
to diagnose β-thalassemia trait. Precision is crucial since the difference in HbA2 
concentration between normal and elevated is narrow, and the upper limit for normal 
has been set at 3.5% (Higgins et al. 2009).  
The quantitation of delta globin chain from the mass spectrum of the denatured 
protein globin chains is based on the assumption that the relative intensities obtained 
after deconvoluting multiple charged envelopes to true mass scale are proportional to 
the concentrations of the proteins (chains) (Roberts et al. 1997). 
 
Based on Roberts et al. work, it is straightforward to investigate whether the 
measurement of intact proteins in diluted whole blood using ESI-MS could allow for 
the easy and rapid quantitation of minor hemoglobin A2, through quantifying the 
intensity of the delta globin chain relative to that of the beta globin chain in the mass 
spectrum. The analysis of diluted whole blood by direct infusion may provide an 
attractive solution for population screening, without the additional cost of utilising 
chromatographic separation or enzyamtic cleavage steps.  
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Aims and objectives 
 
Mass spectrometry is a powerful technique, which can be used for the identification 
of Hb variants, screening for thalassemias and also for quantification of HbA2 and 
glycated hemoglobin. These different applications have, however, not been 
integrated on a single platform. While an MRM approach can identify known 
variants, it is not possible to screen for all potential 1000 single point variants in a 
reasonable-time scale and the method cannot identify novel variants, therefore 
additional measurements are necessary.  
MS has not yet become an established clinical screening method in this field due to 
the required background knowledge for the interpretation of results in more complex 
cases. Processing of MS data requires software-based solutions, and/or the usage of 
an in-house-built database (Basilico et al. 2007). These solutions can make the 
analysis easier, more automated and provide integration of prior knowledge. The aim 
is to develop MS methods which can be easily automated, and applied in high-
throughput screening with the potential of automated data processing and reporting. 
 
The work presented in this Chapter aims to: 
 
 Develop mass spectrometry based approaches for the diagnosis of hemoglobin 
disorders based on previously published methodologies for available mass 
spectrometry instrumentation.  
 Implement different methods on the same platform; these methods should be fast, 
sensitive, accurate, financially competitive with existing approaches, more 
comprehensive than current methods and capable of detecting most known and 
previously unidentified single-point mutation variants.  
 Test methods on reference standards or a set of clinical samples, where available. 
 Optimise methods and sample preparation for high-throughput screening 
applications in preparation for a clinical trial, which will involve the analysis of 
hundreds of samples per calendar week.  
 To assess the suitability of two different triple quadrupole mass spectrometers 
(Waters Acquity TQD and Waters Xevo-TQ) and corresponding data processing 
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software (QuanLynx
TM
 and TargetLynx
TM
) to obtain the highest level of 
automation possible. 
 To assess the need for further optimisation of the different methods 
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2.2 Materials and methods  
 
Origin of analysed samples 
 
For method development, commercial lyophilized HbA0, HbS and HbA2 samples 
were used (Sigma Aldrich). For assessing glycated hemoglobin measurements a 
ClinTest reference standard with known concentration of HbA1c (11011, RECIPE 
Chemicals + Instruments GmbH, Munich, Germany), and for delta chain level 
determination the WHO 1
st
 international reference reagent for HbA2 (89/666, 
National Institute of Biological Standards and Control) were used. For method 
testing, final optimisation and the identification of unknown variants; patient blood 
samples provided by the Haematology Department at University Hospitals Coventry 
and Warwickshire NHS Trust were measured (in collaboration with Dr Nicholas 
Jackson).  
The samples analysed are summarised in Table 2.1.   
 
Sample origin Number of 
samples 
analysed 
Sample type Purpose of analysis, applied 
MS-approach 
Standard – Sigma 
Aldrich 
3 
HbA0, HbA2, HbS 
lyophilised powder 
Method development 
Standard - 
NIBSC 
1 
Lyophilised HbA2 standard 
with HbA2 level 5.3% 
Control 
Standard – 
ClinTest 
1 HbA1c standard 9.3% Control 
Clinical samples 
- Birmingham 
60 
Clinical samples from 
individual patients with no 
previous information  
Testing MRM 1 method on 
clinical samples 
Clinical Samples 
-UHCW 
94 
Clinical samples from 
individual patients, 
information about disease 
conditions and HbA2 levels 
by ce-HPLC 
Testing Intact and MRM 2 
method on clinical samples 
Clinical Samples 
UHCW 
3 
Samples from patients 
with unidentified Hb 
variants 
Identification of rare variants, 
testing the used protocol 
 
Table 2.1. Summary of samples used for different applications during method 
development  
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A batch of samples were also provided by Dr. Patel (University of Birmingham, 
Centre for Cardiovascular Sciences), which was used in the early testing with the 
first developed MRM-method. 
 
2.2.1 Sample preparation  
 
Two main types of sample preparation were necessary for the analysis of intact 
chains and tryptic peptides. The sample preparation steps are described here for 
different applications used during the method development procedure. 
 
2.2.1.1 Intact globin chain analysis  
 
The healthy range of hemoglobin concentration in blood of adult women is 115 to 
165 mg/mL and for men 130 to 175 mg/mL. For 3 months old babies only 95-135 
mg/mL and for children up to 12 years it is lower at 105 to 145 mg/mL (NHS 2013). 
Based on these values, standard stock solutions were prepared at 3 mg/mL in 
deionised water to obtain a hemoglobin concentration similar to that of a 50-fold 
diluted whole blood sample.  
In the case of anonymised patient blood samples, stock solutions were prepared as 
follows: 20 µL of blood was diluted in 980 µL deionised water, and stored at -20ºC.  
For intact globin chain analysis, 20 µL of stock solution was diluted 20-fold in 380 
µL 50 % ACN containing 0.2 % formic acid. For the purpose of high-throughput 
analysis using the Nanomate, 280µL of these dilutions were transferred into 96 well 
plates with a 350µL well volume. The Triversa Nanomate is a chip-based 
electrospray ionization technology from Advion (Advion Biosciences Ltd., Ithaca, 
NY, USA).  
 
Prior to intact mass analysis, samples were desalted either by agitation for 5-10 
minutes with approximately 3-5 mg of AG 50W-X8 cation-exchange beads (Bio-Rad 
Laboratories) or with use of Amicon Ultra-0.5mL Centrifugal Filters with a 
membrane cutoff 10kDa (Merck Millipore).  
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2.2.1.2 Peptide analysis  
 
Variant identification on the peptide level: 
 
Tryptic digestion was performed according to the protocol published by (Wild et al. 
2001) 200 μL of stock solution was mixed with 20 μL of 50% ACN containing 0.5% 
formic acid, 6 μL of 1 M ammonium bicarbonate solution and 5 μL of 5mg/ml 
trypsin (from bovine pancrease TPCK Treated, lyophilized powder, Sigma Aldrich) 
solution, incubated for 1 hour or in some cases overnight at 37°C.  
 
Targeted peptide analysis by MRM method 1 
 
For initial method development commercially purchased lyophilised HbA0, HbS and 
HbA2 were used. Tryptic digested peptide mixtures were prepared following the 
previously described protocol. The digests were diluted 10 or 20-fold prior to direct 
infusion into the standard ESI-source of the Acquity TQD system (Waters 
Corporation, Manchester, UK). 
In order to test the method on clinical samples a batch of blood samples by Dr. Patel 
(University of Birmingham, Centre for Cardiovascular Sciences) was provided and 
prepared for analysis by diluting 1 µL of whole blood in 50 µL of water and 10 µL 
of 50 % ACN containing 0.5 % formic acid within a 96-well plate. Tryptic digestion 
was performed to the concentrations outlined in the protocol published by Wild et al. 
The pre-diluted sample solutions were mixed with 3 µL of 1 M ammonium 
bicarbonate solution and 2.5 μL of 5mg/ml trypsin (from bovine pancrease TPCK 
Treated, lyophilized powder, Sigma Aldrich) solution, incubated overnight at 37°C.  
Prior to analysis by the UPLC-MRM method the digested blood samples were 
further diluted in 266 µL deionised water.  
 
Targeted peptide analysis by MRM method 2  
 
Initial method development and optimisation were performed by analysing standard 
samples with known amounts of tryptically digested HbA0 and HbA2 samples. The 
standard samples were individually digested and then mixed to produce a series of 
mixtures containing 1, 2, 3, 4, 5, 6, 8, 10, 12 and 15% of HbA2.  
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Clinical blood samples provided by UHCW were prepared for analysis by diluting 
200 µL of stock solutions with 40 µL of 50 % ACN containing 0.5 % formic acid. 
Tryptic digestion was performed according to the protocol published by Wild et al. 
(Wild et al. 2001). The pre-diluted sample solutions were mixed with 12 µL of 1 M 
ammonium bicarbonate solution and 10 μL of 5mg/ml trypsin solution, incubated 
overnight at 37°C.  
After incubation, digested samples were centrifuged at 10000rpm (9503 g) for 3 
minutes to remove solid particles and remaining precipitated proteins. Prior to 
analysis samples were further diluted 7-fold in 10% ACN with 0.5% formic acid. 5 
µL of these diluted peptide mixtures were loaded on the LC column for separation.  
The accuracy of delta chain quantification was assessed by measuring digested 
international HbA2 standard using the optimised UPLC-MRM method.  
 
2.2.2 Mass spectrometry and data processing methods 
 
Sample Introduction  
 
Two types of sample introduction were employed in these studies; directly 
introducing the sample into the source of mass spectrometry or after a 
chromatographic separation step. Direct injection can be implemented via a syringe, 
using the fluidic system of the instrument or using an automated sample introduction 
system TriVersa NanoMate (Advion Biosciences Ltd., Ithaca, NY, USA). 
Chromatographic separation and sample introduction were achieved via the Acquity 
UPLC system.  
 
Intact globin chain analysis and multistep hemoglobin variant identification 
 
The use of a triple quadrupole system for the analysis of intact globin chains is 
described and optimized for its application in a high-throughput manner to analyse a 
significant number of samples. For high-throughput applications, sample 
introduction needs to be performed in an automated manner to allow the 
measurements of multiple samples to be carried out 24 hours a day.  
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A Xevo-TQ (Waters Corporation, Manchester, UK) equipped with a standard flow 
ESI source and controlled by MassLynx
TM 
(version 4.1) software (Waters 
Corporation, Manchester, UK) was used for method development and testing on 
standard samples. Samples were introduced into the ESI source from a 250 µL 
syringe at a flow rate of 5 µL/min using a syringe. In other cases the fluidics system 
of the Xevo TQ instrument was used, and 1 ml of sample prepared in a 1.5 ml vial 
which was then introduced to the ESI source again at a flow rate of 5 µL/min. 
For high-throughput method development the Xevo-TQ (Waters Corporation, 
Milford, Manchester, UK) equipped with a TriVersa NanoMate (Advion Biosciences 
Ltd., Ithaca, NY, USA) automated sample introduction system was used to acquire 
data on clinical samples.  
The instrument was operated in ESI positive mode with a capillary voltage of 3 kV, 
cone voltage 40 V and source temperature 150ºC for all experiments.  
The mass analyser was calibrated using the alpha-chain multiple charged peak series 
of a control blood sample.  
Data were acquired through the tune page of the MassLynx
TM
 software for 3 minutes 
in multi-channel acquisition (MCA) mode at a scan speed of 1 spectrum/sec.  
The measured ESI-MS spectrum was background subtracted with a 25-order 
polynomial to allow 5% of the data to fall below the new baseline, this subtracted 
spectrum was then deconvoluted onto a true mass scale by use of a maximum 
entropy based MaxEnt application program, which is available within the MassLynx 
software. The mass output parameters were set for mass range 14800-16800 Da at a 
resolution of 0.15 Da/channel. A Gaussian model was used: peak width 0.8 Da, 40% 
minimum intensity ratios were set and the algorithm was allowed to iterate until 
convergence. The deconvoluted spectrum obtained from MaxEnt was smoothed and 
centred, and a mass correction was applied so that the alpha-chain mass was set to 
the expected 15126.38 Da.  
Samples were assessed for the presence of single-point mutation hemoglobin 
variants, δ-chain and glycation levels. 
 
The TriVersa NanoMate (Advion Biosciences Ltd., Ithaca, NY, USA) automated 
sample introduction system utilises an ESI micro fluidics chip containing an array of 
400 nano-electrospray nozzles. The system was controlled by ChipSoft software. 
Sample introduction was performed with 5 µL spray volumes and 1 µL air aspirated 
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after the sample, spray gas pressure 0.8 psi (later 1psi), a 1.55 kV (later 2.1 kV) 
voltage applied to the tip, sample plate temperature was kept at 15ºC. A 25 second 
delay time was applied for the inlet start sign to be sent to the mass spectrometer 
allowing a stable spray to form.  
Data were acquired in triplicate through use of an automatic sample list. For each 
sample, a three minute acquisition was performed in multi-channel acquisition 
(MCA) mode at a scan speed of 1 spectrum/sec.  
 
To interpret and process raw data measured in the high-throughput analysis 
BioPharmaLynx
TM
 software (version 1.2, Waters Corporation) was used. 
BioPharmaLynx
TM
 allows one to deconvolute multiple spectral outputs, 
deconvolution parameters are set up in the processing method, and results are listed 
in a table format for each processed sample. This way the calculated intensities for 
the different globin chains can be easily extracted. The extraction process of the 
required information needs to be automated to fit to the high-throughput manner of 
the analysis.  
The processing parameters in the BioPharmaLynx
TM
 method were the following:  
A Gaussian damage model was used (an isotope damage model is not available 
within this software package). The mass accuracy was linked to a lock mass of 
1081.46 Da, with a mass tolerance of ±0.5 Da, MS mass match tolerance for 
deconvoluted mass peaks was 80 ppm. Deconvolution parameters: range 930-1210 
Da, protein MW range 14,800-16,800, peak width 0.8 Da. Background subtraction of 
the deconvoluted data prior to deconvolution with a background threshold of 5% and 
a polynomial order 25. The deconvoluted mass spectrum was smoothed with the 
mean algorithm twice with a smoothing window of 6 channels. The spectrum was 
also centred using the top 90% and the areas or the heights of the deconvoluted 
peaks were reported. 
After analysis the count number for intensities of pre-identified masses (at greater 
than 10 % intensity) for the α, β, βSICKLE, δ and glycated globin chains were listed 
and extracted into Microsoft Excel for three replicates of each measured sample. The 
percentages of the δ-chain intensity and glycated α- and β-chain intensity were 
calculated within the software.  
The percentage of glycated hemoglobin present was calculated as described by 
Roberts et al. and shown in Figure 2.1 (Roberts et al. 2001). The determination of 
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glycated hemoglobin level is based on several assumptions. It is assumed that there 
is no significant contribution to glycosylated hemoglobin from other globin chains, 
that all α-chain species have the same sensitivity and that all β-chain species have the 
same sensitivity. The results obtained when these assumptions were applied were 
shown by Roberts et al. to correlate with those obtained by other techniques (Roberts 
et al. 2001). Results shown later in this Chapter suggest that the calculation of only 
beta-chain glycation might be necessary to obtain an estimation of the overall 
glycated hemoglobin level.  
 
 
 
Figure 2.1. Schematic of the direct infusion method for glycated hemoglobin level 
quantitation 
 
Assessment of δ-chain levels was achieved by carrying out a ratio calculation of δ-
chain intensity to β-chain intensity, based on the assumption that the β- and δ-chains 
have similar ionisation efficiencies. This approach uses a δ:β ratio of the intact 
chains to provide a surrogate marker of Hb A2 levels as illustrated by Figure 2.2.  
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Figure 2.2. Schematic of the direct infusion method for delta chain quantitation 
 
A summary of the processes and methods is simplified in Figure 2.3.  
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Figure 2.3. Illustration of the direct infusion method for the intact globin chain analysis and hemoglobin variant identification 
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MS/MS strategy for MRM method development for clinically significant 
variants and HbA2 quantitation 
 
UPLC separation for initial MRM-based method (MRM 1) 
 
The MRM approach requires peptide separation prior to mass spectrometric 
detection. This was performed using an Acquity UPLC system (Waters Corporation, 
Manchester, UK) coupled to the TQD instrument. 
2 µL of diluted peptide mixture was loaded to the Acquity UPLC BEH C18 column 
(1.7µm, 2.1 × 50mm) equilibrated with 95% solvent A at a flow rate of 0.8 ml/min. 
The composition of solvent A was 0.3% formic acid in water, solvent B was 0.3% 
formic acid in acetonitrile. The peptides were resolved by increasing the organic 
solvent concentration from 5% to 13.5% in the first 0.5 minute, then with a quasi-
isocratic step further increased to 13.7% in the following 4 minutes, to 23% in 
another 0.5 min, and finally up to 32% by 6 minute of the run. In the last two 
minutes the organic concentration was increased to 99% to elute all the remaining 
but not monitored components of the mixture and the column was re-equilibrated 
with 5% B at a constant temperature of 40ºC. 
 
Mass spectrometry method 
 
Samples were tryptically digested to produce the necessary peptides. Preliminary 
measurements were necessary to choose the unique peptides to be monitored. 
MS/MS experiments on the chosen peptides were performed to determine the 
optimal parameters to obtain the highest intensity peaks from MRM measurements 
for specific fragmentation routes. Figure 2.4 shows possible unique peptides based 
on sequence differences for the relative quantitation of the HbA/HbA2 ratios. For 
clinically significant variant detection and quantification, the target peptides were 
chosen based on the location of the mutation relevant to the specific variant, as 
detailed in Table 2.2. For sickle cell hemoglobin the first tryptic peptide of the beta 
chain was relevant.  
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Figure 2.4. Differences in amino acid sequences between beta and delta globin 
chains 
 
Name  
Position  
(Tryptic peptide affected 
by mutation) 
Mutation 
Mass Change of the β 
chain (Da) 
Hb S β6 (βT1) Glu→Val -30 
Hb C β6 (βT1 new peptide) Glu→Lys -1 
Hb D-Punjab (or Hb D-
Los Angeles) 
β121 (βT13) 
Glu→Gln -1 
Hb E β26 (βT3 new peptide) Glu→Lys -1 
Hb O-Arab β121 (βT13 new peptide) Glu→Lys -1 
 
Table 2.2. Tryptic peptides affected in clinically significant variant chains and the 
mass shift associated with the mutations.  
 
In order to develop an MRM-based screening method for relevant hemoglobin 
variants, suitable transitions needed to be determined. As the transitions are based on 
fragmentation processes from a precursor ion to a product ion, several MS/MS 
experiments had to be carried out. The peptide ion of interest must be fragmented in 
the collision cell and product ion spectrum acquired. During these product ion scan 
measurements collision energy, collision gas flow, and solvent conditions can be 
optimized.  
Optimization was predominantly carried out on commercially available samples. 
Lyophilized HbA, HbA2 and HbS were used. The solid Hb samples were diluted in 
water to prepare stock solution, and then an appropriate amount of the stock solution 
was digested by trypsin. When using a sequence specific protease such as trypsin, 
the series of peptides produced can be predicted based on the sequence of the 
protein. As the clinically significant variant mutations affect the T1, T3 and T13 
tryptic peptides of the beta chain (Table 2.2), and the beta and delta chains differ in 
the T2, T3, T5, T10, T12, T13 peptides of the beta chain (as shown in Figure 2.4), 
suitable MRM transitions need to be developed for the peptide ions listed in Table 
2.3. As the specific peptide to be selected is known, it is possible to predict the mass-
to-charge ratio of the ionised species to be selected by mass spectrometry. To 
investigate which mass-to-charge values of the predicted ions can be detected, tryptic 
VHLTPEEKSAVTALWGKVNVDEVGGEALGRLLVVYPWTQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDG
VHLTPEEKTAVNALWGKVN VDA VGGEA LGRLLVVYPWTQRFFESFGDLSSPDA VM GN PKVKA HGKKVLGAFSDG
LAHLDNLKGTFATLSELHCDKLHVDPENFRLLGNVLVCVLAHHFGKEF TPP V Q AAYQKVVAGVANALAHKYH
LAHLDNLKGTFSQLSELHCDKLHVDPENFRLLGNVLVCVLARNFGKEFTPQMQAAYQKVVAGVANALAHKYH
75
75
146
146δ 76
δ 1
β 76
β 1
T2 T3 T5
T10 T12 T13
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digested peptide mixtures were measured, looking for the selected ion peaks. These 
can be singly or multiply charged peptides. Fragmentation of doubly charged ion 
species typically require lower collision energies, and these ions are favoured. 
Doubly charged peptides are characteristic of tryptic peptides. One charge is 
distributed on lysine/arginine and other charge is on an amino group; occasional 
additional charges are usually taken up by histidine or happen because of missed 
cleavages. 
50% ACN and 0.2% formic acid was initially used to dilute tryptically digested 
lyophilized blood samples, increasing the acid content of the solvent up to 0.5% 
when necessary. Not all targeted peptides were observable in the spectra, but for 
those with high intensity, tandem MS measurements were performed, and product 
ion spectra were obtained. The solvent composition was altered from 0.1% formic to 
higher formic acid content (0.3% and later 0.5%) to increase chances of generating 
ions for the targeted peptides, to produce doubly charged ions for the peptides of 
interest, and to influence their retention times facilitating their elution at a later time. 
The optimal transitions for MRM method were then selected for evaluation using 
clinical samples.  
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Tryptic 
peptide 
Mutation 
correlated 
Amino acid sequence [M+H]
+
/Da 
[M+2H]
2+
/
Da 
Wild-type 
βT1 
Hb Sickle, HbC VHLTPEEK 952.51 476.76 
HbS βT1 - VHLTPVEK 922.53 461.77 
HbC βT1 - 
VHLTPK 
                    EK 
694.43 
276.16 
347.72 
138.58 
Wild-type 
βT2 
Differs from the 
δT2 
SAVTALWGK 932.5  
Wild-type 
δT2 
Differs from the 
βT2 
TAVNALWGK 959.5   
Wild-type 
βT3 
Hb E, Differs from 
the δT3 
VNVDEVGGEALGR 1314.67 657.84 
HbE βT3 - 
        VNVDEVGGK 
                                   ALGR 
916.47 
416.26 
458.74 
208.64 
Wild-type 
δT3 
Differs from the 
βT3 
VNVDAVGGEALGR  628.9 
Wild-type 
βT5 
Differs from the 
δT5 
FFESFGDLSTPDAVMGNPK  1030 
Wild-type 
δT5 
Differs from the 
βT5 
FFESFGDLSSPDAVMGNPK  1023 
Wild-type 
βT13 
Hb D-Punjab,  
Hb O-Arab 
Differs from the 
δT14 
EFTPPVQAAYQK 1378.70 689.85 
HbO βT13 - 
          K 
              FTPPVQAAYQK 
147.11 
1249.66 
74.06 
625.33 
HbD βT13 - QFTPPVQAAYQK 1377.72 689.36 
 
Table 2.3. List of tryptic peptides and variant tryptic peptides and expected mass to 
charge ratios. (Corresponding peptides are clustered based on what part of the amino acid sequence 
they comprise, first the wild-type peptide present in normal adult hemoglobin)  
 
MRM 1 method using Waters Acquity TQD system  
 
For HbA2 quantitation the corresponding T2, T3 and T5 peptides were chosen. T5 
peptides have not been used for this purpose in the literature up to date. T2 peptides 
were not studied further since the resolved peaks were not suitably intense after 
chromatographic separation in the Acquity TQD system with the applied sample 
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preparation. The chosen MRM transitions can be seen in Table 2.4. Baseline 
separation of the different peptides with the UPLC system was not possible. A multi-
step gradient method was therefore applied, where all corresponding pairs of 
peptides were separated, but only βT2 and δT2 peptides are fully separated from 
each other. This method was used for the analysis of 60 patient blood samples. 
Further optimisation was required from the initial method based on commercially 
available samples. During measurement the ion source was maintained at 150ºC, 
desolvation temperature 320ºC, desolvation gas flow at 800L/hr, and cone gas flow 
at 50L/hr.  
 
Peptide Retention 
time window 
(min)  
Target 
Precursor 
Ion  
(Da) 
Target 
fragment ion  
(Da) 
Cone Voltage 
(V)  
Collision Energy 
(V) 
β T2 2.80-3.30 932.5 (z=1) 
675.4 
774.5 
60 45 
δ T2 1.80-2.10 959.5 (z=1) 
688.4 
787.4 
50 50 
β T3 1.20-1.60 657.8 (z=2) 
887.5 
1002.5 
35 22 
δT3 1.20-1.60 628.8 (z=2) 
829.5 
944.5 
35 25 
βT5 5.40-5.70 1030 (z=2) 
928.5 
1116.5 
35 22 
δT5 5.40-5.70 1023 (z=2) 
1015.5 
1102.5 
35 25 
 
Table 2.4. The developed MRM transitions for T3 and T5 peptides in the beta and 
delta chains of hemoglobin on a Waters TQD . 
 
Data Analysis  
 
QuanLynx
TM
 software (MassLynx
TM
, Waters Corporation, Manchester, UK) was 
used for automated data processing. Examples of peak integration are illustrated in 
Figure 2.5. The processed data were extracted into Microsoft Excel and the 
percentage of δ-chain peptides relative to the sum of all non α-chain peptides 
calculated based on Equation 2.1. Only T3 and T5 peptides were used, since T2 
peptides were not sufficiently intensive to provide reliable values using the 
calculation.  
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          a)      b) 
Figure 2.5. Chromatogram of the MRM channels, integrated for T3 (a) and T5 
peptides (b) 
 
For the δ-chain level determination the following equation was used.  
 
          Equation 2.1. 
 
The scheme for the MRM 1 analysis can be seen in Figure 2.6. 
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Figure 2.6. Scheme of the MRM 1 approach for specific peptide pair relative quantification to obtain estimation of the HbA2 levels 
 
Data Analysis
MS1
Collision
cell MS2
Peptides quantified monitoring specific
fragmentation routes for predetermined
MRM transitions.
Characteristic peaks observed at specific
retention times.
QuanLynx software used  
for automated data 
processing
Integrated peak areas 
from the MRM 
chromatogram used for 
quantification
MS Acquisition
Blood Sample
Sample Preparation for LC-MRM 
analysis
UPLC Separation
RP-LC separation on Acquity UPLC system: Analytical 
Column: BEH™ C18 (2.1mm × 50 mm, 1.7 μm), 
A: Water with 0.3% HCOOH, 
B: Acetonitrile with 0.3% HCOOH
Gradient: 5 – 32% B over 6 min at 0.8 mL/min, 
Total Run time: 8 min
1 μL of blood diluted in 50 μL water , 10 
μL 50 % ACN 0.5 % HCOOH , then 
digested with trypsin , after digestion 
further diluted in water in a 1:5 ratio.
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MRM 2 method using Waters Xevo TQ  
 
UPLC separation for final MRM-based method (MRM 2) 
 
Tryptic peptides were separated by RP-LC prior to MRM analysis. RP-LC 
separation was performed on a standard flow Acquity UPLC system, equipped with 
a C18 column.  
 
5 µL of the diluted peptide mixture was loaded onto the Acquity UPLC BEH C18 
column (1.7µm, 2.1x50mm) previously equilibrated with 98% solvent A at a flow 
rate of 0.8 ml/min. The composition of solvent A was 0.5% formic acid in water, 
solvent B was 0.5% formic acid in acetonitrile. After keeping the composition at 2% 
of solvent B for one minute, the peptides were resolved with increasing the organic 
solvent concentration from 2% to 27% over a 4 minute period, then with a steep 
gradient further increased to 95% to elute all the components of the mixture, and the 
column was re-equilibrated with 2% B for an additional 1.5 minutes at a constant 
temperature of 40ºC. 
 
Mass spectrometry method 
 
For HbA2 quantitation the corresponding T2, T3 and novel T5 peptide pairs were 
chosen, for clinically significant variants the corresponding variant peptides were 
monitored after chromatographic separation in the Xevo TQ system. The optimised 
MRM transitions can be seen in Table 2.5. Full separation of all of the peptides with 
the UPLC system was again not possible, and a linear gradient method was applied, 
where all corresponding pairs of peptides were separated, but only β T2 and δ T2 
peptides were fully separated from each other. During measurement the ion source 
was maintained at 150ºC, desolvation temperature 350ºC, desolvation gas flow at 
900L/hr, and cone gas flow at 50L/hr. 
For all peptides at least 3 MRM transitions were optimised, and where possible, four 
MRM transitions have been chosen to obtain higher specificity.  
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Peptide Retention 
time window  
(min) 
Target 
Precursor Ion 
(m/z) 
Target fragment ions 
(Da) 
Cone 
Voltage 
(V) 
Collision 
Energy (V) 
β T2 3.80-4.29 466.8 (z=2) 390.2 
675.1 
774.2 
18 22 
18 
16 
δ T2 3.51-3.79 480.4 (z+2) 390.2 
688.3 
787.3 
20 22 
18 
18 
β T3 3.30-3.50 657.8 (z=2) 758.4 
887.5 
1002.5 
28 25 
32 
28 
δT3 3.30-3.50 628.8 (z=2) 829.5 
944.5 
1043.4 
25 28 
26 
25 
βT5 4.75-5.02 1030 (z=2) 928.5 
1116.5 
1229.6 
1401.6 
38 30 
32 
35 
35 
δT5 4.75-5.02 1023 (z=2) 1015.5 
1102.5 
1215.6 
1387.7 
35 35 
35 
35 
35 
β T1 2.15-2.40 476.8 (z=2) 237.2 
502.5 
603.3 
716.4 
25 20 
22 
20 
18 
β T1 
HbS 
2.48-2.72 461.8 (z=2) 237 
472.3 
573 
686.2 
25 18 
22 
20 
18 
β T1 
HbC 
1.80-2.14 694.4 (z=1) 237 
244 
345 
350 
40 40 
40 
35 
35 
β T3 
HbE 
2.41-2.50 916.8 (z=1) 214.2 
261.2 
360.1 
40 50 
45 
42 
α T9 (2) 
HbG 
4.3-4.7 771.5(z=3) 708.3 
807.4 
839.4 
1078.6 
35 35 
30 
35 
30 
β T13 
HbO  
3.30-3.50 625.3(z=?) 708.4 
904.5 
1001.6 
25 32 
25 
20 
 
Table 2.5. Tryptic peptide ions and targeted fragment ions on the Xevo TQ 
instrument used for MRM transitions.  
 
Data Analysis  
 
The TargetLynx
TM
 software (MassLynx
TM
, Waters Corporation, Manchester, UK) 
was used for automated data processing. The HbA2 values were calculated on the 
same basis as in the case of the results of MRM 1 method with the use of Equation 
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2.1., and the variant peptides were confirmed with the observation of the presence of 
a peak in the corresponding MRM chromatogram.  
Peptide peak areas were calculated by integrating the smoothed and combined 
chromatogram from all corresponding MRM channels. Results have been exported 
to Excel and area ratio calculations for different corresponding peptides have been 
performed. Standard deviation for 3 replicates and the corresponding coefficient of 
variation percentages have been calculated.  
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2.3 Results and Discussion 
 
2.3.1 HbA2 and Glycated hemoglobin level determination analysing 
intact globin chains 
 
Standard samples with known levels of HbA2 and HbA1c were analysed and used to 
assess the suitability of the proposed quantification process.  
 
HbA2 standard measurement 
 
The NBISC Reference standard with a known concentration of HbA2 (5.3%) was 
used to test the intact globin chain quantitation method to assess the reliability of the 
results. The deconvoluted ESI spectra of three replicates centred based on peak 
intensities and areas provided 4.9% (standard deviation (stdev): 0.2, coefficient of 
variation (cv%): 5) and 6.8% (stdev: 0.3, cv%: 4.5) for HbA2, respectively. The 
percentage calculated based on peak intensities are closer to the actual value, and 
differ only by -0.4%, while the percentage based on area differs by +1.5%. Standard 
deviation and cv% results suggest this measurement is reproducible. Figure 2.7 
illustrates a typical deconvoluted mass spectrum of the standard used for δ-chain 
level calculation.  
 
 
Figure 2.7. Deconvoluted mass spectrum of intact globin chain analysis of 
international reference reagent for HbA2 level determination 
 
mass
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%
0
100
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HbA1c standard measurement 
 
The deconvoluted ESI spectrum was centred based on peak intensities and areas 
provided the following results from calculations using intensities for αG 2.9% (stdev 
0.33, cv% 11.35), for βG 6.3% (stdev 0.33, cv% 5.25) and for (αβ)G 4.6% (stdev 
0.29, cv% 6.31). Results obtained by area calculations for the αG 3.3% (stdev 0.24, 
cv% 7.40) for βG 7.7% (stdev 0.11, cv% 1.42) and for (αβ)G 5.5% (stdev 0.12, cv% 
2.26).  
The quantitative values obtained for different glycated chains and overall 
hemoglobin are significantly different. The α-globin chain glycation value is 
approximately half of the calculated β-chain glycated value. All measured values, 
including the highest glycated β-chain levels, are lower than the theoretical 9.3%. 
The theoretical value describes the HbA1c levels, which is defined as the β-globin 
chain glycated on the N-terminal valine.  
Figure 2.8 illustrates a typical deconvoluted mass spectrum of the standard used for 
glycated chain level calculation. 
 
 
 
Figure 2.8. Deconvoluted mass spectrum of intact globin chain analysis of reference 
standard with known level of HbA1c  
It can be observed on the mass spectrum that the peak corresponding to glycated β-globin chain is 
significantly more intense than the peak corresponding to glycated α-globin chain. 
mass
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Method optimisation on clinical samples 
 
HbA2 level determination 
 
A sample batch compromising 96 samples was analysed, measuring three replicates, 
calculating the percentages, the average of the three replicates and standard 
deviations with corresponding coefficients of variation for each sample. The 
analysed dataset provided comparable HbA2 values to those determined by HPLC 
from current clinical screening settings. There was a total number of 92 clinical 
samples, and sample replicates of HbA2 and HbA1c standards were also included.  
 
The data revealed that delta chain levels were overestimated with a certain bias using 
the ESI-MS method. In the multiply charged peak envelope, mass-to-charge ratios 
originating from delta globin ions and possible salt adducts of ions can overlap. Poor 
resolution of these ions may have an adverse effect on quantitation following 
deconvolution. It was therefore hypothesised that the intensity of these interfering 
ions could be reduced with the application of desalting techniques. The phenomenon 
was assumed to cause more erroneous results where samples had been stored for a 
relatively long period of time. Here the results were obtained from relatively fresh 
samples, which were analysed within one to two weeks after the blood was taken 
from the patient, and stored at 4ºC. 
 
Desalting techniques were evaluated using fresh clinical samples. The calculated 
HbA2 levels can be seen in Figure 2.9 a) with and without desalting the samples with 
cation exchange beads. Desalting samples with spin columns was not performed on a 
bigger sample set as it would significantly increase the cost of the analysis.  
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a) b) 
Figure 2.9. Results of 15 samples analysed with (blue dots) and without (red dots) 
desalting prior to analysis (a) and showing the correlation calculations by plotting the 
results of different sample preparation methods against each other (b) 
Correlation between calculated values from the MS measurement to the cation exchange 
chromatography measurements are similar with and without the desalting step in sample preparation. 
 
 
Plotting the results of the desalted and untreated samples against HPLC results 
demonstrates that the difference in the values and their distribution is not significant. 
Plotting the two set of results against each other the correlation was investigated in 
figure 2.9 b). The untreated samples resulted in slightly higher HbA2 levels, but there 
was no systematic difference between the results for the two types of sample 
preparation. For the purpose of minimising the sample preparation and analysis time 
it was decided that the analysis of further clinical samples would not include a 
desalting step.  
 
For the automated sample introduction with the NanoMate system, a particle-free 
sample solution was necessary to prevent blockage of the nozzle, which would 
terminate the formation of sample spray during measurement. To avoid blockage, 
samples were centrifuged and the effects of this step on delta chain level quantitation 
were assessed by comparison of calculated values for 24 clinical samples. The 
results of this comparative analysis can be seen in Figure 2.10. 
The difference shown in figure 2.10 a) is not significant, but the values are slightly 
lower for the samples which had been centrifuged. The correlation between the two 
sets of data is good, with a few values further away from the fitted trendline as 
swhown in figure 2.10 b). It was observed that centrifuged samples blocked the 
y = 1.5235x - 0.8275
R² = 0.8027
y = 1.3333x + 0.1022
R² = 0.7965
0
1
2
3
4
5
6
7
0 1 2 3 4 5 6 7
In
ta
ct
 M
S
 C
a
lc
u
la
te
d
 H
b
A
2
%
ce-HPLC HbA2 %
MS - DS  - HbD% MS - HbD%
y = 1.0045x - 0.4028
R² = 0.736
0
1
2
3
4
5
6
7
0 1 2 3 4 5 6 7
In
ta
ct
 M
S
 c
a
lc
u
la
te
d
 H
b
A
2
%
 -
d
e
sa
lt
e
d
Intact MS calculated HbA2% - Not desalted 
CHAPTER 2 – METHOD DEVELOPMENT 
91 
 
nozzle less frequently and therefore it was decided to include this extra 
centrifugation step in the sample preparation.  
 
a) b) 
Figure 2.10. Results of 10 samples analysed investigating the effects of centrifuging 
prior to analysis plotted against HPLC determined HbA2 values (a) and showing the 
correlation calculations by plotting the results against each other (b) 
Correlation between calculated values from the MS measurement to the cation exchange 
chromatography measurements are similar with and without the centrifugation step in sample 
preparation. 
 
 
Figure 2.11. Results of 92 samples - intact globin chain analysis determined HbA2 
values plotted against HPLC values 
 
The analysis of a larger clinical sample set showed a similar correlation to the HPLC 
values as the results obtained with smaller sample numbers during sample 
preparation optimisation experiments.  
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The determined HbA2 levels by intact MS analysis of blood samples plotted against 
HPLC values are shown in Figure 2.11. The method provided values distributed in a 
fairly wide range around the expected values provided by HPLC. The calculated 
levels are usually higher than that expected. Samples with known elevated HbA2 
levels resulted also in relatively higher levels obtained by MS. The MS method 
provides a good indication of sample abnormality. For a statistically relevant normal 
range of healthy levels based on the MS technique, a larger sample set needs to be 
analysed. The average coefficient variation for the delta-chain level was calculated to 
be 10.3%. This reproducibility may be considered as good for biological sample 
analysis.  
 
The error of experimental masses to theoretically expected masses  
 
Based on the literature, error in α- and β-chain measurement could be used to 
indicate the presence of an α- or β-chain variant (with a mass shift 6 Da or less).  
The presence of structural variants resulting in a mass shift of more than 6 Da is 
assumed to be readily visible on the deconvoluted mass spectra by the presence of an 
additional peak at greater than 20 % intensity. (Note that the used instrument here is 
a low resolution instrument, therefore the mass shift needs to be higher than a certain 
observable mass difference.) 
In Figure 2.12 (a) the experimental mass errors can be seen for 96 samples and three 
replicates for alpha-chain and beta-chain mass errors. The majority of the mass 
errors are between 0.1 and 0.4 Da, and the alpha-chain mass errors are generally 
higher than those ones calculated for beta-chain mass measurements.  
It is generally observed that there is a higher chance to have a β-chain variant than an 
α-chain variant, all monitored clinically significant variants are β-chain variants, so it 
is more likely that the α-chain mass is the true mass corresponding to the normal α-
chain. Note, if there is a mass difference believed to be a result of a -1 Da β-chain 
variant, and after thorough investigation there is no variant identified, the possibility 
of the presence of a ±1 Da α-chain variant will be investigated. With this assumption 
of the alpha-chain masses being correct, adjustment to beta-chain mass error can be 
applied with the deduction of alpha-chain errors. The corrected beta-chain errors can 
be seen in Figure 2.12 (b). This adjustment places the majority of the mass errors of 
this dataset between 0 and -0.4 Da, slightly higher than the ±0.1 Da mass accuracy 
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reported by Rai et al. (Rai et al. 2003). There is an observed mass error difference 
seen in case of the calculated α- and β-chain masses. This difference may be 
explained with the processing parameters. The α-chain is used as a calibrant before 
the measurements and also one of the multiply charged mass peaks belonging to the 
α-chain is used as a lock mass. These settings would affect the calculated masses for 
the α-chain differently as they do for the β-chain masses. To obtain similar mass 
errors for both chains further investigation and optimization of the processing 
parameters is advised.  
 
  
a) b) 
Figure 2.12. (a) Mass errors of different globin-chains resulted from the analysis of 
96 samples in three replicates, and (b) corrected mass errors of beta globin-chain 
black dots for normal samples, red for sickle variants, and yellow for -1 Da variants diagnosed in the 
hospital lab  
 
Samples with a much higher mass error may be explained as clinically significant 
variants, but not in every case, and at this stage it is not advisable to be dependent on 
these values for diagnosis. These error values may give erroneous results, although 
in some cases they may indicate the presence of a variant correctly.  
The diagnosed variants have not resulted in higher than average mass errors in all 
cases. The sickle variant differs by -30 Da to normal β-globin chain mass. Based on 
the hypothesis that -1 Da variants will shift the masses by 0.1 Da if they are present 
at least at 10%, the presence of sickle variant should not affect the mass accuracy. 
For two of the sickle samples no significant outstanding mass error is observed. For 
one sickle sample there is an observed mass error of +0.3 Da. This sample was 
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homozygous for the sickle variant, with a low level of normal beta-chain, which had 
potentially remained in the patient’s blood system after a previous blood-transfusion. 
Since the level of the normal β-chain is low the observed mass difference is not 
considered abnormal.  
The samples diagnosed with HbC, HbE or HbD-Punjab variants by clinical methods 
did not show significant mass errors in every case. Six samples were diagnosed as 
clinically significant -1 Da variants. Three of these samples were confirmed by MS 
to have one of each mentioned conditions ( HbC, HbE and HbD ). Two of the other 
three samples were identified as carriers of a +14 Da α-chain variant, HbG-
Philadelphia. The third sample classed as HbD-Punjab carrier was not confirmed to 
have this condition on the tryptic peptide level analysed by high-resolution MS.  
 
The observed error distributions of different mass measurements are illustrated by 
box plots in Figure 2.13. The three different box plots show in which ranges the 
majority of these mass errors can be found. It is clear, that α-chain mass errors are 
generally higher than β-chain mass errors, and that the corrected mass errors for the 
β-chains are below zero.  
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Figure 2.13. Mass error distribution of the globin chains separately and adjusted 
beta-chain errors.  
 
The samples with green stars are within the 1.5 IQR (interquartile range) from the 
upper and lower quartiles distributed around the mean difference. Looking at only 
the corrected β-chain mass errors four samples are outside of the acceptable range, 
including those three samples which were observed to be abnormal in Figure 2.12 (b) 
(yellow squares). 
Based on these results it can be proposed that intact mass error values may be 
indicative for the presence of -1 Da variants, if the values fall outside of the 1.5 IQR  
of the upper and lower quartiles for a certain local distribution of the mass errors of 
normal samples.  
 
HbA1c level determination 
 
As mentioned previously, intact globin chain analysis can provide an estimation of 
glycosylated hemoglobin levels. Calculations were performed to obtain estimated 
glycation levels for the globin chains separately and for the overall glycation 
assuming that glycation occurs at the same rate on both chains. There were no 
accessible values measured by screening methods, therefore calculated values could 
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not be correlated to predetermined HbA1c levels. The ClinTest HbA1c standard was 
included in the sample set to obtain an estimation, or a correction factor based on the 
levels determined by the measurement of the standard with known levels of HbA1c. 
The HbA1c level of the standard was 9.3%. The measured values for the standard 
were largely under estimated as previously at 3.9%, 8.4% and 6.1% for alpha-chain, 
beta-chain and united respectively. The calculated value for the glycated beta-chain 
level was closest to the expected value. The combined value from both chains was 
much lower due to the fact that the alpha-chain glycation levels were less than half 
the expected 9.3%. Plotting all the calculated results in ascending order for all three 
calculated levels, the general trends observed are similar in Figure 2.14.  
 
 
 
Figure 2.14. Calculated glycation levels for separate globin chains and based on the 
average glycation originated from both chains (average of 3 replicates) 
 
There are some examples where opposite deviating values were observed, but were 
compensated to an average level by the combined calculation.  
Assuming that the beta levels are more reliable and closer to actual values, the 
combined calculation can give incorrect results. This observation would benefit from 
further investigation. Assuming that alpha- and beta-chains are glycated at a similar 
rate, one would assume there is significant correlation between the values obtained 
for the different globin-chains. To test this correlation calculated glycated beta levels 
were plotted against glycated alpha-chain levels. The result can be seen in Figure 
2.15. 
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Figure 2.15. Correlation analysis between calculated glycation levels of the different 
globin chains  
 
For a high proportion of the samples this hypothetical correlation seems to be 
confirmed, but there are samples where the elevated glycated beta-chain levels are 
observed. This indicates there may be a requirement to establish whether both chains 
can be used to contribute to the calculation of glycation levels. 
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2.3.2 Targeted peptide analysis 
 
2.3.2.1 Initial method developed for delta chain quantitation on a Waters TQD 
system – MRM method 1 
 
The results for mixed digests of HbA0 and HbA2 demonstrate good correlation (R
2 
= 
0.995) with the expected values for the calculated HbA2 levels. Calculated average 
values are presented with error bars of the standard deviation across 3 replicates for 
quantitation determined using T3 peptides in Figure 2.16.  
The measured and calculated values for T3 peptide ratios are double that of the 
expected HbA2 levels, but the correlation between theoretical and calculated values 
suggests that the method may provide a good indication of HbA2 levels relative to 
HbA present in patient blood samples. The average coefficient of variation for T3 
peptide ratio calculations was 17%, and for method validation of mass spectrometry-
based clinical applications the requirement is to be below 15% (Kollipara et al. 
2011). 
The calculated values for T5 peptide ratios are closer to the expected HbA2 levels, 
than the T3 ratio results, as shown in Figure 2.17. The average coefficient of 
variation for T5 peptide ratio calculations was 19%, again higher than the required 
15%.  
The slope of the gradient in both cases suggests the future measurement of a 
reference standard may be required to adjust measured values to get real HbA2 
levels.  
 
CHAPTER 2 – METHOD DEVELOPMENT 
99 
 
 
Figure 2.16. HbA2 calculated levels based on T3 peptide ratios - average from 3 
replicates  
R
2
 value is 0.995, which is promising for method evaluation, although error of the measurements are 
noticeably high for some of the values.  
 
 
Figure 2.17. HbA2 calculated levels based on T5 peptide ratios - average from 3 
replicates 
 
Although the method at this stage did not meet all the requirements for a competitive 
mass spectrometry-based method to be used in clinical screening, it was tested on 
clinical samples to evaluate the effects of the complex biological matrix.  
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60 patient blood samples were analysed at the peptide level. It is possible that the 
biological matrix could introduce interfering ions, which may make quantification 
difficult. Results are shown in Figure 2.18 for T3 (a) and T5 (b) peptides. There was 
no preliminary information provided about the actual values regarding HbA2, but 
samples were analysed by intact globin chain analysis in our lab by Charlotte Scarff, 
and the same three samples showed elevated HbA2 levels by T3 peptide ratio 
calculations as the intact globin chain analysis. The T5 peptide results show elevated 
levels for only two samples, and did not show significant increase compared to 
average levels in the case of the third sample. The majority of the calculated T3 
values were between 4-6 %, with the elevated levels above 8%, for the T5 peptides 
the majority of the produced results were between 1.5 and 3%, elevated levels at and 
above 4%. This was to be expected for both when considering the correlation 
indicated in Figure 2.16. and 2.17.  
 
 
Figure 2.18. Calculated percentages for the 60 clinical samples based on T3 (a) and 
T5 (b) peptide ratios  
 
Based on observed values when measured the premixed samples with known 
theoretical HbA2 levels, it is expected that the T5 peptide ratios will be lower than 
T3 peptide ratios. The T5 peptides of the different globin chains are structurally 
more similar to each other than T3 peptides, since for the latter the differing amino 
acids are on the different end of the polarity scale, while for the T5 peptides Ser and 
Thr are both amino acids with polar sidechains. 
The significant difference observed between values of corresponding peptide ratios 
was assumed to be due to the varying ionisation efficiencies of different peptides. 
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Average CV values are based on two measurements for T3 peptides 12.6% and for 
T5 peptides 21.6%.  
This method showed promise for clinical applications at this stage, but needed 
further development and optimisation. It has been demonstrated that the method is 
capable of detecting elevated levels of HbA2. The measurement of a standard, with 
known levels of HbA2, is necessary to obtain correction factors for these peptide 
ratios from which true δ-chain levels may be calculated. 
Whilst the method has been shown to be able to indicate the presence of β-
thalassemia when δ-chain intensities are significantly outside the normal range, this 
may not be the case when slightly elevated δ-chain levels are present. Further 
development work was necessary, with special focus on the novel T5 peptides.  
Measurements need to be conducted on blood samples, where HbA2 levels have been 
previously determined by the validated ce-HPLC method currently used in the 
clinical laboratories.  
 
2.3.2.2 Optimized Method for Clinical Sample Analysis on a Waters Xevo 
system – MRM method 2  
 
HbA2 quantitation 
 
The previously presented MRM method has been adapted and further optimised on a 
Waters Xevo TQ system. The new method has also been further developed to 
monitor the presence of certain characteristic peptides of clinically significant 
variants.  
The results for mixed protein digests of HbA0 and HbA2 demonstrate a good 
correlation to expected values for the calculated HbA2 levels with significantly lower 
error values than with the previous method. The calculated results plotted against the 
theoretically expected values are shown in Figure 2.19. R
2
 values are 0.982, 0.998 
and 0.989 for T2, T3 and T5 peptides respectively. The values for T2 peptide ratios 
are the highest, slightly above expected, the T5 peptides give the closest values to 
expected, while the T3 peptides slightly underestimate the theoretical HbA2 levels. 
This was to be expected when the structural similarities between T5 peptides and 
between T3 peptides from the different globin chains were investigated.  
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Figure 2.19. Calculated percentages based on T2, T3 and T5 peptide ratios shown 
against the theoretically expected HbA2 level  
R
2
 values of 0.98-0.99 are promising for method evaluation, the differences between the slope of the 
gradients for different peptides highlight the need for the measurement of a standard for accurate 
HbA2 level determination to get realistic quantitative results 
 
 
A smaller sample set comprised of 20 patient blood samples were analysed using this 
method, and HbA2% was calculated using integrated peak area ratios of the 
corresponding peptides of beta and delta-chains.  
The results demonstrate excellent correlation to the ce-HPLC values as illustrated in 
Figure 2.20. The T2 peptide pair had slightly higher values than expected, the T3 
peptides had slightly lower values, and the novel determination of T5 peptide ratios 
were closest to the expected values. This is the same tendency as observed. This was 
expected based on previously reported results and observations by Daniel et al, who 
used a reference standard to calculate correction factors for all corresponding peptide 
pairs to calculate values which were not biased by ionisation differences between 
peptides (Daniel et al. 2007) 
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Figure 2.20. Calculated δ-chain % (HbA2 levels) for 20 clinical samples as results of 
a preliminary testing calculated based on three different peptide ratios 
 
 
To further evaluate the method a larger sample number was analysed under the same 
conditions.  
96 samples including 4 standards (previously analysed by intact globin chain 
method) were enzymatically digested by trypsin and analysed using the MRM 2 
method. The results of the T3 and T5 peptide ratios are in excellent correlation with 
the HPLC values as illustrated in Figure 2.21. T2 peptides showed a poor 
correlation, and the calculated values were not accurate as shown in Figure 2.22. 
This could be due to problems with chromatographic separation or with enzymatic 
digestion, as the trypsin used was not of high-quality sequencing grade. Use of 
highly purified trypsin would not suit the requirements of a cost effective screening 
method, and has not been tested here.  
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a) b) 
Figure 2.21. Calculated percentages of δ-chain based on T3 (a) and T5 (b) peptide 
ratios for 96 samples  
 
 
Figure 2.22. Calculated percentages of δ-chain based on T2 peptide ratios for 96 
samples  
 
Calculated R
2
 values and their correlations for T3 and T5 peptides can be seen in 
Figure 2.21. Similarly to the analysed 20 samples, T3 peptides are lower and again 
the T5 peptides are closer to HPLC values; correlation coefficients in both cases are 
higher than 0.95 and the coefficient of determination (R
2
) is slightly higher for T3 
peptides (0.93 compared to the 0.9 value of T5 peptide ratio). Although the 
application of R and R
2 
values may not be the most appropriate since there are two 
groups present for normal and for elevated levels, it is used here as an initial 
visualisation tool to describe the relationship of MS values to HPLC values. For 
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appropriate method comparison other statistical methods need to be used, for 
example the Bland-Altman plot. These measurements all support the suitability of 
the MRM 2 method, especially the T5 peptide pair, for delta chain level relative 
quantitation to beta-chain levels, and that measuring the peptide ratios can be used as 
an indication for HbA2 levels, the potential biomarker for beta-thalassemia.  
The use of T5 peptides ratios proved to be the most promising, which is important as 
the possibility of using this peptide pair for relative quantitation of HbA2 has not 
been presented or published previously, and results show that the obtained values 
from the T5 peptides could be more reliable to estimate true values than the already 
patented use of peptide pairs (T2 and T3). Daniel et al. developed methods for HbA2 
quantitation on β(δ)T2, β(δ)T3 and βT13 (δT14) peptides (Daniel et al. 2007). The 
reliable observation of the βT13 and δT14 peptides was not possible during method 
development and the method developed using T5 peptides proved to be most useful 
for HbA2 level determination.  
 
Monitoring characteristic peptides for Hb variant detection 
 
For clinically significant variants the peptides monitored provided definitive 
diagnosis and confirmation of the presence of the genetic mutation. The MRM-based 
detection of the peptides characteristic to HbS, HbE and HbC have been 
demonstrated.  
During the analysis of the 92 clinical samples already presented this chapter, 
predetermined and targeted peptides for the clinically significant variants were also 
screened for inclusion in the MRM 2 method.  
Nine samples had diagnosed abnormalities by a combination of clinical screening 
methods. Three of these samples were diagnosed to be carriers of HbS. Two of these 
were homozygous and one heterozygous. The method unambiguously identified all 
three samples with the sickle mutation. The homozygous samples were calculated to 
have 99.8% and 94.8%, while the heterozygous sample had 43.3% of sickle peptide 
level. These values were obtained by ratio calculation using the integrated areas of 
the combined MRM chromatogram peaks of sickle βT1 and normal βT1 peptides. 
The intact globin-chain analysis indicating the -30 Da mass shift and the 
confirmation of the presence of the sickle βT1 by the MRM 2 method is illustrated 
for the heterozygous sample in Figure 2.23.  
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It is observed that the percentage of the sickle β-chain is around 40% determined by 
the MRM method and also by the intact globin chain analysis in case of 
heterozygous sickle carriers. It would be expected to be equal to the normal β-chain 
levels. This phenomenon is explained by the observation that α-chains have a greater 
affinity for normal β-chains than for sickle β-chains, which leads to the formation of 
relatively more HbA than HbS (Matthay et al. 1979 , Bain 2006c).   
 
 
       a)        b) 
  
Figure 2.23. Intact globin-chain analysis (a) and MRM tryptic digest analysis (b) of 
a patient sample with heterozygote HbS 
Presence of HbS mutation is confirmed with the detection of peak in the MRM in the corresponding 
MRM channel.  
 
For the remaining six abnormal samples one HbC, one HbE and four HbD mutations 
had been detected in the hospital lab. The HbC and HbE mutations were confirmed 
by the MRM 2 method, after observing a slight mass shift during the intact globin-
chain analysis. Illustration of the chromatographic peaks confirming the presence of 
these two variants is given in Figure 2.24.  
Ratio calculations for HbC βT1 and normal βT1 peptide provided an average value 
of 62.7% for the proportion of HbC hemoglobin in the patients’ blood. Performing 
similar calculations for the HbE detected variant, the average ratio calculations of the 
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novel HbE βT3 peptide peak areas to the normal βT3 peptide peak areas showed a 
low level for the variant of 7.1%. Despite the low level it was still reliably detected 
with the MRM 2 method.  
 
 
a)                           b) 
 
Figure 2.24. Intact globin-chain analysis (a) and MRM tryptic digest analysis (b) of 
a patient sample with HbC or HbE 
Presence of HbC and HbE mutations are confirmed with the detection of peaks in the MRM in the 
corresponding MRM channels.  
 
In case of HbD-Punjab carriers, two of the samples were identified to have α-chain 
variants during intact globin chain-analysis.  
The HbD-Punjab mutation does not result in any new tryptic peptides with a mass 
difference higher than 1 Da to the wild-type peptide. The lack of a new peptide and 
significant mass difference makes it more challenging to confirm the presence of this 
mutation. Daniel et al. developed and used so called pseudo MRM channels to 
screen for the presence of the variant peptide mass (Daniel et al. 2007). This was not 
developed or included in the MRM 2 method here. 
All four samples were enzymatically digested with trypsin and analysed in full scan 
mode using a high-resolution Q-TOF instrument (Waters Synapt HDMS). 
Confirmation of the presence of HbD-Punjab variant was obtained for only one of 
the samples, one was not confirmed and the other two were identified only with the 
α-chain variant. One sample did not show any additional m/z peaks in the tryptic 
peptide mixture as indication for any mutations present. This may have happened 
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because the variant was present at a low level, and information may have been lost 
during enzymatic cleavage. The results of the full scan high resolution analysis to 
confirm the presence of the HbD-Punjab mutation compared to a control healthy 
sample is illustrated in Figure 2.25. 
 
 
 
Figure 2.25. High resolution tryptic digest mass spectra of patient sample with HbD-
Punjab and a control tryptic digest  
The analysis of tryptic peptide mixture shows additional peak for the patient sample at m/z 689.36 
 
As observed the doubly charged peptide ions for the -1 Da HbD-Punjab peptide are 
present at m/z 689.36 in the patient sample, and missing in the control sample. Only 
the m/z (689.85) for the doubly charged wild type peptide ion is present. Sequencing 
the variant peptide provided further confirmation of the mutation.  
For the two remaining patient samples, it was unambiguously confirmed that those 
samples were not carriers of the HbD-Punjab mutation. The identification of the 
mutation can be found in section 2.3.3.2 below. The identified variant peptides were 
used to develop MRM transitions for this specific condition and included in the 
MRM 2 method to improve detection and guarantee the exclusion of the possibility 
for further misdiagnoses. The chromatographic peak is detected in the targeted MRM 
channel if the variant is present, as it is shown in Figure 2.26 b.  
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                              a)                         b) 
 
Figure 2.26. Intact globin-chain analysis (a) and MRM tryptic digest analysis (b) of 
a patient sample with HbG-Philadelphia 
Chromatographic peak is present when a patient sample with the α-chain variant is analysed.  
 
The MRM 2 method, including the MRM transitions for HbG-Philadelphia identified 
both samples with this mutation unambiguously.  
The MRM 2 method can be further extended to any mutations identified, and can 
allow for the detection of those conditions with no requirement for additional sample 
preparation or analysis.  
The developed method proved to be a definitive diagnosis tool for the targeted 
mutations HbS, HbC, HbE and HbG-Philadelphia.  
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2.3.3 Identification of Hemoglobin variants  
 
Clinical samples which showed abnormality during general screening in the hospital 
laboratory at UHCW were analysed using the mass spectrometry-based methods 
developed here. To confirm the presence of a hemoglobin variant, and if possible, 
identify the mutation present in the sample, measurements of intact globin chains 
and digested peptide mixture were performed using the Waters Xevo TQ triple 
quadrupole MS instrument as a first step. Further measurements were carried out 
using the Waters Synapt HDMS instrument, when higher resolution was required to 
achieve more detailed information.  
Following the protocol for hemoglobin variant identification published by Wild et al. 
(Wild et al. 2001), the presence of a sickle cell mutation was confirmed. A -14 Da 
variant of the alpha chain (Hb-J-Broussais, which occurred in two different samples), 
a +44 Da alpha chain variant (Hb-J-Nyanza) and a -14 Da variant of beta chain (Hb-
Andrew Minneapolis) were also identified in collaboration with the Haematology 
Department of UHCW. Results of the identification steps of the sample with HbJ-
Nyanza are presented below.   
During method development and optimisation two clinical blood samples diagnosed 
to have HbD-Punjab mutation based on current clinical laboratory techniques were 
observed to have a +14 Da α-chain variant, HbG-Philadelphia. Identification of this 
variant is also shown, and the variant peptide has been included in the MRM 2 
method for future screening purposes.  
 
2.3.3.1 Case study A: Identification of the +44 Da alpha chain variant – Hb J-
Nyanza 
 
The patient blood sample was diluted and the denatured globin chain mixture 
analysed using the Xevo TQ mass spectrometer. Figure 2.27 shows the denatured 
intact globin chain mass spectrum, which contains peaks at the mass-to-charge ratio 
values corresponding to the multiply charged globin chain ions. A third ion series 
adjacent to the expected normal α- and β-chain multiply charged ionseries is also 
observed. The spectrum was deconvoluted onto a true mass scale, shown in Figure 
2.28, which highlights the presence of a +44 Da alpha chain variant. A +44 Da shift 
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considering single point mutations of the globin coding genes could suggest an 
amino acid substitutin of Ala→Asp or Cys→Phe.  
 
 
 
Figure 2.27. Mass spectrum of the intact blood sample showing +44 Da variant.  
Acquired mass spectrum of anonymised blood sample on the Xevo TQ MS instrument, scan time 1s, 
scanned range m/z 930-1210 and data were collected for 3 minutes in MCA (Multi Channel Analysis) 
acquisition mode  
 
 
 
Figure 2.28. Deconvoluted mass spectrum of sample with +44 Da α-chain variant 
 
To determine which mutation had occurred and at which position of the globin chain, 
tryptic digestion was performed on both the sample, and a control blood sample. The 
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peptide mixtures were analysed using a high resolution mass spectrometer and the 
resulting MS spectra were compared as shown in Figure 2.29. Additional peaks were 
observed in the variant sample and due to the high resolution measurement, the 
charge state of the ion could be determined, which helps in identifying the variant 
tryptic peptide. The mutation occurred affecting the αT4 peptide.  
 
 
 
Figure 2.29. Spectra of the tryptic digested +44 Da variant sample and a control 
blood sample 
Additional peaks are observed at m/z 525.3 (orange shade), which suggests a triply charged ion, are 
not present in the spectrum of the control sample (grey shade).  
 
 
Tandem MS analysis was performed to determine the amino acid sequence of the 
variant peptide, and to identify the exact position of the mutation (Figure 2.30). 
Tandem MS experiments were also performed on the wild-type peptide to confirm 
the mutation site. The b4 fragment ions are present with the same m/z for in both 
MS/MS spectra, and mass shift only observed affecting the b5 fragment ion and 
onwards, the position of the substitution is determined. The peptide comprising α-
chain sequence from 17 to 31 amino acids, and the fifth position of this peptide is 
taken up by an Ala residue. These results showed that the mutation occurred at 
position α21 as a result of an Ala→Asp substitution. Using the HbVar database 
(HbVar) the mutation was identified as Hb J-Nyanza .  
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Figure 2.30. Product ion spectra of variant and control peptides 
MS/MS analysis of the additional peak at m/z 525.3 (3+) corresponding to the variant peptide ion and 
of the wild-type peptide ion at m/z 765.4 (2+) are compared and mass shifts of fragment ions are 
investigated. Mutation site is visible at the b5 fragment ion 
 
2.3.3.1 Case study B: Identification of the +14 Da alpha chain variant – HbG 
Philadelphia 
 
A sample from a patient diagnosed to be a carrier of HbD-Punjab mutation has been 
analysed. Intact globin chain analysis indicated the presence of a +14 Da α-chain 
variant, while the mass accuracy of the β-chain did not indicate the presence of any   
-1 Da variants affecting that globin chain. The deconvoluted mass spectrum of the 
patient sample is shown in Figure 2.31. A +14 Da mass shift could suggest the 
following substitutions: Asn → Lys, Asp → Glu, Gly → Ala, Ser → Thr and Val → 
Ile/Leu. As a follow up step, the patient sample and a healthy control sample have 
been enzymatically digested with trypsin and analysed using the Synapt HDMS high 
resolution mass spectrometer in order to identify the mutation. The comparison of 
the resulted spectra revealed the presence of additional peaks at m/z 717.4 and 771.4 
as illustrated in Figure 2.32 a.  
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Figure 2.31. Intact mass spectrum of sample with +14 Da α-chain variant 
 
The peak at m/z 717.4 belongs to a singly charged ion, while the peak at m/z 771.4 
belongs to a triply charged ion. The appearance of two additional peaks and the 
listed possibilities for the amino acid substitutions support the hypothesis of a 
Asn→Lys substitution. Following this hypothesis, the patient and control sample 
have been enzymatically digested by α-chymotrypsin, which cleaves the amino acid 
sequence after Tyr, Trp and Phe residues, whereas trypsin hydrolyses proteins after 
Arg and Lys residues.  
The results of comparing the mass spectra of the patient and control α-chymotryptic 
peptide mixtures are shown in Figure 2.32 b. This comparison exposed an additional 
peptide at m/z 741.5, as a doubly charged ion. The proposed mutant peptide mass is 
1481 Da, 14 Da higher than the expected mass for the αY11 peptide. This peptide 
covers the α-chain sequence from residues 67 to 80. This narrows down the tryptic 
peptides possibly affected to αT9, with the amino acid sequence covering the region 
for 62 to 90 amino acids. This peptide comprises of two Asn amino acids. 
Performing calculations for expected peptide masses with both possible substitutions 
revealed that the mutation affected the first Asn residue in the tryptic peptide 
resulting in two smaller tryptic peptides than the original αT9. The outcome of this 
calculation is illustrated in Figure 2.33.  
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a) b) 
Figure 2.32. a) MS analysis of tryptic digest mixture of sample with variant and 
control sample b) MS analysis of α-chymotryptic digest mixtures of variant and 
control sample 
Blue circles show the position of additional peaks, grey circles show same location in control sample 
 
The first, smaller unit was expected to have a singly charged ion peak at m/z 717.4, 
while the second larger unit results in a mass of 2311.2 Da and an expected triply 
charged ion at m/z 771.4. These results confirmed that mutation of Asn→Lys 
substitution had taken place at position 68 of the α-chain. Searching the HbVar 
database (HbVar) the mutation was identified as Hb G-Philadelphia, a fairly 
common α-chain variant, which can be mistaken for HbD-Punjab mutation based on 
ce-HPLC and electrophoretic methods (Bain 2006).  
 
 
 
Figure 2.33. αT9 peptide and the theoretical new peptides resulted by the amino acid 
substitution of Asn→Lys  
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Additional identified Hb variants 
 
 Hb-J-Broussais: The analysis of the intact globin chains showed the presence of a  
-14 Da alpha chain variant, which could suggest the following substitutions: 
Lys→Asn, Glu→Asp, Ala→Gly, Thr→Ser, Ile/Leu→Val. After tryptic digestion an 
additional peak was observed in the spectrum of the tryptic peptide mixture at m/z 
651.15. This was proposed to be the +5 charged ion for the variant peptide of α(T9-
10) with a missed cleavage site because of Lys→Asn substitution. Tandem MS 
measurement confirmed this hypothesis, and determined the position of the 
mutation. The mutation is α90 (Lys→Asn).  
 Hb-Andrew Minneapolis: The analysis of the intact globin chains showed the 
presence of a -14 Da beta chain variant, which could imply the substitutions detailed 
for the previous variant. The additional peak in the spectrum of the tryptic peptide 
mixture was at m/z 718.4, corresponding to a doubly charged βT(14-15)2+ variant 
ion, which suggests a missed cleavage site because of Lys→Asn substitution 
between the T14 and T15 peptides. Tandem MS measurement confirmed this 
hypothesis, and determined the position of the mutation. The mutation is β144 
(Lys→Asn). 
These cases confirm that the established protocol for hemoglobin variant 
identification can be carried out by the use of Waters Xevo TQ, in combination with 
high resolution mass measurements for the analysis of tryptic peptide mixtures.  
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2.4 Conclusion  
 
Mass spectrometry-based methods have been developed using Waters Acquity TQD 
and Xevo TQ instruments (Waters Corporation, Manchester, UK). The developed 
methods have been optimised on reference standards and tested on patient samples in 
collaboration with the Haematology Department of UHCW.  
Initial method comparison has been carried out in preparation for a clinical trial. 
Methods for sample preparation and mass spectrometric analysis in combination 
with data processing methods have been tested to facilitate a high-throughput 
application for future sample analysis.  
Intact globin chain analysis for the quantitation of HbA2 level determination proved 
to give good correlation to HPLC values. Elevated HbA2 levels are unambiguously 
detected. Although this quantitation method for δ-chain levels relies on previously 
published principles, the quantitation method itself has not yet been published. The 
same method is capable of the quantitation of glycated hemoglobin chains. The 
glycated levels of the different globin chains are most of the time in good 
correlation, but the glycated β-chain level may be more informative for future 
diagnostic purposes. 
Mass accuracy measurements for the β-chain mass provided a mass window of ±0.2 
Da, Since α-chain mass errors used to adjust the β-chain masses are generally higher 
than β-chain mass errors, all the corrected mass error values for the β-chain are 
below zero, and therefore gave a systematic error. Clinically significant -1 Da variant 
samples with a higher mass error could be still detected based on the assumption of 
causing a mass shift if they are present at levels higher than 20%.  
MRM 1 method was able to indicate elevated delta-chain levels, but based on its low 
reproducibility rate, it needed further development. The new method developed on 
the Waters Xevo TQ system proved to be more reliable for quantitation and also 
capable of detecting clinically significant variants such as HbS, HbC and HbE. 
A novel peptide ratio for the T5 peptides have been included in the developed MRM 
method. The clinically significant variants were unambiguously identified based on 
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the developed MRM transitions, and samples from homozygous and heterozygous 
sickle cell carrier patients were easily distinguished. The peptide ratios for T3 and T5 
peptides gave excellent correlation to HPLC values, but problems with enzymatic 
cleavage was indicated based on the results of a larger sample set comprising 94 
samples. T5 peptide ratios resulted in values closest to the expected true HbA2 levels 
determined by ce-HPLC, and it is suggested to use these peptides for further 
developments and screening for elevated HbA2 levels. 
The published protocol by (Wild et al. 2001) utilising intact globin chain analysis 
followed by peptide analysis, successfully identified rare hemoglobin variants.  
Two different MS-based methods have been developed using the same platform and 
in combination in a high-throughput screening method that may be able to 
unambiguously identify the clinically significant and occasional rare variants. The 
developed MRM methods did not target the detection of HbD-Punjab variants. In 
case a sample shows abnormality indicating the presence of a -1 Da variant on the 
intact level, and is not diagnosed to have either HbC, HbE or potentially HbO-Arab 
mutations based on MRM results, high resolution mass analysis of the tryptically 
digested peptide mixture would be the only solution for a confirmative diagnosis.  
At this stage both developed methods need a trained person to interpret the data; 
whilst the available software tools are helpful, the data processing is not fully 
automated. Sample introduction is automated for both methods, which are able to 
support high-throughput screening applications with overnight measurements.  
Mass spectrometry methods revealed a potential problem with current clinical 
methods, where two samples classed as HbD-Punjab by the hospital lab were 
identified as carriers of a fairly common α-chain variant HbG-Philadelphia.   
The combined application of developed methods on the same platform are hoped to 
provide a competitive diagnostic technique as a potential first line screening tool in 
future clinical lab applications.  
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3.1 Introduction 
The development of a comprehensive, high-throughput screening method for 
hemoglobinopathies is an increasing demand. The current methods used for routine 
screening are able to confirm the presence of clinically significant variants, but are 
slow, laborious and non-specific, and incapable of characterising novel variants.  
As discussed in previous Chapters, there are a number of different mass 
spectrometry-based techniques which have been implemented in the research field of 
hemoglobinopathy diagnosis. There is widely reported literature supporting the view 
that mass spectrometry could become the sole technique in definitive hemoglobin 
variant detection and identification in the clinical lab. The requirement is to develop 
a single platform using mass spectrometry which could replace current methods, 
more precisely the need for the employment of combined methods. Several mass 
spectrometry-based methods have been tested on larger numbers of clinical samples 
previously. A method capable for population screening has to be able to compete 
with current methods regarding some key points. Previous evaluations of mass 
spectrometry-based methods on relatively large sample sets has given the 
opportunity to discuss what key features needed to be considered in order to 
implement the most appropriate method for hospital use. These features include cost, 
speed, sensitivity, specificity, potential for automation allowing high-throughput 
applications and prospective additional diagnostic information. The method needs to 
be robust for a clinical lab environment involved in population screening. For 
population screening, the confident diagnosis of clinically significant variants is the 
most important criteria. Mass spectrometers are sensitive but complex techniques, 
and to demonstrate their robustness and stability for a screening application a higher 
number of sample amounts need to be analysed with a high reproducibility rate. 
Previously developed mass spectrometry-based methods have tested sample sets 
ranging from hundreds to thousands. The most widely used protocol described by 
Wild et al. has been tested on over 250 samples to prove its suitability for diagnostic 
purposes (Wild et al. 2001). A smaller set of samples with 147 dried blood spot 
cards have been also analysed by the same group and showed potential for newborn 
screening (Wild et al. 2004).  
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The proposed MRM method introduced by Daniel et al. has been presented with the 
analysis of 200 samples for the detection of clinically significant 
hemoglobinopathies (Daniel et al. 2005). The feasibility of the extended method for 
HbA2 quantitation was tested on an additional 319 samples (with 105 of these having 
increased HbA2 levels, 43 delta-chain variants and 8 Hb Lepore carriers) with the 
application of a cut-off value for normal levels of 3.4% (Daniel et al. 2007). 
Following this the analysis of 40,000 samples have been presented on the Annual 
Meeting of the American Society of Hematology in 2008 with the same MRM-based 
approach for both clinically significant variant detection and HbA2 quantitation 
(Daniel et al. 2008). This method has been demonstrated to be capable of high-
throughput and fast screening, but only gives definitive answers for the known 
variants included in the set-up. There have been no observed discrepancies between 
the tandem mass spectrometry method and the routine screening techniques. 5,000 
samples have also been analysed with data-dependent acquisition for peptide 
sequencing experiments suitable for the identification of rare hemoglobin variants. 
This has showed a further applicability beyond targeted screening methods for 
clinically significant variants, by addressing the above mentioned issue about the 
approach not being able to detect unknown variants. The presented method is fast 
and the acquisition time is only 60 seconds which is important in population 
screening applications. 
At the same time another group presented results with a similar approach. Boemer et 
al. also utilised an MRM-based method and performed a comparative study with IEF 
results on 2082 samples from newborns with no discrepant results to clinical 
laboratory techniques observed (Boemer et al. 2008). The described method did not 
target and therefore did not detect individuals with Hb-Barts, α-chain variants or any 
other unknown variant. In further applications over a three year period the total 
number of samples analysed were 43,736 (Boemer et al. 2011). Screening has not 
been considered for some clinically significant variants such as HbD-Punjab, HbO-
Arab and Hb Lepore, based on the low prevalence of these variants in the Belgian 
population. Although it has been shown that the tandem mass spectrometry method 
allows the detection of major hemoglobin disorders with the exception of HbH 
disease, it has also highlighted the fact that misinterpretation can happen in case of 
rare β-globin chain variants. It has been suggested that other methods may be 
necessary as second-line tests to discriminate between, for example HbSS and 
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HbS/β-thalassemia, since the β-chain produced at a normal level in newborns is still 
relatively low. The major advantage of the MRM-based method developed here is 
that for different targeted peptides four MRM transitions are used, while Daniel et al. 
has only used one transition per peptide. The additional confidence that would be 
obtained from the higher number of transitions means that the total acquisition time 
is longer, but is still only 150 seconds. The specificity required for diagnostic 
purposes like hemoglobinopathy detection makes it necessary to obtain the highest 
specificity possible based on multiple MRM transitions to reduce the rate of false 
positives. Daniel et al. did not report the occurrence of false positive identifications 
with their method and this remains an open question (Boemer et al. 2009).  
 
Kleinert et al. reported the analysis of 2145 blood samples (Kleinert et al. 2008). 
They analysed diluted lysed blood samples with either ESI-MS or MALDI-TOF MS, 
and also utilised FT-ICR measurements in the case of -1 Da variants. This study 
indicated that MS can be used for the unambiguous identification of Hb variants but 
was not focused on the development of fast and automated screening techniques. 
They demonstrated that the MS approach detected four chromatographically silent 
mutations, and one sample, which had been incorrectly identified by 
chromatographic methods as β-thalassemia, was diagnosed as a mutation referred to 
as Hb Malay. Although this study stated that variants with mass shifts lower than 6 
Da could not be detected (eg. clinically significant variants like HbC, HbD-Punjab, 
HbO-Arab, HbE), the feasibility of MS for detection of Hb variants was 
demonstrated and they proposed the use of MS as a supplementary method. 
Considering the restriction imposed for detectable variant chains to differ by more 
than 6 Da, 92% of currently undetected variants are still able be detected with MS 
methods (Kleinert et al. 2008). The restriction for the 6 Da difference is not a valid 
limiting factor today. The important outcome of their study is that MS is capable of 
the detection of variants which do not show any significant charge-difference which 
is necessary for detection by electrophoretic methods or alterations in hydrophobicty 
needed to be observable by HPLC techniques.  
 
All here mentioned studies were performed on a larger set of neonatal samples, and 
none of them focused on antenatal screening , which is in terms of preventive health 
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care also essential. Also no studies were conducted on a larger sample set applying 
top-down protein analytical methods.  
It needs to be emphasized that structural hemoglobin variants require detailed and 
confirmative analysis. The identification of variants based only on mass shifts 
observed at the intact protein level is already proved to be not confirmative enough 
for the diagnosis of known mutations. The -30 Da mass shift from the sickle cell 
mutation could also be a result of other amino acid substitutions, at the same or 
different position on the β-globin chain. Excluding βSICKLE, there are 19 possible β-
chain variants with -30 Da mass differences (HbVar). Detection of sickle cell 
mutation based only on the mass difference at the intact level can therefore lead to 
false positives (Wild et al. 2004) (HbVar). The possible amino acid substitutions 
comprise Thr→Arg, Ser→Gly, Met→Thr and Glu→Val. Although these 
theoretically possible mutations are much less frequent than the sickle cell mutation, 
their possibility must not be overlooked. 
There are also a number of outcomes that could result in -1 Da variants. There are 25 
possible variants with the same mass difference. Four of the clinically significant 
variants result in a -1 Da mass shift affecting the β-chain. If the presence of a -1 Da 
mass shift is observed, this is not conclusive enough to reveal the exact nature of the 
mutation and the affected amino acid along the sequence to distinguish between the 
four important variants. Amino acid substitutions based on single point mutation, 
which result in a -1 Da mass difference between the mutant and the normal chain 
comprise Asp→Asn, Glu→Gln, Asn→Ile and Glu→Lys (Wild et al. 2004).  
Applied diagnosis methods need to be able to distinguish between the mutations at 
the amino acid level to give conclusive diagnosis. The previously described method 
of targeted peptide analysis may be one solution, alternatively a method for the direct 
fragmentation of the intact variant globin chain could be employed.  
 
The two main workflows for protein identification which includes mass spectrometry 
are: the bottom-up strategy involving peptide tandem mass spectrometry sequencing 
while the other is the top-down strategy involving the direct fragmentation of intact 
protein molecules. In a bottom-up experiment the proteins are enzymatically cleaved, 
most often by trypsin, to produce peptides with length of 10-20 amino acids, but it is 
inevitable that information is lost during the process of transformation of the protein 
into peptides, and many of the peptides may not be observed upon mass 
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spectrometric analysis (Reid and McLuckey 2002). In the top-down approach 
multiply charged ions of the intact proteins are broken using a number of 
dissociation techniques (Cui et al. 2011). There are different strategies within the 
top-down class presented by McLafferty and co-workers (Kelleher et al. 1999). The 
growing interest in developing top-down analysis methods is supported by the fact 
that substantial structural information can be obtained without time-consuming 
sample preparation.  
 
For hemoglobinopathy analysis the application of top-down strategies has not been 
frequently reported compared to the use of bottom-up strategies, and no clinical trial 
has been conducted. The top-down strategy has not become as popular, presumably 
because of the more complex spectra due to the number of ions, and the difficulty in 
interpretation which can be caused by overlapping peaks of multiply charged 
fragment ions (Zhou et al. 2012). There is an increasing demand for the development 
of bioinformatics softwares and deconvolution algorithms. A key step is to assign 
product ion identities, which needs either mass spectrometers with high resolving 
power or ion charge state manipulation (Reid and McLuckey 2002).  
The possibility of minimising analysis time excluding sample preparation steps such 
as enzymatic cleavage with the analysis of whole protein with tandem mass 
spectrometry may be attractive for real clinical applications, hence the effort for the 
development of top-down techniques. Shackleton et al. expressed the desirability of 
developing top-down methods to be applied in the hemoglobinopathy field after 
early studies using FT-ICR mass spectrometers (Shackleton and Witkowska 1996).  
In the early 1990s after the introduction of ESI with tandem mass spectrometry 
becoming a routine tool in the analysis of intact proteins (Loo et al. 1990), research 
groups in the field of hemoglobinopathy analysis started looking at the option of 
tandem mass spectrometry on intact globin-chains as a potential alternative to 
analysing peptides. The CID process produces fragment ions characteristic of the 
amino acid sequence. Light-Wahl et al. showed results for tandem mass 
spectrometry of the intact hemoglobin β-chain by application of CID (Light-Wahl et 
al. 1993). It was established that β-globin chain variants can be differentiated based 
on the observed mass shifts of the fragment ions to reveal in which part of the 
molecule the mutation has taken place. The sequence information obtained covered 
approximately 29% of the molecule. 
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Witkowska et al. proposed that intact protein ESI-tandem mass spectrometry could 
be used as a sole technique to identify hemoglobin variants (Witkowska et al. 1995). 
An α-chain variant has been identified without any separation prior to mass 
spectrometric analysis. The investigation of major fragment ions narrowed down the 
possible mutation site and further examination of low abundance fragment ions 
allowed the unequivocal identification of the mutation.  
A more comprehensive coverage of the sequence was obtained using cyanogen 
bromide (CNBr) digestion of whole blood in addition to acquiring a low-energy CID 
mass spectrum of the complete protein (Summerfield et al. 1996).  
Charge-stage dependent fragmentation was investigated by ion trap collisional 
activation of β-chain ions from 2+ charges to 17+ charges in an ion trap analyser 
(Schaaff et al. 2000). A similar study has been performed on the α-chain charge 
states ranging from 4+ to 20+. A total sequence coverage of 62% was obtained. MS
3
 
involving subsequent activation may also be considered to achieve higher sequence 
coverage (Mekecha et al. 2006). 
Rai et al. have used ESI tandem MS for the rapid identification of β-chain variants 
and the low proportion Hb Lepore-Boston-Washington (Rai et al. 2004, Rai et al. 
2002). The obtained sequence coverage for the β-chain was approximately 50%, but 
the inner region was still not covered, which made peptide analysis necessary in the 
case of variants affecting that region (Rai et al. 2002).  
The application of CID only is clearly not sufficient since it does not cleave all the 
bonds required to give the full information desirable on the primary structure of a 
polypeptide or protein (Zubarev et al. 2008). 
With the introduction of Electron Capture Dissociation on FT-ICR instruments an 
alternative fragmentation method has become available (Zubarev et al. 1998). The 
ECD process results in different fragmentation routes and product ions providing a 
complementary level of information accessible in top down strategies. With the 
development of the Electron Transfer Dissociation (ETD) technique on lower cost 
instruments like ion traps (Syka et al. 2004) the non-CID top-down route has 
become more widely accessible. Fragmentation occurs predominantly along the 
peptide backbone, which results in a predictable product ion spectra and therefore 
easier interpretation. Formation of c- and z-type product ions containing the N and C 
termini of Pro are however not observed in either the ECD or ETD spectra (Syka et 
al. 2004). The ECD/ETD activation techniques are more suitable for fragmentation 
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of larger polypeptides and intact proteins, when compared to CID, based on the 
narrower dynamic range in fragmentation when higher molecular masses are 
involved (Zubarev et al. 2008). 
Ion/ion reactions such as proton transfer reactions (PTR) have been introduced by 
McLuckey and co-workers to simplify the product ion spectra of multiply charged 
ions to singly charged ions, which may be more easily interpreted (McLuckey and 
Stephenson 1998, Reid and McLuckey 2002).  
ETD may prove to be a better technique for the rapid sequencing of intact proteins 
simultaneously from both N and C termini (Coon et al. 2005). Multiply charged 
protein ions are allowed to react with fluoranthene anions. Electrons are transferred 
to the multiply charged ions which promotes the random dissociation of the N-Cα 
bonds. The charged fragment ions are then involved in a second ion/ion reaction 
where they are deprotonated. The reaction is controlled by both the amount of 
reagent and the reaction time allowed for ETD and PTR. ETD reaction time is kept 
low to avoid multiple electron transfer events, while the PTR period is slightly 
longer to allow enough time and cycles for the fragment ions to be simplified to 
predominantly 1+ charge (Coon et al. 2005). The PTR is necessary because direct 
fragmentation of intact proteins leads to spectra with highly charged c- and z-type 
fragment ions, and performing this type of experiment on a bench-top ion trap mass 
spectrometer can make interpretation challenging, since the ion trap has a limited m/z 
resolution. The resulting singly and doubly charged ions may be used to read the 
sequence of 15-40 amino acid long segments on both termini of the protein. With the 
application of this method the analysis of mutant protein forms revealed amino acid 
changes. The obtained sequences were compared against database entries to reveal 
up to four amino acid changes. In a study of top-down fragmentation of ubiquitin 
(MW= ~8.5 kDa) c- and z-type ions, 17 amino acids of the N-terminus and 16 amino 
acids of the C-terminus have been identified (Mikesh et al. 2006).  
While CID fragmentation depends significantly on the presence and order of amino 
acids, ETD has the advantage of producing homologous series of c- and z-type ion 
series which can allow direct reading of the protein’s amino termini. This 
predictability makes this technique applicable for the development of an automated 
de novo sequencing method, which would not need the usual database searching 
currently necessary for processing data obtained by CID fragmentation.  
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Théberge et al. utilised different fragmentation techniques on a LTQ-Orbitrap to 
develop a method which could be used for characterisation of variant proteins with 
stepwise MS/MS analysis (Théberge et al. 2011a). They first recorded a mass profile 
to detect any mass shifts revealing the presence of a variant, then performed nozzle 
skimmer dissociation (NSD), and identified the fragment ion(s) containing the amino 
acid substitution. The fragment ion was then selected for MS/MS analysis in the ion 
trap to obtain sequence information allowing the identification of the variant. This 
stepwise approach has been shown to be capable of identification of the sickle cell β-
globin chain, and also of the characterization of post translational modifications like 
S-glutathionyation. Although high sequence coverage was achieved, the method 
does not provide specific information for every amino acid position. 
It has been shown by the same group that additional information can be gained by 
the use of ETD and higher energy C-trap dissociation (HCD) activation techniques, 
and also by the combined use of CID and ETD fragmentation techniques (Théberge 
et al. 2011b). They demonstrated that ETD was useful for sequencing the core region 
which can be challenging using CID. The choice of precursor ion charge state can 
have an influence on the obtained sequence coverage as expected. For the β-chain, 
the 18+ charge state was chosen to perform tandem MS experiments. β-chain 
coverage achieved with the use of multiple activation techniques was 85%.  
 
In recent years other groups have recognized the need for alternative methods and 
started applying different top-down strategies for the identification of hemoglobin 
variants. An interesting application is to perform direct sequence analysis of samples 
obtained from dried blood spots from newborns by liquid extraction surface 
sampling using NanoMate technology (Edwards et al. 2011). This recently presented 
method employed CID tandem mass spectrometry using an Orbitrap instrument for 
unambiguous identification of common variants HbS, HbC and HbD-Punjab, the 
latter two differing from normal β-chain by only 1 Da. The β-chain [M+15H]15+ ions 
were isolated and subsequently fragmented with a sequence coverage of 32-38% 
obtained. The HbD variant proved to be more challenging because of overlapping 
isotope peaks. Following this study Cooper and co-workers have shown results 
obtained with the same sample introduction and the use of CID and ETD to produce 
variant-specific fragment ions (Edwards et al. 2012). Six abnormal neonatal samples 
were analysed, which could not be identified using current screening techniques. It 
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was shown that CID, combined with ETD is capable of identifying unknown 
hemoglobin variants. Sequence coverage obtained for the normal β-chain was: 68% 
with CID only, 44% with ETD only and the combined sequence coverage by 
CID+ETD was 81%. It was lower for a variant β-chain Hb Headington: 46%, 34% 
and 63% respectively.  
 
As a potential screening tool, top-down ETD application for hemoglobin disorders 
using a quadrupole ion trap instrument was described recently (Graca et al. 2012). 
The ion trap being a lower cost instrument is more likely to be considered as a 
potential clinical laboratory tool than a significantly more expensive and complex 
Orbitrap mass spectrometer. A pseudo-SRM ETD assay has been used for the 
detection of HbS and HbC, monitoring three fragment ions for all analysed globin 
chains.  
The disadvantages of the presented approach were the lengthy sample preparation 
and the nano-LC separation, which makes this method less robust for real clinical 
applicability, where short run time and minimal sample preparation is highly 
desirable (Graca et al. 2012).  
A top-down ETD direct infusion method of diluted whole blood without these time 
consuming steps could have a high potential for population screening in an 
automated manner to replace current technology. This mass spectrometry-based 
approach could give the required high specificity for confirmative diagnosis of 
clinically significant variants, and the ETD technology could also offer the 
opportunity for the occasional identification of unknown variants. Recently this 
group have extended their approach to HbE and HbD variants and developed the 
method to involve HbA2 and HbA1c quantitation (Scherl et al. 2013).  
 
For mass spectrometry to be a competitive and potential replacement technique for 
population screening, it has to be shown to provide the confirmation of the presence 
of variants of clinical significance, according to the requirements outlined in the 
NHS Sickle Cell and Thalassemia Screening Programme. It has to be capable of 
quantifying HbA2 and HbF levels, which can be used as surrogate markers for 
thalassemic disorders and other clinical conditions (NHS 2012b) The clinically 
significant variants have been detailed in Chapter 1, section 1.3.1.  
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Additional requirements for a good screening method would be a high degree of 
automation regarding sample preparation, analytical measurement and data analysis 
in order to facilitate a high-throughput approach with a minimum requirement for 
expert staff. The ideal population screening method is fast with a short turn-around 
time to give the answers for the appropriate diagnosis as soon as possible, while 
maintaining the overall cost is the same or lower than it is for currently used 
methods.  
 
The research presented here involved working with human blood, therefore certain 
ethical considerations had to be followed. According to the Human Tissue Act 
(HTA) (Human Tissue Act 2004) any research projects involving human tissue 
needs to be authorised and approved by the regional NHS Research Ethics 
Committee if samples from NHS patients are used. To obtain a valid ethical approval 
for the project an application form detailing the research was filled in through the 
Integrated Research Application System (IRAS) and submitted to West Midlands 
Research Ethics committee. Approval was granted for the project involving the 
analysis of anonymised patient samples within a three months period for mirrored 
testing with developed mass spectrometry-based methods.  
 
Collaboration was established with the Haematology Department of University 
Hospitals Coventry and Warwickshire NHS Trust (UHCW). Methods were 
optimised using a small set of clinical samples prior to a clinical study analysing all 
samples investigated under hemoglobinopathy screening in the hospital during a 
period of three months.  
In this Chapter, results obtained using the developed mass spectrometry-based 
methods are compared to cation exchange HPLC, which is used as the first line of 
testing for the detection of Hb variants, HbA2 and HbF quantitation in the hospital 
laboratory. The second line testing for confirmation of abnormalities used in the 
hospital is gel-electrophoresis (acid and alkaline), therefore, presented results are 
correlated to both HPLC and electrophoresis methods in cases where a significant 
variant is observed. Unequivocal identification of hemoglobin variants can only be 
obtained through either protein sequence analysis or DNA analysis. The latter is very 
rarely performed because of its relatively high cost (Ryan et al. 2010). The ability to 
perform protein sequencing analysis is readily available with MS.  
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In collaboration with the Haematology Department of UHCW, over 2,000 patient 
samples were analysed with two different mass spectrometry based techniques using 
a Xevo TQ instrument (Waters, Manchester, UK) and over 1,000 samples were 
analysed with a top-down ETD method as part of a pilot study. 
 
At the Haematology Department of UHCW approximately 7,000 samples are 
analysed annually for antenatal screening purposes. The screening protocol set in the 
NHS lab manual is followed (NHS 2012b). Initial measurements include assessing 
the red cell indices: MCH (mean corpuscular volume), MCV (mean corpuscular 
hemoglobin) and Hb concentration defined in section 1.3.3. If the measured MCH is 
lower than 27 pg and the MCV lower than 80 fL this may indicate abnormalities, and 
further investigation is required.  
Alongside these measurements in most cases a family origin questionnaire (FOQ) is 
filled out by the patient to determine whether the individual is a descent of a high 
prevalence area, and so require further screening.  
The research undertaken here is aimed at antenatal screening, no attempts at 
newborn screening have been made. Samples in rare occasions are from newborns or 
from babies up to few months old.  
The current clinical screening strategy employs first and second line screening steps 
to confirm certain mutations. It has been presented in a previous Chapter that method 
development was focused on obtaining information at the intact protein globin chain 
level and also at the peptide level. Intact globin chain analysis alone is not 
confirmative for clinically significant variants, only preliminary indication can be 
gained, and analysis at the peptide level is a necessary follow up step. In the work 
presented here the two methods have been evaluated and used in combination to 
obtain full confirmation of variants detected during the intact measurement but not 
fully characterised. Where possible, the MRM method was used for the purpose of 
confirmation. This method was able to confirm HbS, HbC, HbE variants, but it was 
only tested on one sample with HbO-Arab. For the HbD-Punjab mutation, high 
resolution MS measurements were required. Here we suggest that two-step analysis 
needs to be performed to obtain definitive diagnosis, since neither of the developed 
methods are able to give diagnosis alone. Both of these methods utilise the same 
instrument, therefore, an efficient analytical protocol could be created involving the 
different approaches but only using a single instrument.  
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In tthe second part of this chapter the potential of developing a screening method 
based on top-down ETD methodology is tested using a mass spectrometer with an 
ion trap analyser. The suitability of such a method in clinical sample analysis has 
been assessed in a preliminary study involving patient blood samples. Detection and 
identification of point mutations can be achieved by intact protein analysis and top-
down sequencing measurements. A screening method developed by combining the 
previously presented intact globin chain analysis and a top-down ETD MS/MS 
methods can offer a powerful tool to replace the limited screening techniques 
currently used in the clinical labs.  
 
Initially sequence coverage studies were performed to confirm that the method 
would be capable of providing fragment ions characteristic of clinically significant 
variant globin-chains. To detect and identify the position of the mutation in a fairly 
complex MS/MS spectrum, the mass spectrometer needs to be able to resolve m/z 
peaks differing by less than 1 Da. Multiply charged ions with charge states up to 5+ 
may also be present.  
For a triply charged fragment ion where the variant is only 1 Da apart from the 
normal chain, peaks with 0.3 Da difference are expected. These peaks need to be 
resolved, and the charge state identified. Proton transfer reaction will be used to 
deprotonate the multiply charged ions and reduce the charge state as much as 
possible, preferably to a single charge.  
The resolution of an ion trap analyser is potentially higher than that of quadrupole 
analysers. They provide sufficient resolution to resolve fragment ions with 3-4 
charges, where the isotope peaks are spaced at 0.33-0.25 Da distances. Additional 
software tools may need to be used to obtain deconvoluted mass spectra.  
 
Statistical Power analysis has been used to assess the necessary sample number to be 
analysed (Cohen 1992, Cleophas 2009) Calculations indicate that at least 1500 
samples need to be analysed to confirm agreement with the existing method at a 
sensitivity of 95% and a specificity of 90%. The sample size required for sensitivity 
assessment is 1460, and for specificity assessment 146.  
Factors such as sample preparation and ageing were not investigated, nor were the 
limit of detection or lowest limit of quantitation determined. The dilution factor for 
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sample preparation has been based on published literature protocols, with occasional 
optimisation to obtain optimum peak-shapes and intensities. The aim of the research 
at this stage was not method validation with neither method applied. The focus was 
on testing developed MS-based approaches on a larger set of clinical samples, 
identifying aspects of sample preparation and MS-method which require 
optimisation and preparing for future method validation to obtain a robust and high-
throughput approach.  
When making a comparison of clinical measurements, a new measurement technique 
with an established one, it is necessary to investigate whether they agree sufficiently 
for the new to replace the current one. Such investigations are often analyzed 
inappropriately, notably by relying only on correlation coefficients. The use of 
correlation obtained by simple linear regression methods sometimes can be 
misleading. Alternative approaches based on graphical and model based statistical 
methods were used to study the relation between results from the different analytical 
techniques. Assessment of reproducibility and robustness, consistency of the 
methods were also tested. 
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Aims and Objectives 
 
The first part of the work presented in this Chapter attempts to provide a versatile 
clinical study and focuses on the evaluation of mass-spectrometry based methods and 
the potential for additional future clinical studies. It is aimed to highlight issues and 
facilitate further improvements to eliminate shortcomings in order to develop a robust 
mass spectrometry-based approach to be implemented in the clinical setting. 
 
Primary aims:  
 To test the developed methods on a larger clinical sample set and to 
investigate their robustness, sensitivity, automation and required analysis 
time. These factors should ideally be equal or better than current clinical 
methods. 
 
 To assess the need for further developments and optimisation. Often a 
method is developed on purified standards and small number of samples, and 
constant usage of the instrument may require further work.  
 
 To analyse samples on a statistically relevant size of sample-number. It has 
been shown in method development involving clinical samples that the HbA2 
levels determined by MS methods differ in absolute values to ce-HPLC 
values. Analysing a larger sample set it is hoped to provide a realistic 
estimation of ranges for normal values obtained by MS and helps to define 
the cut-off value for HbA2 with the different MS approaches.  
 
 To estimate the incidence of certain clinically significant variants in the 
investigated population, and if possible investigate the ethnic background and 
the proportion of variants in certain ethnic groups. 
 
 To assess whether a single mass spectrometry platform is suitable for 
screening for detection and confirmation of clinically significant variants, 
quantification of HbA2 and HbA1c levels, detection of elevated HbF levels 
and detection of other rare hemoglobin abnormalities.  
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The second part of the work presented here is a pilot study, therefore the aims are 
less ambitious and the results cannot be fully implemented into the clinical trial. 
Since the sampleset is partly the same the results are presented together with a 
different focus and set of objectives.  
 
A top down ETD method developed in collaboration with Bruker Daltonics has been 
tested and initial results analysing clinical samples are presented. Work carried out 
by collaborators is described in the text.  
 
The primary aims were: 
 
 To test a mass spectrometer with an iontrap analyser for the quantitative 
analysis of HbA2 and HbA1c levels 
 To evaluate the sequence coverage achievable by the top down ETD – based 
method. In case of the -1 Da variants the substituted amino acids are 
relatively close to the N- or C-terminus. It needs to be assessed whether 
suitably high sequence coverage, covering the affected regions, can be 
obtained reproducibly.  
 To assess the mass accuracy which can be obtained at the deconvoluted intact 
globin chain level to evaluate the possibility of reliably detecting mass shifts 
based on mass errors higher than the average expected ±0.2 Da necessary for 
first line detection of variant hemoglobin chains.  
 To use the method for the detection of clinically significant variants and 
identify characteristic fragment ions. 
 To test the developed method and chosen reporter fragment ions on a larger 
set of clinical samples and assess the reliability of detection of clinically 
significant variants. 
 To test the top-down ETD approach for the identification of rare variants.  
  
CHAPTER 3 - RESULTS OF THE CLINICAL TRIAL 
135 
 
3.2 Materials and methods 
 
3.2.1  Materials for analyses performed on the XEVO mass spectrometer 
 
Samples admitted to the Haematology Department of UHCW for hemoglobinopathy 
screening within the 12 weeks mirrored testing period were transported to our 
laboratory on a weekly basis. 12 batches of samples arrived to our lab containing 
sample numbers ranging from 93-280. The blood samples were in EDTA tubes, 
anonymised by the NHS Laboratory. For discussions between the hospital lab and 
our lab the barcode numbers used were given as a patient identifier by the hospital. 
For ease of handling, a different identification number was given to each sample 
using the letters of alphabet for different weeks and numbers. The samples can be 
tracked back only at the hospital site, but their origin is not directly identifiable for 
the researcher.  
The number of samples in different weekly batches and the number of abnormalities 
detected by current clinical methods are summarised in Table 3.1.  
 
Week Batch Name Sample Number 
Number of samples where abnormalities 
detected by Hospital Lab 
1 B 136 3 
2 C 155 4 
3 D 108 8 
4 E 280 16 
5 F 251 10 
6 G 93 6 
7 H 228 18 
8 I 114 8 
9 J 144 20 
10 K 166 9 
11 L 180 3 
12 M 162 7 
 
Total 2017 112 
 
Table 3.1. Analysed samples for a period of 12 weeks used for comparative study to 
current methods  
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Standards with known levels of HbA2 (WHO 1
st
 international reference reagent) and 
HbA1c (ClinTest standard) have been used as reference points for quantitation 
purposes.  
 
Sample preparation  
 
Samples were aliquoted and stored at -80 ºC. 1 ml of stock solutions from fresh 
samples were prepared by adding 20 µL of the blood sample to 980µL water.  
Solutions for direct infusion measurements were prepared by diluting 20 µL of stock 
solution in 380 µL of a solution composition of 50% ACN and 0.2% HCOOH. These 
samples were centrifuged for 3 minutes at 9503 g. 280 µL transferred into 96-well 
plates (well volume 350 µL). A single plate was composed of a maximum of 94 
patient samples, HbA2 reference standard and HbA1c reference standard. The plates 
were covered with aluminium foil to prevent sample evaporation. For the HbA2 
standard a stock solution was prepared every month during the three months trial. 
The HbA1c ClinTest is purchased as a solution which is approximately 250-fold less 
concentrated than normal human blood level, and therefore a further four-fold 
dilution was performed in 50% ACN/0.2% HCOOH.  
 
Tryptically digested blood samples were prepared by mixing 200 µL of stock 
solution with 40 µL of 50% ACN and 0.5% HCOOH, incubating at room 
temperature for 5 minutes and then adding 12 µL of 1M ammonium bicarbonate 
(Sigma Aldrich) solution and 10 µL 5 mg/ml trypsin solution (Sigma Aldrich). The 
samples were kept at 37 ºC overnight, and then centrifuged for 3 minutes at 9503 g. 
35 µL of the digest mixture was diluted in the 96-well plates with 210 µL of 10% 
ACN containing 0.5% formic acid. All prepared 96-well plates contained the 
digested HbA2 reference standard, and a control sample containing HbG-
Philadelphia digested peptide mixture. During initial measurements it was observed 
that trypsin originating from different production batches with different LOT 
numbers had different cleavage efficiencies in yielding the required peptides. The 
presence of the characteristic peptide for HbG-Philadelphia could be used to monitor 
the efficiency of the enzymatic cleavage. Trypsin, which contained contaminating 
proteolytic enzymes, resulted in no HbG Philadelphia peptide when overnight 
incubated, and also resulted in erroneous results for monitored peptide ratios.  
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3.2.2 Materials for experiments performed on the amaZon speed ETD 
mass spectrometer 
 
Standard preparations were used for optimisation and preliminary studies. For 
assessing glycated hemoglobin measurements the ClinTest reference standard with 
known concentration of HbA1c (11011, RECIPE Chemicals + Instruments GmbH, 
Munich, Germany) was used, and for delta chain level determination the WHO 1
st
 
international reference reagent for HbA2 (89/666, National Institute of Biological 
Standards and Control) was used. Lyophilised HbS powder (Sigma Aldrich) and 4 
patient samples with clinically significant variants, and a control healthy sample 
were also used for method development and optimisation.  
A subset of clinical samples provided by the Haematology Department at University 
Hospitals Coventry and Warwickshire NHS Trust for the clinical trial were used for 
method testing. The numbers of analysed clinical samples are listed in Table 3.2. 
 
Batch 
Sample 
numbers 
Number of abnormal samples (clinically 
significant variants / other condition) 
J  144  15 / 5  
G  93  4 / 2  
H  228  14 / 4  
L  180  3  
E  190 6 / 2  
M  162  6 / 1 
C  48  1  
Selected samples with 
variants from all batches*  
90  80  
 
Table 3.2. Clinical samples analysed using the developed top-down ETD method 
*This selection also includes some samples which were previously analysed as part of the batch 
analysis 
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Sample preparation  
 
Standard solutions were diluted in 50% aqueous acetonitrile with 0.2% (and in some 
cases with 0.5%) formic acid to achieve a final concentration of hemoglobin of 
approximately 7.5-15 ng/µL. 
20 µL of whole blood was diluted in 980 µL deionised water to provide a stock 
solution (approximate concentration 3 mg/ml). The stock solution was further diluted 
for direct infusion experiments 200- and 400-fold in 50% aqueous ACN containing 
0.5% formic acid.  
The stock solutions of clinical samples for introduction with HPLC auto sampler 
were diluted 1 in 100 in 50% aqueous ACN containing 0.5% formic acid.  
 
 
3.2.3  Intact globin chain analysis combined with full scan tryptic digest 
mixture analysis 
 
MS method as described in Chapter 2 detailed in section 2.2.2. Triversa NanoMate 
(Advion Biosciences Ltd., Ithaca, NY, USA) was used for automated sample 
introduction (settings: aspirated sample amount 5 µL, gas pressure, applied voltage). 
The intact MS measurement was a 3 minute measurement in MCA mode with a 
scanning range of m/z 930-1210 and scan time 1 second. All samples were measured 
in three replicates. All data were processed with the BioPharmaLynx
TM
 software 
(Waters, Manchester, UK) and exported and analysed in Excel.  
 
For identification of rare variants the tryptic peptide mixture of the sample was 
analysed in full scan mode with a Synapt HDMS or Synapt G2 system, using gold 
plated needles and nanoESI source.  
 
3.2.4 LC-MRM-based mass spectrometry analysis 
 
The described method in section 2.2.2 referred to as MRM2-method on the Waters 
Xevo TQ instrument was used for the clinical trial: Targeted peptide analysis as 
described in the previous chapter for the normal β- and δ-chain peptides and 
hemoglobin variant specific peptides.  
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For data processing TargetLynx
TM
 (Waters, Manchester, UK) software was used, 
and results were exported into Microsoft Excel, where further quantitative 
calculations were performed.  
 
3.2.5 Top down ETD Method 
 
Experiments were performed using a Bruker amaZon speed ETD iontrap mass 
spectrometer (Bruker UK Limited, Coventry, UK).  
 
Sample introduction 
 
Sample introduction was achieved using either using a 500 µL syringe with a syringe 
drive at a flow rate of 3 µL/min or the auto sampler of the HP 1100 LC system. The 
initial flow delivered by the LC pump was 0.5ml/min decreased to 0.15 ml/min in 
the first 30 seconds, from which a lower, approximately 10-20 µL/min, flow rate was 
achieved with the use of a split line in front of the sample loop. 100 µL of the diluted 
whole blood sample was introduced into the mass spectrometer with the aid of a 
100µL sample injection loop and the LC flow. 
The solvent delivered by the LC system was equivalent to the dilution solvent 50% 
aqueous ACN containing 0.5% formic acid.  
 
Mass spectrometry methods during preliminary studies 
 
For intact globin chain analysis the mass spectrometer was operated in UltraScan 
mode (with a scan speed of 32,500 m/z per second) to achieve a mass spectrum of 
low resolution which, after deconvolution, provides accurate intact mass results for 
the average globin masses. Scan range was m/z 250-3,000, the number of averaged 
scans were 20, while the rolling average 2.  
 
For ETD fragmentation experiments of the protein globin chains the mass 
spectrometer was operated using Enhanced resolution mode (with a scan speed of 
8,100 m/z per second employed). Different ETD parameters were tested including 
number of reagent anions and ion/ion reaction times. ETD reagent anions were odd-
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electron fluoranthene radical anions (C16H10
-
) while the PTR reagent anions were 
even-electron fluoranthene anions (C16H11
-
).  
 
Mass spectrometry methods for the analysis of a clinical sample set 
 
The applied ETD fragmentation method was developed by Ralf Hartmer, (Bruker 
Daltonik GmbH, Germany, Bremen) and further developed by Julia Smith (Bruker 
UK Limited, Coventry, UK).  
Sample introduction was performed as described above with the HP 1100 LC 
system. The automated sample introduction was controlled using the HyStar 
software.  
The acquisition method contained 5 different segments with different measurement 
settings for different purposes. The schematic of the acquisition can be seen in 
Figure 3.41. 
 
 
 
Figure 3.1. Schematic of acquisition for hemoglobin variant diagnosis using the 
Bruker amaZon speed ETD mass spectrometer 
 
Ion source settings for all measurements: capillary voltage 4.5 kV, end plate offset 
500V. 
 
Segment 1: Optimised for intact globin chain analysis and HbA1c quantitation. 
UltraScan mode, ICC Target 300,000, maximum accumulation time 50 ms, scan 
range m/z 250-3,000, averages 20, rolling average 2 (funnel 1 settings in 100, out 35, 
lens 25) 
 
Segment 2: Optimised for intact globin chain analysis and HbA2 quantitation. 
UltraSscan mode, ICC Target 300,000, maximum accumulation time 50 ms, scan 
Intact 1 Isolation
Intact 2 ETD fragmentation
Intact 3
Time/min
0 0.47 2.77 3.12 14.62 16.2
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range m/z 250-3,000, averages 20, rolling average 2 (funnel 1 settings in 100, out 95, 
lens 85) 
 
Segment 3: Isolation of precursor ion β18+ at m/z 882.7 in a two step isolation. First 
step isolation of 885.5 width 10.0 m/z, second step isolation of 882.7 width 3.0 m/z. 
UltraScan mode, ICC Target 225,000, maximum accumulation time 50 ms, scan 
range m/z 250-3,000, averages 10. 
 
Segment 4: ETD fragmentation of isolated β-chain ion, subsequent PTR reaction for 
charge state reduction of fragment ions. Enhanced resolution mode, ICC Target 
175.000, maximum accumulation time 10 ms, scan m/z 250-3,000, averages 10. 
Isolation as in Segment 3. ICC ETD 250,000, ETD Cutoff 120 m/z, reaction time 20 
ms, PTR Target 150,000, PTR cutoff 120 m/z, reaction time 80 ms.  
 
Segment 5: Optimised for intact globin chain analysis. UltraScan mode, ICC Target 
175,000, maximum accumulation time 10 ms, scan range m/z 250-3,000, averages 
10, rolling average 2 (Funnel 1 settings in 100, out 95, lens 85) 
 
Data analysis  
 
Acquired data were processed using the Data Analysis software (ver. 4.1., Bulid 359, 
Bruker Daltonik GmbH, Bremen, Germany) 
Processing methods: A Maximum Entropy algorithm was used for intact globin 
chain analysis, SNAP II was used for deconvolution of the ETD spectra.  
Following the analysis of clinical samples a processing script written by Zoltan 
Czentar (Bruker Daltonik GmbH, Bremen, Germany) was used. The script 
performed MaxEnt deconvolution of the intact protein data, deconvolution of the 
ETD spectra with SNAPII, and generated a pdf report showing four predetermined 
m/z windows for the monitoring of clinically significant variants, with a mass 
spectrum of the deconvoluted intact globin chain spectrum, listing the first 20 most 
intensive peaks, their calculated m/z, intensity and relative intensity in percentages. 
The script is capable of batch processing for high-throughput data analysis.  
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3.2.6 Statistical analysis 
 
For comparison of quantitative measurement capabilities of developed methods to 
the current clinical method, the statistical methods used were Bland-Altman and 
Passing-Bablok. These methods were undertaken using the software Analyse-it (free 
trial version, Analyse-it Software, Ltd., Leeds, UK) 
Linear regression within Microsoft Excel: Correlation coefficients were used to 
measure the strength of linear relationship between two sets of variable. Pearson’s 
correlation coefficient (R) was calculated using the assumption that both variables 
are approximately normally distributed. The R
2
 value describes the proportion of 
variance in y that depends on x. This correlation assesses the association not the 
measurement bias. Relationship and comparison studies based on linear regression 
can be useful for first line graphical presentation of possible correlation but 
differential plots and additional statistical methods can only be used for evaluation of 
an acceptable method agreement with the reference method (Petersen et al. 1997).  
 
Bland-Altman is a graphical method used to assess agreement between two 
analytical methods. The difference between values from the two methods are plotted 
against the average of the results (Bland and Altman 1986, 1999). The resultant plot 
is often called a Bland-Altman plot (or difference plot or bias plot). This method 
reveals the relationship between differences and provides a value for the mean 
difference (bias). The limits of agreement between methods is set as a range of ± 2 
standard deviation from the mean difference. The graphical presentation identifies 
potential outliers, and also the pattern may suggest further systematic error or 
proportional bias. It is expected that 95% of data points fall within the limit of 
agreement range for two methods to be interchangeable. It does not say anything 
about possible restriction for the size of the range, that is a decision to be made by 
the clinician. If the difference between two methods is clinically acceptable the two 
methods can be used simultaneously and interchangeably.  
This method has been used by Roberts et al. when compared glycated hemoglobin 
levels obtained by MS to total glycation levels determined by ion exchange 
chromatography (Roberts et al. 2001).  
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The Passing-Bablok method is a model based method for comparison of methods. It 
employs a linear regression procedure with no special assumptions regarding the 
distribution of the samples or the measurement error (Passing and Bablok 1983). The 
result obtained does not depend on the assignment of the methods to X and Y. This 
regression procedure is not sensitive towards outliers and assumes that measurement 
errors have the same distribution in both methods, but it makes no special 
assumption about the type of the distribution, it is not necessarily normal (Bilic-Zulle 
2011). The slope and the intercept are calculated with their 95% confidence 
intervals. If the 95% confidence interval contains 0 for the intercept and 1 for the 
slope, then the hypotheses for not having any constant or proportional bias is not 
rejected.  
The Passing-Bablok comparison method within the Anlayse-it software also tests 
linearity with the Cusum test, which inspects how the regression line fits the data or 
how randomly the data scatters about the line. If a nonlinear relationship between x 
and y is detected, it is expected that too many consecutive data points will be above 
or below the fitted line. This method can also be used to estimate systematic error 
between two methods with two hypotheses tested or whether there is constant bias or 
proportional bias.  
Coefficient of variation histograms and box plots were used to present mass error 
ranges and technical variation. These were generated using the statistical software 
GenStat.  
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3.3 Results and discussion 
Part I: Results obtained on the full sample set 
using the XEVO TQ mass spectrometer 
 
3.3.1 Determination of HbA2 levels 
 
3.3.1.1 Intact globin chain analysis 
 
HbA2 levels were determined for all 2,017 samples using the intact globin chain 
analysis. All samples were measured three times. Their average values and standard 
deviation were calculated, also the coefficient of variation was determined. The 
calculated coefficient variation values are plotted in a frequency histogram in Figure 
3.2. The average coefficient of variation is 7%, and 95% of the values are below the 
expected 15% for clinical MS methods (Kollipara et al. 2011).  
 
 
 
Figure 3.2. Histogram for the distribution of coefficient of variation of the HbA2 
quantitation by the intact globin chain analysis 
 
Correlation of HbA2 values determined by MS and ce-HPLC was  first investigated 
by plotting the MS values against the HPLC values, and with simple linear 
regression analysis the coefficient determination (R
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) values were calculated. In 
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Figure 3.3 an example of this analysis for the samples in Batch M is shown. All of 
these figures for all batches can be found separately in Appendix 1.  
 
 
Figure 3.3. Calculated HbA2 values determined by intact globin chain analysis 
plotted against values provided by the ce-HPLC method for the samples in Batch M  
 
The parameters resulted from the simple linear regression analysis for all batches are 
summarised in Table 3.3. The R
2
 values are shaded based on whether the fitted line 
is thought to give acceptable or better correlation. The limits for this classification 
were arbitrarily chosen. 
The values based on the simple linear regression suggest there is linear relationship. 
This type of analysis, however, can be misleading, since fitting a trend line to two 
almost distinct groups will always give high correlation. R
2
 values are only 
appropriate for an initial visualisation of the correlation. The measured and 
calculated values are in all cases higher than the ce-HPLC values, but with a shift. 
All intercept values are above 1, the average for all twelve batches is 1.61, while the 
slope is around 1. This would suggest a linear relationship with no proportional but 
constant bias. 
When presenting the distribution of the measured values in a dot-histogram next to 
the distribution of the HPLC values (Figure 3.4), it is clearly visible, that there is a 
significant shift, and the samples identified with elevated HbA2 levels are also 
elevated according to the intact MS method. This separation of normal and elevated 
values can be observed for all measured sample batches, and the method consistently 
and reliably identifies the samples with elevated levels.  
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Batch 
ID 
Number of  
Samples 
R
2
 - 
summary 
Intercept Slope 
B 136 0.58 1.625 0.9428 
C 155 0.68 1.2307 1.111 
D 108 0.90 1.3515 1.1468 
E 280 0.73 1.8338 1.0775 
F 251 0.57 1.9888 0.9424 
G 93 0.61 2.4055 0.8811 
H 228 0.65 1.8584 0.9853 
I 114 0.82 1.5562 1.1132 
J 144 0.74 1.3539 1.0577 
K 166 0.72 1.2917 1.0365 
L 180 0.74 1.3233 1.0905 
M 162 0.78 1.5574 1.0588 
Average 0.71 1.61 1.04 
 
best 
 
better 
 
acceptable 
  
   
  
≥0.8 0.6-0.79 ≤0.59   
 
Table 3.3. Results of the correlation analysis for all analysed sample batches by the 
intact globin chain analysis 
 
 
Figure 3.4. Distribution of measured values for the HbA2 quantitation by the HPLC 
method and by the intact globin chain analysis.  
 
To investigate the relationship between values from two methods other statistical 
methods may be more appropriate.  
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Results of the Bland-Altman statistical analysis, while only looking at the 
differences between the values from the reference method and the new method can 
give an estimation regarding systematic bias between the outcomes of the methods. 
The graphical outcome of the statistical analysis can be seen for the samples of batch 
M in Figure 3.5. The figure shows the distribution of the differences around the bias, 
and the outliers, which are not in the range for the limits of agreement. The same 
type of figure for all batches can be found in Appendix 1.  
 
 
Figure 3.5. Difference plot for the comparison of values from HPLC and intact MS 
methods using the values from batch M 
 
The results of this type of analysis for all sample batches are summarised in Table 
3.4. The average bias is 1.73, similar to the average constant bias from the simple 
linear regression. There are a few outliers in case of every batch, but 95% of the 
values are within the limits of agreement. The width of the agreement range varies 
from 1.13 to 2.09 and the average for all batches is 1.53. This range of HbA2 values 
indicates a high fluctuation which may be unacceptable for clinical diagnosis 
considering that the 3.5% limit between normal and elevated values allows only a 
narrow range for variation. The pattern of the graphical presentation may suggest a 
presence of proportional error, since the difference values tend to shift towards the 
higher levels as the average values increase.   
The results from the Passing and Bablok statistical method are somewhat different. 
For batch M it does not suggest constant bias, but 1.64 as proportional bias as shown 
in Figure 3.6. Table 3.5 summarises all the results for all batches. The corresponding 
figures can be found in Appendix 1. In 10 batches the confidence interval for the 
constant bias contains 0, meaning the hypothesis to have no constant bias is not 
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rejected. None of the 95% confidence intervals for the proportional bias contained 1, 
the hypothesis regarding proportional bias is definitely rejected as a result of a 
comparison of the two techniques.  
 
Batch ID 
Number of 
samples 
95% CI range 
of agreement 
(%) 
Width of 
agreement range 
(%) 
Number of 
outliers 
Bias (%) 
B 136 0.67-2.27 1.60 7 1.47 
C 155 0.84-2.21 1.37 9 1.53 
D 108 1.02-2.51 1.49 4 1.77 
E 280 1.26-2.83 1.57 9 2.04 
F 251 1.15-2.83 1.68 5 1.99 
G 93 1.23-2.97 1.74 3 2.10 
H 228 0.8-2.89 2.09 10 1.84 
I 114 1.23-2.49 1.26 4 1.86 
J 144 0.76-2.26 1.50 5 1.51 
K 166 0.72-2.05 1.33 6 1.39 
L 180 1.00-2.13 1.13 10 1.57 
M 162 0.93-2.50 1.57 6 1.72 
Average   1.53 6.5 1.73 
 
Table 3.4. Results of the Bland-Altman statistical analysis for all analysed sample 
batches by the intact globin chain analysis  
 
 
 
Figure 3.6. Passing-Bablok regression analysis for the intact MS results for batch M 
 
All statistical methods support the hypothesis that values from the intact globin chain 
analysis differ with a certain bias observed from the ce-HPLC analysis result. To use 
intact globin-chain analysis as a diagnostic tool for HbA2 level determination either 
this certain bias (constant or proportional or both) needs to be defined and used as a 
correction factor for calculating true values, or an appropriate calibration process 
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needs to be applied. New limits and ranges for HbA2 levels for normal and abnormal 
samples may be defined when the intact globin chain analysis is used. This requires 
further method development and validation.  
 
Batch 
ID 
Number of 
samples 
Constant Bias Proportional 
Bias 
Approximate 
numbers of outliers 
Comment 
B 136 -0.4 1.7 4  
C 155 -0.1 1.59 18 Low constant bias 
D 108 0.69 1.38 13  
E 
280 
0.33 1.62 ~30 Non-linear 
relationship detected 
F 251 0.02 1.80 11 No constant bias? 
G 93 0.8 1.54 4  
H 228 -0.46 1.85 15  
I 114 0.68 1.44 7  
J 144 0.11 1.51 13 Low constant bias 
K 166 0.24 1.43 10  
L 180 0.33 1.45 13  
M 162 0.08 1.64 10 No constant bias 
Average  0.19 1.58 12.3  
 
Table 3.5. Results of the Passing & Bablok Statistical analysis for all analysed 
sample batches by the intact globin chain analysis 
 
 
The intact MS method consistently detected elevated δ-chain levels. The average 
calculated HbA2 level measured by the intact globin chain analysis was 7.5 % for the 
reference standard which had an indicated HbA2 value of 5.3%. With simple ratio 
calculation the 3.5% limit set for the HPLC-method with the MS method would be 
5%. The 5% limit might be appropriate for some of the sample batches, but not for 
all of them, a arbitrarily chosen limit of 6% would provide a more appropriate 
boundary.  
The distribution of HbA2 values by the HPLC method and intact MS is presented in 
Figure 3.7. The limit of 3.5% for the HPLC method clearly separates the elevated 
values based on that method. For the intact MS method a limit of 6% also separates 
all of the elevated values.  
In case of batch M two sample values circled showed elevated HbA2 levels with the 
intact MS method, because those samples were carriers of variants which had been 
not detected chromatographically. Intact globin chain analysis allows calculation of 
δ-chain levels as a ratio to the normal β-chain levels. When a variant β-chain is 
present, this ratio is affected, and in some cases the measured HbA2 levels can be 
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used as indicator for abnormalities other than the elevated δ-chain levels due to β-
thalassemia.  
Based on the results presented here intact globin chain analysis is suggested to be a 
good indicator method for elevated HbA2 levels and other abnormalities, but it has a 
certain bias, which needs to be defined and taken into account or corrected with 
appropriate calibration. For calibration a reference sample series with at least 3-5 
points of different levels would be advised.  
 
 
a) 
 
b) 
Figure 3.7. Distribution of the determined HbA2 values by the hospital laboratory 
using the ce-HPLC method (a) and by the intact globin chain analysis (b) 
Data are shown separately for each batches analysed. Shaded area represents the 3.5% barrier for 
elevated values in case of the HPLC results and the proposed barrier of 6% for the MS method 
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3.3.1.2 LC-MRM analysis 
 
With the MRM–method three different peptide ratios were monitored to quantify 
relative percentage of δ-chain compared to the β-chain, giving an estimation about 
the HbA2 levels. HbA2 levels were then calculated for the three different peptide 
pairs.  
Initial statistical analysis was performed by plotting the calculated values against 
HPLC values. By applying a simple linear regression, R
2
 values and parameters of 
the equation belonging to the fitted line were determined.  
Examples for the graphical outcome of the simple linear regression analysis can be 
seen in Figure 3.8 for all peptide ratios for one batch. Figures for all batches can be 
found separately in Appendix 1. The summarised parameters from the linear 
regression analyses are listed in Table 3.6.  
 
  
a) b) 
 
c) 
Figure 3.8. Calculated HbA2 values determined by the MRM plotted against the 
values provided by the ce-HPLC method for the samples analysed in Batch M. For 
T2 peptide ratios (a), for T3 peptide ratios (b) and for T5 peptide ratios (c) 
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Batch ID No. Samples R2 - T2 R2 - T3 R2 - T5 
Intercept – 
T5 
Slope - T5 
B 136 0.42 0.49 0.81 0.2417 0.9857 
C 155 0.46 0.77 0.72 0.0351 0.9264 
D 108 - 0.44 0.91 0.4902 1.1775 
E 280 0.41 0.81 0.75 0.1894 0.8303 
F 251 0.22 0.62 0.75 0.4528 1.0446 
G 93 0.11 0.48 0.79 0.3565 0.9855 
H 228 0.67, 0.63 0.82 0.73 0.3939 1.0054 
I 114 0.66 0.59 0.90 0.2596 0.7369 
J 144 0.32, 0.60 0.90 0.80 0.4784 1.2577 
K 166 0.21 0.12 0.87 0.7881 1.0877 
L 180 0.52, - 0.53, - 0.53, 0.76 
-0..287, 
0.5687 
1.2578, 
0.7811 
M 162 0.85 0.69 0.86 0.3143 0.9773 
Average 0.47 0.61 0.78 0.3492 1.0041 
 
Best 
 
better 
 
acceptable 
  
   
  
≥0.8 0.6-0.79 <0.59   
 
Table 3.6. Results of the correlation analysis for all analysed sample batches by the 
different peptide ratio analysis using the MRM method 
 
The resultant values from simple linear regression together with the investigation of 
the figures suggest that the T5 peptide ratios are the most consistently useful 
indication for the HbA2 levels. In case of T2 peptides, the distribution of the 
calculated values were in an abnormal range for some sample batches, levels of 60-
90% for the δT2 peptide relative to the βT2 peptide were calculated, highlighting 
some serious issues with enzymatic cleavage. In other cases, for example batch M, 
the values seemed to be perfectly normal and highly correlated to HPLC values. T2 
peptides seemed to be more affected by the incomplete cleavage problem, with T3 
peptides to a lesser extent, and T5 peptides even less. The ranges slightly fluctuate 
for T5 peptides, but the elevated and normal levels are clearly separated. Distribution 
of the measured and calculated values can be seen for all peptide ratios compared to 
the distribution dot histogram of the HPLC values in Figure 3.9.  
The T3 peptide ratios did not show any radical differences from batch to batch, but 
they did not show a consistently high correlation to HPLC values as had been 
displayed by the T5 peptides. The values, based on T5 peptide ratios were able to 
distinguish more easily between normal and elevated values, as shown in Figure 3.9. 
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For further method comparison with previously used statistical methods, only the T5 
peptide ratios were chosen. The parameters of the equation of the fitted lines to the 
T5 values are included in Table 3.6. The intercept values fluctuate from batch to 
batch resulting in an average of 0.35, but calculating mean value here may not be 
appropriate. In case of Batch L the calculated values clearly fall into two separate 
distributions for the two 96-well sample plates measured separately, and therefore 
trend lines were fitted separately and two values are shown for R
2
, intercept and 
slope values.  
 
 
 
Figure 3.9. Distribution of measured values for the HbA2 quantitation by the MRM 
method for different the peptide ratios monitored 
The data points indicating elevated HbA2 levels are circled in red.  
 
All samples were measured in three replicates. The mean values and standard 
deviation were calculated, and the coefficient of variation was determined. The 
calculated coefficient variations for all three different peptide ratio values are plotted 
in a frequency histogram in Figure 3.10. The average cv for T2 peptides was 3.9 and 
98% of the values are below 15%. For T3 peptides the average cv was 7.5, and 91% 
of the values were below 15%. For T5 peptides the average was 6.6 and 95% of the 
values were below 15%. Coefficient of variation values are best for the T2 values, 
but for T5 peptides are still acceptable. The better results for T2 values may be 
explained by the occasionally abnormally high levels. When those were measured 
with the same standard deviation, this resulted in lower cv% values.  
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Figure 3.10. Histogram for the distribution of coefficient of variation of the HbA2 
quantitation by the MRM method a) T2 peptides, b) T3 peptide and c) T5 peptides 
 
 
Bland-Altman statistical analysis has been performed on all twelve batches for the 
HbA2 levels obtained from T5 peptide ratios, results are summarised in Table 3.7. 
The width of the ranges for the differences are slightly smaller than previously 
observed for the intact globin chain analysis. The number of outliers for all batches 
on average is approximately the same. The bias values, however, fluctuate much 
more than observed for the intact MS method. There is a definite bias between the 
MRM-method and the HPLC method. The graphical results of the Bland-Altman-
method can be found in Appendix 1 for all sample batches shown separately.  
Patterns observed for the calculated differences for different sample batches do not 
strongly indicate the presence of proportional bias observed with the intact MS 
method, and for some of the batches no indicative pattern was observed at all. For all 
batches 95% of the data points were in range of agreement. These analyses indicate 
an agreement between the two techniques. One can state that the methods may be 
interchangeable, which forms a subject for further investigation.  
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Batch ID 
Number 
of samples 
95% CI range 
of agreement 
Width of 
agreement range 
Number of 
outliers 
Bias 
B 136 -0.27-0.68 0.95 6 0.2 
C 155 -0.68-0.36 1.04 3 -0.16 
D 108 0.27-1.70 1.43 6 0.99 
E 280 -0.87-0.33 1.2 14 -0.27 
F 251 -0.01-1.15 1.16 10 0.57 
G 93 -0.29-1.03 1.32 3 0.37 
H 228 -0.37-1.19 1.56 6 0.41 
I 114 -0.81-(-0.05) 0.76 5 -0.43 
J 144 0.35-2.01 1.66 7 1.18 
K 166 0.6-1.45 0.85 9 1.02 
L 180 0.63-1.30 1.93 4 0.34 
M 162 -0.29-0.79 1.08 5 0.25 
Average   1.25 6.5 0.37 
 
Table 3.7. Results of the Bland Altman statistical analysis for all analysed sample 
batches by the MRM analysis for the T5 peptide ratios 
 
Results of the Passing-Bablok method comparison are less convincing than for the 
intact MS method. The bias values fluctuate more from batch to batch. The average 
constant bias is a negative value, -0.60, and only in 5 batches is the hypothesis of not 
excluding the possibility for no constant bias not rejected. The hypothesis about no 
proportional bias is rejected for all batches. The number of outliers observed is 
significantly higher, for some larger batches over 30. 
In the case of batches C, H, L and M a nonlinear relationship were detected. This is 
most likely explained by differences between sample plates within one batch. In 
some cases a plate was re-measured, while there was no time to re-measure the 
second plate, and therefore the differences are emphasized. In case of batch L, where 
observation of clearly separated distribution of calculated values was made, the 
nonlinear relationship would be expected.  
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Batch ID Number of 
samples 
Constant 
bias 
Proportional 
bias 
Approximate 
number of outliers 
Comment 
B 136 -0.14 1.13 13  
C 
155 
-0.70 1.21 3 Nonlinear 
relationship 
detected D 108 0.03 1.33 15  
E 280 -0.04 0.9 ~45  
F 251 -0.43 1.38 ~38  
G 93 -0.51 1.32 6  
H 
228 
-1.75 1.81 12 Nonlinear 
relationship 
detected I 114 0.12 0.79 7  
J 144 -0.41 1.60 12  
K 166 0.26 1.28 ~22  
L 
180 
-3.08 2.29 6 Nonlinear 
relationship 
detected M 
162 
-0.54 1.31 9 Nonlinear 
relationship 
detected Average  -0.60 1.36 15.7  
 
Table 3.8. Results of Passing-Bablok Statistical analysis for all analysed sample 
batches by the MRM analysis for the T5 peptide ratios 
 
The distribution for all measured values for all batches separately (Figure 3.11) also 
highlights differences between normal distributions. Elevated values are in most of 
the cases clearly detected. There is no clear barrier which may be set from where 
elevated values are separated for all sample batches.  
 
 
Figure 3.11. Distribution of the determined HbA2 values by the MRM method 
calculating T5 peptide ratios  
Data are shown separately for each batches analysed 
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There is a high HbA2 value obviously present in batch I, which belongs to a sample 
diagnosed as Hb Lepore.  
Using the MRM method monitoring the T5 peptide ratios may give indication for 
elevated levels within one sample batch, or more precisely among the results from 
one sample plate, where the samples have been prepared the same way, with elution 
solvents, chromatography column the same. To avoid such high plate to plate 
fluctuation, employment of calibration is necessary, and it is needed more than it was 
for the intact MS measurements. The issue regarding enzymatic cleavage 
incompleteness also needs to be investigated and addressed.  
When values calculated for the reference standard are plotted for the intact MS 
method and for the T5 peptide ratios from the MRM method it is observed that there 
is a higher level of fluctuation for the MRM-method levels than for the intact MS 
levels (Figure 3.12). This fluctuation of values is mirrored in the previously 
mentioned fluctuation of distribution ranges, which could be a result of problems 
with the enzymatic cleavage, or with the reliability of the monitored transitions. 
 
 
 
Figure 3.12. HbA2 values for the reference standard measured by the intact globin 
chain analysis and by the MRM method based on the T5 peptide ratios 
Each dot represents one data point from one 96-well sample plate 
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3.3.2 Clinically significant variant detection 
3.3.2.1 Intact globin chain analysis 
 
Detection of HbS 
 
Detection of HbS variants on the intact mass level is straightforward based on the 
expected -30 Da mass shift. All samples during the three month trial were analysed 
using the intact globin chain method, and the data were processed using 
BiopharmaLynx to screen for the presence of the βSICKLE mass peak next to the wild 
type β-chain mass peak. The samples classed as heterozygous carriers, compound 
heterozygotes for HbS and HbC or homozygous of the sickle mutation are listed in 
Table 3.9.  
 
Batch Name 
Samples classed as SS 
or transfused SS 
Samples classed as AS Samples classed as SC 
B B127 1 B2,B7 2 - 
C - C1, C103, C154 3 C99 1 
D D92 1 
D86, D87, D90, 
D96, D108 
5 D95 1 
E 
E34, E146, E180, 
E239, 
4 E20, E197, E240, E257 4 - 
F 
F129, F229, F230, 
F231 
4 F50, F116, F128 3 - 
G G92 1 G32,G33,G93 3 - 
H H39, H40, H143 3 H41, H42, H43, H44, H47, H70 6 - 
I I1, I74 2 I7, I9, I39,I53 4  
J 
J48, J87, J106, 
J116 
4 J16, J41, J42, J43, J45, J66 7 J40 1 
K - 
K42, K43, K45, K46, K50, K57, 
K78 
7 - 
L - L49, L130 2 - 
M M42, M154 2 M50, M51, M122 3 - 
Total: 73 22 48 3 
 
Table 3.9. Summary of sickle conditions among all batches analysed in the clinical 
trial.  
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If a peak -30 Da lower than the β-chain was observed, the percentage of the βSICKLE 
was calculated as a ratio to the sum of beta-like chains the same way as for the 
percentage of the δ-chain levels previously shown.  
A mass peak at -30 Da (15,837.3) compared to normal β-chain mass (15,867.2) was 
observed in the mass spectra for all listed samples in Table 3.9. In agreement with 
hospital results that can be indicative of the presence of the sickle variant. Further 
confirmation was necessary, which was achieved using peptide level analysis, which 
is presented later.  
In Figure 3.13 the calculated percentage of HbS for samples classed as AS – 
heterozygous sickle hemoglobin carriers can be seen. The general observation can be 
made that the majority of the calculated values are between 30 to 45%. The 
calculated values are summarised in Table A.1 in Appendix 2.  
 
 
 
Figure 3.13. Calculated βSICKLE-chain levels for the samples classed as heterozygous 
sickle carriers by the hospital laboratory  
The sample H47, shown in red first calculated against normal β-chain which was not present, and then 
against the variant peak which was observed, recalculated value shown in green.  
 
In case of sample H47, there were no normal β-chain mass peaks observed, and 
calculation against normal β-chain resulted in 100% for βSICKLE, but the sample 
contained a significant peak belonging to a rare Hb variant, Hb Iraq-Halabja. The 
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value for this sample has been recalculated using the variant mass peak intensity 
instead of the normal β-chain.  
 
When a sample was classed as SS, homozygous sickle was assumed. In some cases 
that is true and no or very low intensity mass peaks for normal β-chain could be 
observed in the deconvoluted mass spectrum. The graphical presentation of the 
calculated HbS levels can be seen in Figure 3.14. In some cases samples classed as 
SS still had a relatively high level of normal β-chain, and in cases of sample D92, 
E239, I40, I106, I116, M42 and M154 the HbS level were 50% and below. In 
samples F129, F230, F231 and G92 this is explained by the information given by 
hospital stating that the patients had received blood transfusion, which is a known 
way of treating the symptoms of Sickle cell disease. Based on this it is assumed that 
the other samples are from individuals who also have received blood transfusion 
previously but this information has not been provided or the samples were from 
heterozygous carriers.  
 
 
 
Figure 3.14. Calculated βSICKLE-chain levels for the samples classed as compound 
heterozygotes for HbS and HbC (green) or homozygous sickle patients (blue), or 
transfused homozygous patients (purple) 
Samples shown in orange show calculated values only around 50% or lower, suggesting the patient 
only being a heterozygous sickle carrier or given blood transfusion before 
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The calculated percentages of βSICKLE to all β-chains (wild type and sickle) for all 
samples classed as homozygous or heterozygous are summarised in Appendix 2 in 
Table A.2.  
Samples that had been classed as compound heterozygote for HbS and HbC variants 
were also calculated against the mass peak -1 Da shifted relative to normal β-chain 
mass, giving values around 50%, as expected.  
A trend worth mentioning is the slight elevation of the measured δ-chain levels 
compared to normal levels in healthy individuals. δ-chain levels could be calculated 
when a sample during intact measurement provided mass peak for the normal β-
chain next to the variant β-chain, since δ-chain levels are estimated by ratio 
calculation to normal β-chain level intensities. Any time a variant β-chain is present, 
the level of the normal β-chain is lower, and so the calculated δ-chain level relative 
to the normal β-chain present will be higher, highlighting abnormalities with the 
sample. Figure 3.15 shows the calculated values were above 5%, apart from three 
samples J116, F231 and D92, which showed low values of HbS as previously 
presented. Nine samples had values above 5% but less than 6%, and the rest of the 
samples had elevated, above 6% δ-chain levels. The 6% limit for elevated levels is 
suggested as the cut-off limit for the intact-chain level analysis as presented 
previously. In the case of samples E146 and B127 HbS levels were high (84.8% and 
80.7% respectively), and so calculated δ-chain levels against the normal β-chain 
levels understandably resulted in higher levels (19.2% and 19.8%).  
 
 
 
Figure 3.15. Calculated δ-chain levels using the results of the intact-globin chain 
analysis for the samples classed as homozygous or heterozygous sickle carriers by 
the hospital laboratory  
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Indication for the presence of -1 Da variants based on mass error calculations for 
the β-globin chain 
 
Based on published literature, the presence of -1 Da mass difference variants could 
be observed by the mass shift of the beta-chain mass caused if the variant is present 
at 10% or more when using the α-chain mass as internal mass calibrant (Rai et al. 
2003). For this hypothesis to be tested in intact-globin chain analysis the achievable 
mass error by the intact globin chain analysis needed to be assessed for all analysed 
samples within all batches.  
Samples with -1 Da Hb variants such as HbD-Punjab, HbE, HbC and HbO-Arab 
were analysed. The sample numbers with these conditions are summarised in Table 
3.10. for all batches separately. There was only one sample with HbE (H45) and one 
with HbO-Arab (F115) mutation.  
 
Batch 
Samples with -1Da variants (HbE, 
HbO-Arab, HbC, HbD-Punjab) 
Numbers 
B - - 
C C99 1 
D D94, D95 2 
E 
E143, E151, E255, E256, E258, 
E259 
6 
F F115 1 
G - - 
H H45, H46, H48, H138 4 
I - - 
J J40, J44, J46, J69, J140 5 
K K44 1 
L L11 1 
M M121 1 
Total  22 
 
Table 3.10. Summary of the occurrence of -1 Da variants in the 12 batches analysed.  
 
There were only three batches without any -1 Da variants, and three sample batches 
contained 4 or more samples with -1 Da variants. The latter three were Batch E, H 
and J. Calculated mass errors for these batches are shown in Figure 3.16. Equivalent 
figures for all other sample batches can be found in the appendix.  
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In sample batch E (sample number 280) there were 6 samples with conditions of one 
of the -1 Da clinically significant variants. HbD-Punjab mutation in samples E143, 
E151, E255, E259 and HbC mutation in samples E256 and E258 as summarised in 
Table 3.11. The mass errors for the β-chain have been calculated using the α-chain as 
an internal calibrant, assuming it is the correct mass and no -1 Da variants are 
present affecting the α-chain.   
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a)  
b)  
c)  
 
Figure 3.16. Calculated mass errors for the β-chain after corrected by the mass error 
of the α-chain for Batch E (a), Batch H (b) and Batch J (c) 
Green markers represent normal samples, yellow dots correspond to samples with HbS and red 
squares represent -1 Da variants 
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In Batch E the majority of the corrected mass errors of the β-chain are in the range 
+0.1 to -0.3 Da, distributed around -0.1 Da mass error value. This represents a ±0.2 
Da window, which is shaded grey in Figure 3.16 a). This ±0.2 Da would be expected 
to be distributed around 0, but there is a systematic error detected with the mass 
measurement. Based on the achievable mass accuracy of ±0.2 Da, although shifted 
because of the systematic error, the hypothesis by Rai et al. would provide detection 
of -1 Da variants if they were present at 20% or more.  
In Figure 3.16 yellow dots represent the samples with a diagnosed HbS mutation, the 
red squares represent the samples with -1 Da variants. In Figure 3.16 a) all -1 Da 
variants are outside the grey area except one (sample E143), which later was not 
confirmed by full scan tryptic digested peptide mixture analysis to have a HbD-
Punjab mutation. This may suggest that the variant is present only in a low amount, 
less than 20%, or not present at all. The presence of all five other -1 Da clinically 
significant variant in Batch E would be observed. There were additional samples 
with slightly abnormal mass errors. Three of these sample E61, E174 and E187 
(circled red) contained variants. Other samples were not detected with any obvious 
abnormalities. Full scan tryptic digest analysis would be required to reveal any 
abnormalities. It was also observed that samples presented out of range mass errors if 
they have been re-measured. In some cases the measurement of a sample had to be 
repeated the following day, because none or only one of the three replicates resulted 
in a mass spectrum. The cause of the failed measurements is more likely to be nozzle 
blockage during sample introduction with the NanoMate chip.  
An observed phenomenon is that the majority of the samples with HbS or other rare 
variants also had mass error outside the grey area. This would suggest that additional 
peaks close to normal β-chain may have an effect on the detected mass of the normal 
β-chain in many of these cases. The reason for this is not completely clear. There 
may be an interaction or coupling between different ion species adjacent to each 
other on the m/z scale. These multiply charged ions may be coupled on the intact 
level. The sample E187 had a 50% abundant β-chain variant with a +58 Da mass 
difference and caused observable mass shift of the normal β-chain, resulting in 
abnormal mass error.  
In Figure 3.16 b) the same presentation of the mass errors for sample batch H 
(sample number 228) is shown. This batch contained 4 samples with -1 Da clinically 
significant variants: H45 with HbE mutation and H46, H48, H138 with HbD-Punjab 
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mutation. This time the mass error window for the samples was slightly shifted 
above 0, and is not constant among all measurements, probably differing due to 
results for different sample plates. As the sample number in this batch was 228, they 
could only be analysed by preparing three different 96-well sample plates. The mean 
mass error difference between plates is visible, but more obviously present in Figure 
3.15 c) for batch J discussed later. Samples H46 and H138 are clearly outside the 
grey area, which is indicative of a -1 Da variant. Sample H48 is on the borderline, 
which may suggest a variant, but it can also have a slightly larger (shifted into 
negative direction) mass error. Sample H141 was identified with a 
chromatographically silent β-chain variant, causing mass shift and abnormal mass 
error.  
Batch J (sample number 144) represents clearly how mass error fluctuations can 
prevent the detection of -1 Da variants as the central region of the mass error figure 
illustrates. If we only look at mass errors for normal samples in the first and last 
section of the figure, the clinically significant variants are clearly separated, and 
indication for all is observed. The central region would however make an attempt to 
set a reference range for normal values difficult. The reason of the occurrence of 
these erroneous values is not yet clear.  
Summary for samples diagnosed with -1 Da variants, and the mass error calculations 
indicating the presence of a variant can be seen in Table 3.11.  
All samples with SC conditions have been unambiguously detected using this 
method. The majority of other conditions have also been detected, although this 
method still has a level of uncertainty based on different systematic errors observed 
for the calculated values of different batches.  
Systematic error can either come from calibration or from data processing. The 
calibration was performed with a normal sample from each batch prior to analysis of 
the entire batch. The use of a normal sample from a batch may have been 
inappropriate since chromatographically silent variants proved to be present in some 
samples classed as normal. Future studies would benefit from the use of a known 
reference material for calibration.  
Another possible source for systematic errors is processing method and the 
application of a lock mass value corresponding to one of the multiply charged ions of 
the α-chain, or other parameters influencing the calculated mass.  
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The fluctuation of ranges between sample error measurements among all batches is 
illustrated by Figure 3.17. 
 
 
Variant Sample 
δ-chain 
level % 
Variant 
% 
MassError 
Detected/Indication 
based on Intact MS 
1 A O ARAB F/115 4.41 - -0.764 Yes 
2 AC E/256 5.3 - -0.408 Yes 
3 AC E/258 6.5 - -0.535 Yes 
4 AC J/44 4.8 - -0.494 Yes 
5 AC J/46 4.5 - -0.438 Yes 
6 AC J/140 5.5 - -0.5032 Yes 
7 AC K/44 5.2 - -0.599 Yes 
8 CC J/69 6.9 - -1.1431 Yes 
9 SC C/99 7.7 48.3 -1.305 Yes 
10 SC D/95 9.3 52.9 -1.448 Yes 
11 SC J/40 9.7 52.9 -1.575 Yes 
12 AE H/45 7.0 - -0.0989 No 
13 AD D/94 4.6 - -0.692 Yes 
14 AD E/143 7.9 - -0.0976 No 
15 AD E/151 5 - -0.618 Yes 
16 AD E/255 4.9 - -0.627 Yes 
17 AD E/259 4.9 - -0.636 Yes 
18 AD H/46 5.3 - -0.3509 Yes 
19 AD H/48 5.4 - -0.1725 Borderline 
20 AD H/138 5.9 - -0.3463 Yes 
21 AD L/11 4.8 - -0.5631 Yes 
22 AD M/121 4.0 - -0.625 Yes 
 
Table 3.11. Summary of -1 Da variants grouped based on the specific mutation 
conditions (shadings represent different mutations, purple for HbO-Arab, green for HbC, blue for 
HbE and orange for HbD-Punjab) 
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Figure 3.17. Boxplots of error measurement of the β-chain corrected by the α-chain 
mass error.  
Data are shown separately for each batches analysed 
 
The majority of the mass error windows are below 0, but not consistently for the 
overall sample analysis. The problem highlighted by this Figure is that using mass 
error values as indication for the -1 Da variants is not an absolute indicator within all 
measurements at any time. The values are indicative if they are significantly 
different than average mass error for samples measured around the diseased samples 
at the same time with the same instrumental conditions and calibration. 
Measurements within one batch and even within one 96-well plate often did not give 
completely consistent results, and some of the Figures show this phenomenon. The 
presented box plot illustration is no longer a working solution which could point out 
only outliers as was assumed and suggested in the previous method development 
chapter.  
An additional observation worth mentioning, is that samples with elevated δ-chain or 
HbF levels also had slightly abnormal mass errors.  
As mentioned, mass error may significantly depend on the processing method 
parameters during the algorithm applied to the mass spectrum of multiply charged 
ions when deconvoluted to true mass scale. Further investigation and optimisation is 
necessary for the parameters used by the algorithm to be able to provide reliable 
indication about the presence of -1 Da clinically significant variants, especially if the 
intact MS method alone is pursued to be used as a first line screening method in the 
clinical lab.  
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3.3.2.2 LC-MRM analysis and full scan peptide mixture analysis  
 
Detection of HbS  
 
The detection and confirmation of the presence of predetermined clinically 
significant variants using the MRM method is straightforward. The peptides 
monitored are either present or not. The peptides monitored are quantified only if the 
corresponding wild type peptide is present.  
For detection of HbS mutation, the detection of the βSICKLE T1 tryptic peptide was 
necessary. The wild type T1 peptide was monitored with predefined MRM 
transitions. The percentage of the HbS variant was calculated by ratio calculations of 
the peak area of the βSICKLE T1 to the sum of the sickle and normal T1 peptide peak 
areas. The determined HbS levels are shown in Figure 3.18 for the samples classed 
as heterozygous sickle carriers. The calculated values are listed in Table A.3 in 
Appendix 2.  
 
 
 
Figure 3.18. Calculated βSICKLE-chain levels based on the results from the MRM 
method for the samples classed as heterozygous sickle carriers by the hospital 
laboratory  
The sample H47, shown in red was detected with variant beta-chain during intact globin chain 
analysis. Samples shown in orange had significantly lower values than it was calculated from the 
intact globin chain analysis. Sample F128 showed 100% βSICKLE since it did not have peak for the 
wild type β-chain T1 peptide as the individual was a baby with high HbF levels.  
 
Levels determined by the MRM method were significantly lower for the majority of 
the samples than the levels calculated by the intact globin chain analysis. They are 
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also not evenly distributed and show more fluctuation. The majority of them are 
below 20%, which may suggest ionisation or fragmentation efficiency differences 
between the normal and variant peptides. Samples D108, H141, H43, J43, K43 were 
significantly lower, and samples K46, K50, K57, K78 resulted in HbS levels of only 
1-2%. For sample L49 a level of 0.2% was determined, and sample J116 has not 
been confirmed to carry the mutation by the MRM method. Although the variant 
characteristic peak is present and the variant is confirmed by the MRM method in 
most of the cases, this quantitative inconsistency requires further method 
optimisation.  
Levels for samples classed as SS or transfused SS can be seen in Figure 3.19. Those 
samples which were identified as homozygous using the intact globin chain analysis 
had only MRM chromatographic peaks for the βSICKLE T1 tryptic peptide, which 
together with the occasional low levels of HbS determined by the MRM method 
suggest an incomplete enzymatic cleavage and production of tryptic peptides. This 
issue has been noted before, and in case of some of the batches has been shown to 
have a considerable influence on levels of δ/β-chain peptide ratios.  
 
Figure 3.19. Calculated βSICKLE-chain levels based on results from the MRM method 
for the samples classed as compound heterozygotes for HbS and HbC (recalculated 
to HbC peptide in green) or homozygous sickle patients (blue), or transfused 
homozygous patients (purple) 
Samples shown in red show calculated values only around 50% or below, suggesting the patient being 
a heterozygous sickle carrier 
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A comparison of the HbS quantities determined by the two methods is shown in 
Figure 3.20. In Batch I, the values determined by both methods are very similar, and 
in Batch K they are lower when determined by the MRM method and average 30-
40% with the intact globin chain analysis. Samples which resulted in low values 
using intact globin chain analysis had the characteristic peaks in MRM analysis, but 
would not necessarily be confirmative in a real clinical screening application. The 
observed batch to batch variation may also support the suggested explanation, that 
there is an issue with the efficiency of the enzymatic cleavage. During the clinical 
trial, sample preparation conditions were kept as consistent as possible. The bovine 
trypsin used - from Sigma Aldrich, however, was not high quality sequencing grade 
and it was not possible to use only one product with the same LOT number. Batch K 
and Batch I were treated with bovine trypsin from two different production batches. 
Also it has to be taken into account that other experimental error may have occurred 
during the preparation or the measurement of the samples, such as incomplete 
denaturation of the protein chains which can result in incomplete cleavage. This 
needs further investigation and further optimisation, if possible, to provide a method 
which measures HbS values in a reliable manner.  
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Figure 3.20. Calculated levels of HbS determined by both MS methods for all samples diagnosed with some type of sickle disorder and HbC  
Samples highlighted in green resulted in very similar values by both methods, and samples highlighted in yellow resulted in very low levels by the MRM method, 
disagreement in case of sample F128 is highlighted grey, intact levels were calculated taken HbF levels into account while that was not possible using the MRM method 
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Detection and confirmation of HbE, HbC and HbO mutations 
 
The MRM method confirmed the presence of all monitored -1 Da clinically 
significant variants. No peptide was monitored for the confirmation of the HbD-
Punjab variant. Calculated variant levels based on peptide ratios are summarised in 
Table 3.12.  
 
 
Hospital 
number 
Hospital 
comment 
Our 
number 
MRM δ-chain 
peptide ratios % HbS 
% 
HbC 
% 
HbE Comment 
T2 T3 T5 
1 19173162 A O ARAB F/115 1.4 1.9 3.3 - 
  
Only a low intensity 
peak, not confirmative 
2 19083525 AC E/256 2.9 2.5 2.9 - 21.1 
  
3 19112053 AC E/258 4.0 2.9 2.9 - 34.7 
  
4 19310975 AC J/44 0.7 2.0 4.8 - 54.2 
  
5 19429733 AC J/46 0.4 2.2 4.1 - 50.9 
  
6 19529055 AC J/140 1.8 2.2 5.0 - 74.3 
  
7 19464748 AC K/44 1.1 1.1 4.7 - 0.9 
 
Variant confirmed, 
intensity low, possible 
problems with tryptic 
digestion 
8 19509268 CC J/69 0.9 2.0 4.7 
 
99.9 
  
9 18963649 SC C/99 - 1.9 2.4 99.3 99.4 
 
MRM recalculated 
41.1% Sickle and 
58.9%HbC 
10 18925552 SC D/95 - 1.0 4.7 99.6 100 
 
MRM recalculated 
10.9% Sickle and 
89.1% HbC 
11 19395725 SC J/40 1.1 2.3 5.3 99.1 99.9 
 
MRM recalculated 
12.7% Sickle and 
87.3% HbC 
12 19137083 AE H/45 1.8 4.0 6.0 - 
 
+ 
+: MRM peak observed, 
due to RT shifting not 
quantified 
 
Table 3.12. Detection of -1 Da clinically significant variants by the MRM method.  
 
 
In case of compound heterozygous HbS and HbC both peptides were observed, and 
the peptide ratio has been recalculated using the peptide peak areas of the two 
variants. Values of around 50% would be expected for both variants for these 
samples, but this is not the case. Sample D95 and J40 contained high values for 
HbC: 89.1% and 87.3%, respectively. The measurement of sample K44 resulted in a 
low peak area for the HbC variant, despite the fact that this sample displayed a mass 
shift for the β-chain mass measurement during the intact globin chain analysis, and 
the variant is expected to be present at 20% or more. The analysis of batch K for the 
heterozygous sickle samples has shown erroneous results for HbS levels determined 
previously and it is suggested that the value calculated for sample K44 is also low 
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due to the same issue, possibly with the enzymatic cleavage step of the sample 
preparation, resulting in different levels of the variant characteristic peptides. The 
same explanation is considered to be true for the variation of the calculated values 
for heterozygous HbC samples. The observed range is between 21 and 74%, and the 
theoretically expected 50% is only measured for samples in Batch J, first sample 
plate including samples J44 and J46.  
 
There was only one sample available from a patient with HbE mutation. That 
mutation was confirmed based on targeted MRM analysis on its proteotypic peptide, 
but the proportion of the variant was not quantified. The characteristic peak 
corresponding to the HbE variant peptide was observed, but due to retention time 
shifting and selective monitoring of an MRM channel, full peak-shape could not be 
recorded. The sample was not re-measured, since confirmation of the mutation was 
already achieved, which was the primary purpose of the analysis. 
Confirmation of HbO variant proved to be problematic with the MRM method. A 
low intensity peak (~500, while δ chain peptide peak intensities were observed at 
5x10
4
-1.4x10
5, and β-chain peptide peak intensities 1.7x106-3.7x106) was observed 
in the monitored MRM chromatogram, which was not present in other samples. To 
obtain a higher confidence assignment, a full scan analysis of the tryptic peptide was 
used to prove the presence of the variant.  
Recalculated HbC values suggested problems with sample preparation and the 
experimental procedure. The values determined by intact globin chain analysis 
suggest 50% for both mutations.  
The developed MRM method was capable of confirming the presence of the 
mutation, but reliable quantification of certain variants needs further method 
development.  
 
Confirmation of HbD-Punjab mutation with full scan high-resolution MS analysis 
 
Confirmation of the presence of HbD-Punjab variant was only possible by full scan 
analysis of the tryptically digested peptide mixture. No MRM transition was 
developed for the variant, which has -1 Da mass difference for the singly charged 
peptide ion to the wild-type peptide ion and only -0.5 m/z mass difference for the 
doubly charged ions. High resolution mass analysis was used in this instance to 
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provide a definitive assignment. All samples which were classed as HbD-Punjab 
carriers have been analysed using a Q-ToF Synapt G2 instrument to check for the 
presence of the doubly charged variant peptide ion. Table 3.13 summarises findings 
of this analysis. All samples except one were confirmed as carriers of a HbD-Punjab 
mutation. The presence of the variant peptide ion was not observed in sample E143. 
This sample did not show a significant mass error for the β-chain as a result of the 
intact globin chain analysis, providing a discrepancy between the hospital methods 
and the MS methods. The variant did not provide a peak corresponding to HbG 
Philadelphia, which had been mistaken for HbD-Punjab mutation previously. This 
may be explained by the fact that the variant is either not present, or undetectable by 
the methods used here due to its low proportion in the sample.  
 
 
Hospital 
number 
Hospital 
comment 
Our 
number Comment 
1 18977269 AD D/94 Confirmed 
2 19088023 AD E/143 
Peptide is not present, 
mutation not confirmed 
3 19064197 AD E/151 Confirmed 
4 19119480 AD E/255 Confirmed 
5 19114922 AD E/259 Confirmed 
6 19244683 AD H/46 Confirmed 
7 19213295 AD H/48 Confirmed 
8 19310384 AD H/138 Confirmed 
9 19580534 AD L/11 Confirmed 
10 19696761 AD M/121 Confirmed 
 
Table 3.13. Confirmation of HbD-Punjab variant by the analysis of tryptically 
digested peptide mixture in full scan mode   
 
Indication for Hb Lepore variants 
 
During the clinical trial one sample was identified as a Hb Lepore carrier by the 
hospital laboratory. No obvious abnormalities were observed during the intact 
globin-chain analysis for this sample, and the expected masses for the different 
HbLepore variants were not observed. The sample, however, did show significant 
elevated values for all three monitored δ/β peptide ratios. The calculated percentages 
were 14.4% from T2 peptide ratios, 10.1% from the T3 peptide ratios and 13.3% 
from the T5 peptide ratios. 
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Hb Lepore variants are fusion chains of the β- and δ- globin chains differing in 
masses from the normal β-chain mass by -2, -30 and -45 Da as described in Chapter 
1 section 1.3. Sequence homologies can be seen in Figure 3.21 for all Hb Lepore β-
like chains separately. The areas where sequence differences occur between the β- 
and the δ-chains are highlighted. For all three Lepore fusion chains the T2 (9-17 
residues) and T3 (18-30 residues) peptides are the same as the T2 and T3 peptides 
belonging to the δ-chain. In case of the T5 (41-59 residues) peptide, LBW and LB 
has the same peptide sequence as the δT5 peptide, but the T5 peptide belonging to 
the LH fusion chain is the same as the βT5 peptide. This suggests the presence of Hb 
Lepore-Boston-Washington or Hb Lepore-Baltimore, since all monitored peptide 
ratios were elevated, including T5 peptide ratios. Further analysis to obtain the ratio 
between βT10 and δT10 peptides would be beneficial. This peptide covers the amino 
acid residues from 83 to 95, and the T10 peptide of LBW is the same as the δT10 
peptide, while the T10 peptide of the LB is identical to the βT10 peptide. It is 
important to emphasize that intact globin chain analysis did not reveal mass peaks 
for any of these variants, and results from the MRM method, if elevated for all 
monitored peptides at the same time, could be used as indicators for the presence of 
the Hb Lepore variants.  
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Figure 3.21. Sequence homology between β-chain (MW 15867.24) δ-chain (MW 
15924.32) and Lepore Boston Washington- (LBW, MW 15865.23), Lepore 
Baltimore- (LB, MW 15822.20) and Lepore Hollandia- (LH, MW 15836.23) fusion 
chains  
  
β-chain   1VHLTPEEKSAVTALWGKVNVDEVGGEALGRLLVVYPWTQRFFESFGDLST50
β-chain   51PDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFATLSELHCDKLH97
β-chain 98VDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH146
δ-chain   1VHLTPEEKTAVNALWGKVNVDAVGGEALGRLLVVYPWTQRFFESFGDLSS50
δ-chain   51PDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFSQLSELHCDKLH97
δ-chain   98VDPENFRLLGNVLVCVLARNFGKEFTPQMQAAYQKVVAGVANALAHKYH146
LBW      1VHLTPEEKTAVNALWGKVNVDAVGGEALGRLLVVYPWTQRFFESFGDLSS50
LB        1VHLTPEEKTAVNALWGKVNVDAVGGEALGRLLVVYPWTQRFFESFGDLSS50
LH        1VHLTPEEKTAVNALWGKVNVDAVGGEALGRLLVVYPWTQRFFESFGDLST50
LBW      51PDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFSQLSELHCDKLH97
LB       51PDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFATLSELHCDKLH97
LH      51PDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFATLSELHCDKLH97
LBW      98VDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH146
LB      98VDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH146
LH         98VDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH146
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3.3.3 Identification of rare variants 
 
Table 3.14 summarises samples identified as containing rare hemoglobin variants 
which were found during the three month clinical trial.  
Samples E61, M75 and M136 were classed as normal with no indication for any 
abnormalities by the hospital laboratory methods. Samples E187 and F127 were 
detected with additional peaks by HPLC and unknown bands by gel-electrophoresis. 
Sample H47 was recorded as heterozygous Sickle carrier only, and sample H141 was 
detected with elevated HbF level. In five out of seven cases of abnormal samples, the 
results of the mass spectrometric methods are not in full agreement with current 
clinical diagnosis methods, highlighting possible incidences of misdiagnosis. An 
additional two samples classed as normal have been detected with variant peaks of 
significant mass shift, one α-chain (F179, +14 Da) and one β-chain (E174, -28 Da) 
variant. These samples have not yet been fully characterised.  
 
Sample Observed mass shift 
Additional 
Peak(s) (m/z) 
Variant peptide Mutation Identified variant 
E61 Beta chain -10 Da 471.8 (+2) T1 β5(Pro→Ser) Hb Tyne 
E187 Beta chain +58 Da 762.80(+2) 
T2-T3 (missed 
cleavage) 
β16(Gly→Asp) Hb J-Baltimore 
F127 Alpha chain -14 Da 1084.7 (+3) 
T9-T10 (missed 
cleavage) 
α90(Lys→Asn) Hb J-Broussais 
H47 Beta chain +28 Da 480.8 (+2) T2 β10(Ala→Val) Hb Iraq-Halabja 
H141 Beta chain -28Da 623.95(+2) T4 β40(Arg→Lys) Hb Athens-GA 
M75 Beta chain +18 Da 580.05(+3) T12 β114(Leu→Met) Hb ZengCheng 
M136 Beta chain +14 Da 473.8(+2) T2 β11(Val→Leu/Ile) 
"Hb Hamilton" 
or a novel variant 
 
Table 3.14. Summary of identified rare variants found during the clinical trial 
 
Hb Tyne (Sample E61) 
 
A sample classed as normal by the hospital laboratory methods showed 
abnormalities during the intact globin chain analysis. The deconvoluted mass 
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spectrum revealed the presence of a -10 Da β-chain variant (Figure 3.22 a). The 
calculated variant percentage was 45.1%, and the δ-chain level was present at 7.4% 
compared to normal β-chain. This is an indication for abnormality, and the mass 
error of the β-chain was -0.414 Da, which was outside the normal mass error range 
observed for Batch E.  
A -10 Da mass shift can be a result of Pro→Ser substitution. The comparison of 
tryptic digest peptide mixture of the sample to a control sample showed additional 
doubly charged peaks at m/z 471.77 (Figure 3.22.b). The -10 Da mass shift affecting 
the T1 peptide would provide this additional peak.  
 
 
a) b) 
Figure 3.22. Deconvoluted mass spectrum of sample E61 from the intact globin 
chain analysis (a) and mass spectrum of tryptic digest peptide mixture compared to 
control (b)  
The intact mass spectrum shows an additional peak -10 Da to normal β-chain. The tryptic digest 
analysis reveals the doubly charged peak at m/z 471.77.  
 
 
 Figure 3.23. Schematic of T1 tryptic peptide of the β-chain and possible amino acid 
substitution resulting in -10 Da mass shift. 
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Taking into account the only possible substitution triggered by a single base change 
and the number of Pro residues in the peptide, the mutation affects the 5
th
 position of 
the β-chain with a Pro→Ser substitution as illustrated in Figure 3.23. This variant is 
listed in the HbVar database as Hb Tyne (β5(Pro→Ser)).  
 
Hb J-Baltimore (E187) 
 
A sample classed as abnormal based an unknown band by the hospital laboratory 
methods also showed abnormalities during the intact globin chain analysis. The mass 
spectrum revealed the presence of a +58 Da β-chain variant (Figure 3.24 a). The 
calculated variant level was 51%, and the δ-chain levels could not be determined 
since the variant and the δ-chain masses overlapped. The mass error of the β-chain 
was 0.1547 Da, which was outside of the normal mass error range for Batch E.  
 
 
a) b) 
Figure 3.24. Deconvoluted mass spectrum of sample E187 from the intact globin 
chain analysis (a) and mass spectrum of tryptic digest peptide mixture compared to 
control (b)  
The intact mass spectrum shows an additional peak +58Da to normal β-chain. The tryptic digest 
analysis reveals the triply charged peak at m/z 762.73.  
 
A +58 Da mass shift can be a result of Ala→Glu or Gly→Asp substitutions. A 
comparison of tryptic digest peptide mixture of the sample to a control sample 
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showed additional triply charged peaks at m/z 762.80 (Figure 3.24 b). The +58 Da 
mass shift affecting the (T2-T3) peptide, as a result of a missed cleavage, would be 
responsible for this additional peak.  
 
 
Figure 3.25. Schematic of (T2-T3) tryptic peptide of the β-chain and possible amino 
acid substitutions resulting in +58 Da mass shift. 
 
There are three Ala and four Gly residues in the (T2-T3) peptide, providing seven 
possible mutation sites, as illustrated in Figure 3.25. Sequence analysis of the peptide 
by MS/MS experiment was performed to identify the location of the mutation. The 
corresponding MSMS spectra can be found in Appendix 3. +58 Da mass shift of the 
y fragment ion series from the y15 ion and for the b ion series from the b8 ion 
onwards was observed, which highlights the 8
th
 amino acid residue as the potential 
mutation site. The residue at position 8 of the wild type (T2-T3) peptide is a Gly 
residue, which has been substituted in the variant peptide to Asp. The hemoglobin 
variant present in sample E187 was therefore identified as Hb J-Baltimore (β16 
(Gly→Asp)).  
 
Hb J-Broussais (F127) 
 
A sample classed as abnormal based on the detection of an unknown band by 
hospital laboratory methods also showed abnormalities during the intact globin chain 
analysis. The deconvoluted mass spectrum revealed the presence of a -14 Da α-chain 
variant (Figure 3.26 a). The calculated variant percentage was 12%, the δ-chain level 
was not affected, and the mass error of the β-chain was -0.054 Da, which was within 
the normal range for batch F.  
A -14 Da mass shift can be a result of Lys→Asn, Glu→Asp, Ala→Gly, Thr→ Ser, 
Ile→Val and Leu→Val substitutions. A comparison of the tryptic digest peptide 
SAVTALWGKVNVDEVGGEALGR
D
β(T2-T3) (9-30)
Hb J-Baltimore 
DD DE E E
Hb Lufkin 
Hb J-Auckland Hb Moscva
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mixture of the sample to a control sample showed additional triply charged peaks at 
m/z 1084.67 (Figure 3.26 b). The indicated variant peptide is α(T9-T10). Since the  
-14 Da mass shift can be a result of a Lys→Asn substitution which provides a longer 
peptide based on a missed cleavage point, it is strongly suggested this mutation has 
taken place. There are several other possible mutation sites as shown in Figure 3.27.  
 
 
a) b) 
Figure 3.26. Deconvoluted mass spectrum of sample F127 from the intact globin 
chain analysis (a) and tryptic digest peptide mixture compared to control (b)  
The intact mass spectrum shows an additional peak -14 Da to normal α-chain. The tryptic digest 
analysis reveals the triply charged peak at m/z 1084.67.  
 
 
Figure 3.27. Schematic of (T9-T10) tryptic peptide of the α-chain and possible 
amino acid substitutions resulting in -14 Da mass shift. 
 
To verify the point of the mutation sequence analysis using MS/MS experiments was 
performed. The y ion series of the mutant peptide showed a mass shift starting from 
y3 fragment ions, which confirms the mutation Lys to Arg at position 29 of the 
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peptide, and position 90 of the α-chain. The hemoglobin variant present in sample 
F127 was identified as Hb J-Broussais (α90(Lys→Asn)). 
 
Hb Iraq Halabja (H47) 
 
A sample classed as heterozygous sickle carrier by the hospital laboratory methods 
showed additional abnormalities during the intact globin chain analysis. The 
deconvoluted mass spectrum revealed the presence of a +28 Da β-chain variant 
(Figure 3.28 a), which was not detected by current clinical methods. The calculated 
variant percentage was 58.8% as a ratio to βSICKLE-chain, the δ-chain level could not 
be calculated, which is an indication for abnormality, and the mass error of the β-
chain also could not be calculated.  
A +28 Da mass shift can be a result of Ala→Val, Gln→Arg, Lys→Arg substitutions. 
The comparison of the tryptic digest peptide mixture of the sample to a control 
sample showed additional doubly charged peaks at m/z 480.84 (Figure 3.28 b). This 
mass identifies the affected variant as βT2 with a +28 Da mass shift.  
A Gln→Arg substitution is least likely, since this would have resulted in a new 
tryptic peptide based on the introduction of an additional cleavage point. Ala→Val 
and Lys→Arg substitutions would not have resulted in new tryptic peptides, only a 
variant peptide with +28 Da mass shift. Possible mutations affecting the T2 peptide 
are illustrated in Figure 3.29. To confirm the mutation point, sequence analysis using 
MS/MS was performed. The y ion series of the mutant peptide showed a mass shift 
from y8 and for b ion series from the b2 fragment ion, which confirms the mutation 
Ala to Val at position 2 of the peptide, and position 10 of the β-chain. The 
hemoglobin variant present in sample H47 was identified as Hb Iraq-Halabja 
(β10(Ala→Val)). 
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a) b) 
Figure 3.28. Deconvoluted mass spectrum of sample H47 from the intact globin 
chain analysis (a) and tryptic digest peptide mixture compared to control (b)  
The intact mass spectrum shows an additional peak +28 Da to normal β-chain. The tryptic digest 
analysis reveals additional doubly charged peak at m/z 480.84.  
 
 
Figure 3.29. Schematic of T2 tryptic peptide of the β-chain and possible amino acid 
substitutions resulting in +28 Da mass shift. 
 
Hb Athens-GA (H141) 
 
A sample detected with an elevated HbF level using the hospital laboratory methods, 
which can be an indication of thalassemia, showed additional abnormalities during 
the intact globin chain analysis. The deconvoluted mass spectrum revealed the 
presence of a -28 Da β-chain variant (Figure 3.30 a), which was detected by the 
current clinical methods. The calculated variant percentage was 45.4%, the δ-chain 
level was present at 7.8% compared to normal β-chain, which is an indication for 
abnormality, and the mass error of the β-chain was -0.6178 Da, which was outside of 
the normal mass error range for Batch H, also indicative of an abnormality.  
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A -28 Da mass shift can be a result of Val→Ala, Arg→Gln, Arg→Lys substitutions. 
The comparison of the tryptic digest peptide mixture of the sample to a control 
sample showed additional doubly charged peaks at m/z 623.95 (Figure 3.30 b). This 
mass identified the affected variant as βT4 with a -28 Da mass shift.  
 
 
a) b) 
Figure 3.30. Deconvoluted mass spectrum of sample H141 from the intact globin 
chain analysis (a) and tryptic digest peptide mixture compared to control (b)  
The intact mass spectrum shows an additional peak -28 Da to normal β-chain. The tryptic digest 
analysis reveals additional doubly charged peak at m/z 623.95.  
 
There are two Val residues and one Arg residue in the βT4 peptide, providing three 
possible mutation sites, as illustrated in Figure 3.31. Sequence analysis of the peptide 
using MS/MS was performed to identify the location of the mutation. The -28 Da 
mass shift of the whole y fragment ion series was observed compared to normal 
peptide sequence, which suggests the last amino acid residue as the potential 
mutation site. The Arg residue was substituted in the variant peptide to Lys. The 
hemoglobin variant present in sample H141 was identified as Hb Athens-GA 
(β40(Arg→Lys)).  
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Figure 3.31. Schematic of T4 tryptic peptide of the β-chain and possible amino acid 
substitutions resulting in -28 Da mass shift. 
 
Hb ZengCheng (M75) 
 
A sample classed as normal by the hospital laboratory methods showed 
abnormalities during the intact globin chain analysis. The deconvoluted mass 
spectrum revealed the presence of a +18 Da β-chain variant (Figure 3. 32 a). 
The calculated variant percentage was 49.9%, the δ-chain level was present at 11.2% 
compared to normal β-chain, which is an indication for abnormality, and the mass 
error of the β-chain was -0.365 Da, which was slightly outside of the normal mass 
error range for Batch M.  
A +18 Da mass shift can be a result of Ile→Met and Leu→Met substitutions, 
however, there are no Ile residues in the β-chain, which only leaves the possibility 
for Leu→Met substitution. The comparison of the tryptic digest peptide mixture of 
the sample to a control sample showed additional triply charged peaks at m/z 580.05 
(Figure 3.32 b). The +18 Da mass shift affecting the T12 peptide would give this 
additional peak.  
 
LLVVYPWTQRβT4 (31-40)
K/QAA
Hb Athens-GA
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a) b) 
Figure 3.32. Deconvoluted mass spectrum of sample M75 from the intact globin 
chain analysis (a) and tryptic digest peptide mixture compared to control (b)  
The intact mass spectrum shows an additional peak +18 Da to normal β-chain. The tryptic digest 
analysis reveals additional triply charged peak at m/z 580.05.  
 
There are four Leu residues in the βT12 peptide, providing four possible mutation 
sites, as illustrated in Figure 3.33. Sequence analysis of the peptide using MS/MS 
was performed to identify the location of the mutation. 
The y series showed a mass shift from the 7
th
 y ion, confirming the point of the 
mutation as the fourth Leu residue in the peptide, affecting position 114 of the β-
chain.  
 
 
Figure 3.33. Schematic of T12 tryptic peptide of the β-chain and possible amino 
acid substitutions resulting in +18 Da mass shift. 
 
The hemoglobin variant present in sample M75 was identified as Hb Zeng Cheng 
(β114(Leu→Met)).  
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Hb Hamilton or a novel, previously not detected variant (M136)  
 
A sample classed as normal by the hospital laboratory methods showed 
abnormalities during the intact globin chain analysis. The deconvoluted mass 
spectrum revealed the presence of a +14 Da β-chain variant (Figure 3.34 a). 
 
 
a) b) 
Figure 3.34. Deconvoluted mass spectrum of sample M136 from the intact globin 
chain analysis (a) and tryptic digest peptide mixture compared to control (b)  
The intact mass spectrum shows an additional peak +14 Da to normal β-chain. The tryptic digest 
analysis reveals additional doubly charged peak at m/z 473.83.  
 
The calculated variant percentage was 51.7%, the δ-chain level was 12.2% compared 
to normal β-chain, which is an indication for abnormality, and the mass error of the 
β-chain was -0.0116 Da, which is slightly outside of the normal mass error range for 
Batch M.  
A +14 Da mass shift can be a result of Asn→Lys, Asp→Glu, Gly→Ala, Ser→Thr, 
Val→Ile and Val→Leu substitutions. The comparison of tryptic digest peptide 
mixture of the sample to a control sample showed additional doubly charged peaks at 
m/z 473.83 (Figure 3.34.b). The +14 Da mass shift affecting the T2 peptide would 
give this additional peak.  
There are three possible mutation sites resulting in a +14 Da mass shift, these are 
illustrated in Figure 3.35. 
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Figure 3.35. Schematic of T2 tryptic peptide of the β-chain and possible amino acid 
substitutions resulting in +14 Da mass shift. 
 
Sequence analysis of the variant peptide by MS/MS experiment was performed to 
identify the location of the mutation. The +14 Da mass shift of the 3
rd
 fragment ion 
of the b fragment ion series was observed, which highlights the 3
rd 
residue, Val, as 
the potential mutation site. The Val residue can be substituted for either Leu or Ile. 
At this stage it was not possible to identify the exact substitution. Further 
experiments will be necessary to elucidate this.  
The hemoglobin variant present in sample M136 has yet to be fully resolved, but the 
mutation site was identified. According to the HbVar database if the mutation is 
Val→Ile, then the variant present is Hb Hamilton (β11(Val→Ile)). If the mutation 
is Val→Leu, then the variant is a novel variant which cannot be found in the 
database. 
 
Two further samples E174 and F179 have been observed with additional mass peaks 
during data analysis of the results from the intact globin chain analysis. Sample E174 
showed also abnormal mass error for the β-chain, and an additional peak -28 Da to 
normal β-chain. Sample F179 showed abnormal mass errors for both chains, and an 
additional peak +14 Da to normal α-chain. These two samples, together with sample 
M136, require further investigation.  
 
3.3.4 Determination of Glycated Hemoglobin levels 
 
From intact globin chain analysis quantitation of glycated globin chains has been 
obtained. HbA1c levels were estimated in a similar manner to HbA2 levels. 
Unfortunately there were no measured values available for the glycation levels from 
the hospital laboratory, but the data is readily accessible with the same intact globin 
chain analysis and it has been calculated for 10 of the sample batches measured 
during the trial.  
SAVTALWGKβT2 (9-17)
Hb Hamilton
L/I AT
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Previous papers reported average values using the determined glycation levels for 
the different globin chains (Roberts et al. 1997). As previously discussed in Chapter 
2, the assumption of the rate of glycation being the same on both chains may be 
valid, but based on the definition of standard measurement for glycated hemoglobin, 
the beta-chain is considered as primarily glycated and it is referred to as HbA1c 
(Peterson et al. 1998). When analysing the reference standard ClinTest with a known 
HbA1c level of 9.3% the beta chain-glycation level is below the expected, and the 
average glycation level is even lower, since the α-chain glycation level was observed 
at about 1/3 of the beta chain glycation. Correlation between alpha and beta 
glycation levels are usually satisfying, but not excellent. It was therefore decided to 
monitor and utilise only calculated intensities based on the peaks for beta-chain 
glycation.  
The coefficient of variation of the quantitation of the different glycated globin chains 
was calculated based on three replicates for all samples, and plotted as a frequency 
histogram shown in Figure 3.36. The calculated average CV value was 7.4, and 89% 
of the values are below 15%. The method can be considered reproducible.  
Since there are no reference values from the hospital for the glycation levels, only 
the distribution of normal and possibly elevated levels of glycated hemoglobin can 
be assessed. How the determined βG glycation levels are distributed among the 10 
batches is shown in Figure 3.37.  
The ClinTest standard was measured as part of the 96 samples within each analysed 
plate. The calculated values for the standard (each plate three replicates) were used 
to provide an average level obtained for the standard with a known value of 9.3 %. 
The average βG% value obtained for the standard was 8%. Based on reference ranges 
set for HbA1c, normal levels are considered to be below 6%, 6-6.5% potential 
prediabetic and values above 6.5% are classed as elevated, and require further 
investigation (www.diabeticretinopathy.org.uk). With a simple ratio calculation 
using the standard expected and measured values to determine a correction factor, 
the 6.5% level limit for the intact MS measurement would correspond to a measured 
value of 5.6%.  
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Figure 3.36. Histogram of calculated cv% values for the measurement of beta-chain 
glycation levels  
CV% values are calculated based on three technical replicates used for quantitation of glycated globin 
chain  
 
Figure 3.37. illustrates a distribution that resemble those observed in HbA2 level 
quantitation. The majority of the values are distributed in a certain range, and only a 
small number of samples are reported with elevated glycation levels. A 5.6% limit 
(shaded blue range in the figure) would be acceptable for most of the batches as a 
threshold. In case of batch E and batch H, a slightly higher limit of 6% would be 
more appropriate. 
These measurements, although not compared to reference values from the hospital 
have proved the potential applicability of the intact globin chain analysis method to 
provide reproducible additional information about the quantity of glycated 
hemoglobin. This method could be used for hemoglobinopathy screening and as a 
diagnostic method for HbA1c determination. The fact that the values are distributed 
in the same range supports the notion that this method could give consistent 
estimation of βG % among batches. The application of a suitable calibration and the 
analysis of bigger sample sets could develop this method further for providing a 
reliable evaluation of a potentially important biomarker.  
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Figure 3.37. Distribution of measured beta glycated values for the different sample 
batches analysed. 
Shaded area above 5.6% represents the suggested range for elevated values based on ratio calculation 
between measured and expected values for the reference standard. 
 
3.3.5 Detection of elevated HbF levels 
 
For detection of the disorder termed hereditary persistence of fetal hemoglobin 
(HPFH) the monitoring of elevated HbF levels is important. Elevated HbF levels can 
also indicate the presence of some thalassemic disorders, as it is often elevated when 
a patient has β-thalassemia.  
There are two action points set for HbF, if MCH > 27 pg the action point is >10%, if 
MCH<27pg the action is >5% (NHS 2012b). Samples detected with these elevated 
HbF levels are further investigated in the clinical lab.  
For fetal hemoglobin normal levels were detected as 1-2% by the hospital lab. HbF 
levels were not calculated for these samples, since mass peaks were not observed in 
every case. HbF levels for samples with 3% or higher reported HbF% were 
calculated and plotted against the ce-HPLC values in Figure 3.38. The calculated 
HbF values were obtained by adding together the percentages calculated for both 
fetal chains γ1
G
 (MW 15995.3) and γ2
A
 (MW 16009.3).  
It can be seen that the correlation between the HbF levels determined by the intact 
globin chain analysis and the ce-HPLC values is high with an R
2
 value of 0.974. This 
high correlation and the ability to pick up samples with levels above the previously 
mentioned action points (5 and 10%) suggest the intact globin chain analysis can be 
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used for monitoring HbF levels, which is necessary to fulfil the NHS requirements 
for the method wished to be applied for hemoglobinopathy screening.  
 
 
 
Figure 3.38. Calculated HbF% levels based on intact globin chain analysis plotted 
against ce-HPLC values 
 
The calculated coefficient variations for the quantitation of the γ-chains are 
illustrated in histograms for both chains separately in Figure 3.39. Apart from a few 
outliers the majority of the values are below the required 15%.  
 
  
a) b) 
Figure 3.39. Histogram of the calculated coefficient of variation values for the 
quantitation of the different fetal chains, for (a) γ1
G
 and for (b) γ2
A
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Based on information received from the hospital three samples were reported with 
abnormally elevated HbF levels. In other cases where the HbF level was above 5%, 
this can be explained by the presence of a clinically significant variant, or it could be 
that the sample was from a baby. The three samples identified are G49, H141 and 
J68. In the case of G49 only the mass peak corresponding to γ2
A
 (MW 16,009.3) was 
observed at 8.3%, which is considered elevated. The reported hospital value was 
7.3%. Sample H141 was measured at 11.4% for HbF by intact MS and the ce-HPLC 
value was 8.2%. This sample, however, was also identified as a chromatographically 
silent Hb variant, and the intact MS HbF levels have been calculated as a ratio of the 
γ-chains to the sum of the wild type and variant mass peak areas, still showing a 
11.4% elevated level. In case of sample J68 the reported value is as high as 12.6% 
and the combined percentages of the γ-chains provided a HbF level of 20.6%. 
 
Two further samples were diagnosed by hospital methods with HPFH. These 
samples H140 and I114 both resulted in elevated HbF levels, 14.3% and 14.7% 
respectively (9.4% and 8.7% ce-HPLC values) using the intact MS method.   
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3.3.6 Summary of the results from Part I 
 
A total of 2017 samples were analysed during the clinical trial. The numbers of 
samples per batch detected with abnormalities either by the hospital or by MS 
methods are listed in Table 3.15. 
 
Batch Sample 
number 
Number of samples 
with clinically 
significant 
conditions* 
Number of 
variants only 
observed by MS 
Number of 
abnormalities 
not confirmed 
by MS  
Unknown 
band observed 
by ce-HPLC 
B 136 3 - -  
C 155 4 - -  
D 108 8 -   
E 280 14 2 (E61, E174) 
1 (A2Var) 
1 (E143,HbD) 
1 (E187) 
F 251 8 1 (F179) 1 (A2Var) 1(F127) 
G 93 5 - 1 (A2Var)  
H 228 14 2 (H47, H141) 3 (A2Var)  
I 114 8 -   
J 144 16 - 
3 (Alpha zero 
thalassemia) 
1(Coeluting 
variant) 
 
K 166 8 - 1 (A2Var)  
L 180 3 - -  
M 162 6 2 (M75, M136) 1 (A2Var)  
Sum 2017 97 (4.56%) 7 (0.35%) 13(0.6%) 2 (0.1%) 
 
Table 3.15. Table to summarise abnormal samples analysed in the clinical trial  
*Clinically significant conditions here include HbS, HbC, HbD-Punjab, HbE, HbO-Arab, Hb Lepore, 
elevated HbF, Beta-thalassemia and HPFH 
 
The following lists differences observed that occurred between hospital method 
findings and the MS methods. 
 
 There were 7 samples with variants identified which were only detectable 
using the intact MS method.  
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 13 samples which were classed as abnormal by the hospital were not 
confirmed using the MS methods. One of these was a sample with HbD-
Punjab mutation, which is one of the five clinically significant variants. 
 The samples from patients with α0-thalassemia did not show any obvious 
abnormalities with the MS methods.  
 The MS methods did not screen for the presence of low intensity δ-chain 
variants.  
 
 Two samples with hemoglobin variants that were detected as abnormal due to 
the presence of unknown peaks by the chromatography method and with 
unknown bands by gel-electrophoresis were characterised by MS. 
 Samples with HPFH showed elevated HbF levels during the intact globin 
chain analysis, which could be used for indication of this condition in the 
future.  
 Samples with elevated HbA2 levels were correctly identified.  
 One Hb Lepore sample did not show abnormalities during intact globin chain 
analysis, but showed significantly elevated levels of δ-chain levels for all 
monitored peptide ratios with the MRM method.  
 Mass errors of β-chain were indicative of the presence of -1 Da variants, and 
also other abnormalities, when abnormal globin chain with higher mass 
difference was present. Elevated δ-chain levels were also indicative for the 
presence of variant β-globin chains.  
 
Table 3.16 summarises the samples with different conditions, calculating their 
proportion in all analysed samples during the clinical trial. It is also stated whether 
either of the mass spectrometry methods were able to detect, identify or confirm the 
presence of an abnormality. As mentioned before there was one clinically significant 
structural variant which was not confirmed by MS. Some samples classed as SS 
(homozygous sickle carriers) were detected with only ~50% of HbS with the 
presence of normal β-globin chain. It is suspected that in these cases the patient 
received a blood transfusion, which would explain the presence of the normal β-
chain. 
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Variant condition Numbers Proportion Identified by MS? 
SS( or transfused SS) 22 1.09% All, one not confirmed by MRM 
AS  48 2.38% All 
SC 3 0.15% All 
AC 6 0.3% All 
AD 10 0.5% 9 confirmed, 1 is not confirmed 
CC 1 0.05% All 
AE 1 0.05% Confirmed by MRM 
AO 1 0.05% All- full scan tryptic digest 
analysis 
Beta thalassemia 1 0.05% Indication 
HbLepore Carrier 1 0.05% Strong indication from MRM 
HPFH 2 0.1% Elevated HbF detected 
Elevated HbF 3 0.15% All 
Other 
abnormalities 
picked up by 
HPLC* 
Alpha 
zero thal 
3 0.15% Not investigated 
A2 Var 
(δ-chain 
variant) 
8 0.4% Not investigated 
Variants only picked up 
by MS 
7 0.35% All 
Normal 1898 94.20%  
 
Table 3.16. Summary of different conditions, numbers and proportions of clinically 
significant variants  
 
117 abnormal samples were identified, which is 5.8% of the total analysed samples. 
A graphical presentation of the proportion of hemoglobin disorders is shown in 
Figure 3.40 a.  
The proportion of different conditions within the abnormal samples shows that 63%  
were carriers of sickle β globin chain either in heterozygous or in homozygous status 
(Figure 3.40 b) This high proportion of sickle mutation was expected based on the 
incidence of hemoglobinopathies reported in the literature.  
Only one sample was diagnosed as HbE and only one as HbO-Arab. The HbD-
Punjab mutation is represented by a higher number of samples than would be 
expected.  
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a) 
 
b) 
Figure 3.40. Pie-charts showing the proportion of the hemoglobinopathies in the 
whole set of samples (a) and the proportion of different hemoglobin disorders (b) 
 
From the total number of δ-chain (A2) variants and α0-thalassemia carriers, 10% of 
the abnormal samples were not confirmed using the mass spectrometry methods, and 
6% of abnormalities were only detected using mass spectrometry.  
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Ethnic origin of abnormal samples 
 
Where it was possible the ethnic origin of those patients with abnormal samples were 
investigated. A graphical presentation of the findings can be seen in Figure 3.41. 
Abnormalities are highest amongst African or African-Caribbean, but a high 
percentage of the conditions were from individuals of Southern or other European 
origin (Figure 3.41 a). When considering carriers of sickle disorders, African and 
African-Caribbean origin was more than double that of Southern or Other European 
origin (Figure 3.41 b).  
a)  
b)  
 
Figure 3.41. Pie-charts showing the proportion of the hemoglobinopathies within 
different ethnic groups (a) and the proportion of Sickle carriers within different 
ethnic groups (b)   
33%
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D= Other Non-European
E= Southern and Other 
European
F=United Kingdom
M= Mixed
N=None Stated
38%
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Part II: Results of the pilot study of the top 
down MS method, on the partial sample set of 
the clinical trial using the amaZon speed ETD 
mass spectrometer 
 
3.3.7  Preliminary experiments 
 
3.3.7.1 Sequence coverage studies for normal samples 
 
A control blood sample was prepared using 1/10,000 dilution in 50% ACN and 0.2% 
formic acid. 
MS/MS spectra with ETD fragmentation of the 18+ charged ions of the β-chain were 
collected with previously optimised parameters (ETD reaction time 20 ms, PTR 
reaction time 80 ms). Based on the observed fragment ions sequence matching was 
performed in BioTools. The ions observed were predominantly from the c- and z+1 
ions series. z+1 ions are produced and not z-ions, which would be expected from 
fragmentation reactions in ETD. This is due to additional reactions taking place in 
the iontrap analyser.  
Figure 3.42 illustrates the obtained sequence coverage for the β-chain. 58% of the 
sequence is covered by the observed and assigned fragment ions.  
 
 
Figure 3.42. Sequence coverage for beta-chain 
Red bricks represent matched c (upper bricks) or z+1 (lower bricks) ions 
 
For the development of a screening method the primary aim was to cover the 
affected amino acids and sequence region of the β-chain, where the mutation occurs, 
which was achieved in all investigated cases. Amino acids at position 6, 26 and 121 
were covered, where amino acid substitutions are expected for HbS, HbC, HbE, 
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HbD-Punjab and HbO-Arab mutations. For the identification of unknown variants 
the highest sequence coverage obtainable is desirable. Samples with clinically 
significant variants were analysed and are presented in Section 3.3.7.4.  
 
Preliminary sequence coverage studies on the α-chain were also performed. The 17+ 
α-chain ion was fragmented. Settings: for dual isolation first step m/z 895 and for 
second step m/z 890 were chosen, the reaction times were ETD 20 ms and PTR 100 
ms.  
Figure 3.43 illustrates the obtained sequence coverage for the α-chain. Fairly good 
coverage was observed for the N and C-termini with few fragments observed for the 
core region. An overall sequence coverage of 35% was obtained based on the results 
from BioTools. No further optimisation for higher sequence coverage was attempted 
at this stage. The analysis of sample A5 with HbG-Phildelphia did not result in 
sufficient information for the mutation to be identified simply from MS/MS 
measurements. This mutation occurs with a Asn→Lys substitution at position 68 of 
the α-chain, for which no amino acid fragment ions were observed.  
 
 
 
Figure 3.43. Sequence coverage for alpha-chain.  
Red bricks represent matched c (upper bricks) or z+1 (lower bricks) ions 
 
For higher sequence coverage to be obtained for both the α- and β-chains, further 
method development would be necessary. At this stage the sequence coverage 
studies focused predominantly on the β-chain to develop a screening method for the 
clinically significant variants, which affect exclusively the β-chain. Clinical samples 
analysed and presented in this chapter have not been separately evaluated for 
sequence coverage information, since that was not the primary aim of the work.   
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3.3.7.2 HbA2 and HbA1c quantitation 
 
Intact globin chain analysis performed on the amaZon speed ETD iontrap analyser 
instrument was assessed for quantitation of HbA2 and HbA1c levels. 
 
HbA2 level determination 
 
A clinical sample from a healthy adult and the HbA2 reference standards were 
measured. δ-chain levels based on peak intensities and peak areas were calculated. 
The data for each resulted from a 15 minute acquisition, processed after the initial 5 
minutes and for the whole 15 minutes. Results are summarised in Table 3.17. 
 
Sample Expected HbA2 
level 
δ-chain 
level % - 
 5 min 
δ-chain 
level % -  
15 min 
HbA2 standard –
Intensity Calc. 
5.3% 6.1 6.2 
HbA2 standard – 
Area Calc. 
5.3% 7.2 7.7 
Clinical sample – 
Intensity Calc. 
2.8% 3.7 3.9 
Clinical Sample – 
Area Calc. 
2.8% 4.6 5.2 
 
Table 3.17. Results of HbA2 quantitation for a clinical sample and the reference 
standard 
 
The calculated values are higher than theoretically expected for both intensity and 
area calculated values. This was expected based on measured values using the 
Waters Xevo TQ mass spectrometer which have been presented in previous 
Chapters. The results after 5 minutes and after 15 minutes were very similar, 
showing that a shorter intact measurement time provides similarly reliable results to 
the longer 15 minute one.  
Calculated values based on peak intensities are lower, closer to the expected values.  
The iontrap analyser has been shown to be potentially capable of quantifying HbA2 
levels based on intact globin chain analysis in the same way as demonstrated for the 
triple quadrupole instrument. For further evaluation reproducibility studies need to 
be performed.   
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HbA1c level determination 
 
A clinical sample from a healthy adult and previously used reference standards were 
measured and levels based on peak intensities and peak areas were calculated for 
glycated α-chain and glycated β-chain ion peaks. The data were obtained from a 15 
minute acquisition. Results are summarised in Table 3.18. 
 
Sample Expected 
HbA1c level 
% 
Glycated α-
chain level 
% - 5min 
Glycated α-
chain level 
% -15min 
Glycated β-
chain level 
% - 5min 
Glycated β-
chain level 
% - 15 min 
HbA1c standard 
–Intensity 
Calc. 
9.3 3.2 3.2 6.4 6.4 
HbA1c standard 
– Area Calc. 
9.3 3.7 3.9 7.9 8.3 
Clinical 
sample – 
Intensity Calc. 
- 2.6 2.6 5.4 5.4 
Clinical 
Sample –  
Area Calc. 
- 3.9 4.2 8.0 8.5 
 
Table 3.18. Results of HbA1c quantitation for a clinical sample and the reference 
standard 
 
The calculated values are lower than theoretically expected for both intensity and 
area calculated values for the reference standard. This was again expected based on 
measured values using the Waters Xevo TQ mass spectrometer presented in previous 
Chapters. There was no information available for the clinical sample about glycation 
levels. Considering only the glycated β-chain levels as informative values, the 
clinical sample had a very similar, supposedly elevated level for glycated β-chain to 
the reference standard. The same phenomenon was observed when this sample was 
analysed using the Waters Xevo TQ instrument, proving that the Bruker amazon 
speed ETD instrument with an iontrap analyser could provide a reliable technique for 
HbA1c quantitation. The values calculated based on peak areas are closer to the 
expected values here, which was not the case for HbA2 quantitation.  
 
The iontrap analyser is potentially capable of quantifying HbA2 and HbA1c levels 
based on intact globin chain analysis. Further investigation on larger number of 
clinical samples would be necessary to prove this hypothesis. The analysis of ~1000 
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clinical samples was performed using the Bruker amaZon speed ETD mass 
spectrometer. Data resulting from the analysis of HbA2 and HbA1c levels will not be 
presented in this Chapter. The results cannot be used for an accurate representation 
of the method for quantitation purposes due to significant carry-over issues from the 
LC sample introduction system that occurred during the measurement of the clinical 
samples, which affected the intact globin chain analysis. Further method 
development would need to focus on eliminating carry-over and choosing 
appropriate peak properties for estimating globin-chain levels.  
 
3.3.7.3 Mass accuracy of intact measurement 
 
Selected samples with and without variant globin chains were measured and the 
mass accuracy for the beta-chain mass was investigated.  
Reference standards for HbA2 and HbA1c are expected to have normal α- and β-
chains, therefore assessment of mass accuracy was made using these samples. 
Patient blood samples including a control healthy adult sample, and samples with 
HbS, HbC, HbE, HbD-Punjab and HbG-Phialdelphia were also analysed. The mass 
error of the samples were calculated for each measurement and plotted in Figure 
3.44.  
 
 
 
Figure 3.44. Mass error calculated for the Beta-chain using the Alpha-chain as 
internal standard.  
 
Mass errors calculated for the reference standards and the control sample are in a 
range of ±0.2 Da distributed around 0, which indicates normal distribution and no 
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systematic error as previously observed for the measurements performed on the 
Xevo TQ instrument.  
An interesting observation is that the samples containing heterozygous variants were 
not measured with abnormal mass errors as had been observed with the intact globin 
chain analysis performed on the Waters Xevo TQ instrument. This is probably due to 
higher resolution of iontrap data.  
This observation allows one to distinguish easily between normal samples and 
samples with -1 Da variants. A disadvantage is that it does not provide detection of 
other abnormalities, which were observed previously based on the mass errors with 
the Xevo TQ intact MS method.  
The aim of the work presented in this Chapter was to develop and apply an ETD 
fragmentation method for clinically significant variants based on acquired MS/MS 
spectra. Analysing every patient sample looking for the presence of characteristic 
fragment ions to indicate the presence of a certain mutation makes the mass accuracy 
measurement a less crucial point as the variants of interest with -1 Da mass 
difference should be revealed based on the ETD spectra. Ideally, all clinically 
significant variants which result in a -1 Da mass difference to the normal β-chain 
would be detected based on the observed fragments. It may, however, occur that a -1 
Da α-chain variant is present, which would not be detected, since the automated 
MS/MS method would screen for β-chain variants only, fragmenting exclusively the 
corresponding β-chain ion. For these cases detecting possible abnormal mass errors 
is still desirable.  
 
3.3.7.4 Clinically significant variants 
 
To assess whether a top-down fragmentation method using electron transfer 
dissociation could be used for the detection and definite diagnosis of clinically 
significant hemoglobin variants, samples with these conditions have been measured.  
Four samples with clinically significant variants have been analysed in order to 
assess the potential of the ETD-method for sequence coverage of the variant globin 
chains and find characteristic fragment ions, which if present could be used as 
reporter ions to confirm the presence of certain mutations.  
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HbS mutation 
 
The most important variant that needs definitive detection is the HbS mutation. As 
previously mentioned, a fully resolved variant beta-chain is present in the intact ESI-
MS spectrum. The Glu residue at position 6
th
 of the beta chain is replaced by a Val 
residue. It has previously been shown that ETD fragmentation is capable of 
providing fragments covering this sequence region, since it is close to the N-
terminus. The mutation results in a -30 Da mass shift, and the fragment ions are 
expected to be present -30 Da lower compared to the mass to charge ratio of 
fragments from the wild type β-chain.  
The 18+ charged β-chain ion was fragmented in the iontrap using ETD with the 
previously detailed parameters. The resultant ETD spectrum revealed a number of 
fragment ions from the c-ion series predicted for the βSICKLE-chain by the BiotoolsTM 
software (Bruker Daltonik GmbH, Bremen, Germany). The obtained ETD spectrum 
of the sample was compared to that of a ETD spectrum obtained from a control 
healthy sample. The resultant differences and the fragment ions characteristic of the 
HbS mutations are shown in Figure 3.45. The entire mass spectrum contained 
numerous fragment ions from the mutated β-chain which covered many amino acids 
including the site of the substitution and residues from the position 6
th
 onwards. The 
majority of fragments were doubly charged c-ions. The c6
1+ 
ion (m/z 664.49) was 
observed and present in the mass spectrum, but at lower intensity than observed for 
the c7
1+ 
ion (m/z 793.52). For a variant specific reporter ion therefore the c7
1+ 
ion
 
peak
 
was chosen for further diagnostic purposes.  
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Figure 3.45. Fragment ions observed for sickle β-chain (Black spectra represent the control sample while red spectra are obtained from HbS sample) 
βSICKLE-chain   1VHLTPVEKSAVTALWGKVNVDEVGGEALGR30
91LHCDKLHVDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH146
31LLVVYPWTQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFATLSE 90
β-chain          1VHLTPEEKSAVTALWGKVNVDEVGGEALGR30
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HbC mutation 
 
A sample with the clinically significant variant HbC was analysed. This mutation 
affects the same position of the β-chain sequence as HbS, but the Glu residue is 
replaced with a Lys residue. The resulted variant chain only differs by -1 Da to the 
normal β-chain, and the possible fragment ions have the same mass shift.  
The ETD spectrum was a fragmentation rich spectrum as previously observed for the 
HbS mutation. Fragments from the c-ion series were observed for the substitution 
site and for amino acids after that. Selected fragment ions for the variant and the 
control sample are compared in Figure 3.46. The variant c6
+
 ion is present at m/z 
693.51 at low intensity and the control sample also contains some low intensity noise 
peaks at this m/z. The c7
+ 
and c8
+
ions are more intense at m/z 822.48 and m/z 950.58 
respectively. Since the sample is a mixture of normal and variant β-chains, the 
isotopic envelope observed for these fragment ions, due to the only -1 Da difference, 
represents both fragment ions from the two globin chains, and not clearly isolated 
with a -30 Da difference as observed for the HbS mutation. From the c9
2+
 ions 
onwards several c ions are observed in their doubly charged forms, only 0.5 Da apart 
from the fragment ions for the normal chain, but still clearly present and 
unambiguously showing the presence of the HbC variant. As a reporter c8
+ 
or
 
c7
+
 ions 
may be used. The consistent observation of characteristic fragment ions needs to be 
assessed on larger number of clinical samples, which will be presented later in this 
Chapter. As an initial preference for reporter ion c8
+
 was chosen.  
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Figure 3.46. Fragment ions observed for HbC β-chain (Black spectra represent the control sample while green spectra are obtained from HbC sample) 
βC-chain   1VHLTPKEKSAVTALWGKVNVDEVGGEALGR30
91LHCDKLHVDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH146
31LLVVYPWTQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFATLSE 90
β-chain    1VHLTPEEKSAVTALWGKVNVDEVGGEALGR30
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HbE mutation 
 
A sample with the clinically significant variant HbE was analysed. This mutation 
affects position 26 of the β-chain sequence, the Glu residue is replaced with a Lys 
residue. The substitution results in a -1 Da difference to the normal β-chain, and 
possible fragment ions have the same mass shift. This variant detection is slightly 
more challenging since the mutation site affects a position of the amino acid 
sequence further away from the N-terminus, closer to the core region of the globin-
chain sequence. There were less fragment ions observed in the mass spectrum for the 
investigated region and their intensities were also lower than those observed for the 
HbS and HbC variant chains. Only two fragment ions were observed with high 
confidence in the ETD spectrum for this mutation (Figure 3.47). For the position of 
the substitution the c26 ion can be observed in doubly and triply charged ion forms, 
and the c29 fragment is also observed in its triply charged form. As a reporter ion 
either the c26
2+ 
(m/z 1381.8)
 
or c26
3+ 
(m/z 921.6) ion may be used, although in the 
control sample at the same m/z values low intensity noise peaks are present, and the 
c29
3+ 
(m/z 1001.95) ion
 
may be more appropriate. The application of c26
3+ 
(m/z 921.6) 
is not advised since it has the same m/z as the c8
+
 ion observed for the HbS β-globin 
chain. As an initial decision the c29
3+ 
 was chosen. 
 
 
 
 
Figure 3.47. Fragment ions observed for HbE β-chain (Black spectra represent the control 
sample while blue spectra are obtained from HbE sample)  
βE-chain   1VHLTPEEKSAVTALWGKVNVDEVGGKALGR30
91LHCDKLHVDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH146
31LLVVYPWTQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFATLSE 90
β-chain    1VHLTPEEKSAVTALWGKVNVDEVGGEALGR30
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HbD-Punjab mutation  
 
The HbD-Punjab mutation is a result of the substitution of Glu 121 residue with a 
Gln residue, resulting in a -1 Da mass difference to normal β-chain.  
Multiply charged fragment ions for the (z+1)-series were observed. The intensity and 
the confidence of these fragment ions are lower based on possible overlapping noise 
peaks in the mass spectrum. The ions for the (z+1)-series are less intense and the 
coverage is not as complete as was observed for the c series, which poses a challenge 
for confirming the presence of this mutation.  
The observed fragment ions at the position of substitution and onwards are shown in 
Figure 3.48. The observed fragment ion (z+1)26
3+ 
(m/z 931.54)
 
at the point of the 
mutation confirms the position of the substitution. The (z+1)27
3+
 ion at m/z 974.25 
was initially selected as a reporter ion for further studies. Based on comparison of 
the ETD mass spectra of the HbD-Punjab and control sample, there were no or 
insignificantly low interfering ions at the m/z of the (z+1)28
3+ 
ion (m/z 993.2). 
Depending on the outcome of analysis of further samples with the HbD-Punjab 
mutation, this ion may be suggested as an alternative reporter ion. The consistent 
presence of this ion peak in clinical samples needs to be investigated in order for this 
decision to be made.  
 
 
 
 
Figure 3.48. Fragment ions observed for HbD-Punjab variant β-chain  
(Black spectra represents the control sample while orange spectra are obtained from HbD sample)  
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β
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Based on preliminary analysis, the fragment ions selected for monitoring the 
clinically significant variants in patient blood samples are summarised in Table 3.19.  
 
Sample ID Variant Position  Mutation Chosen reporter 
fragment ion and 
m/z 
A04 HbS 6 Glu→Val c7
1+
 793.5 
A02 HbC 6 Glu→Lys c8
1+
 950.61 
A01 HbE 26 Glu→Lys c29
3+
 1001.95 
A03 
- 
HbD-Punjab/ 
(HbO-Arab) 
121 Glu→Gln 
Glu→Lys 
(z+1)27
3+
 974. 25 
 
Table 3.19. Summary of hemoglobin variants and chosen reporter fragment ions for 
the detection of different conditions  
 
These reporter ions were chosen based only on one analysed example for all 
mutations. More samples were analysed to build a list of observed ions, which may 
provide additional information to suggest a suitable reporter ion for diagnostic 
purposes. 
Since the mutation HbO-Arab affects the exact same position of the β-chain as the 
mutation HbD-Punjab, also resulting in a -1 Da mass difference, it is assumed that 
the fragmentation pattern for the two mutations would be the same. In case the 
characteristic fragment ions for HbD-Punjab mutation are observed, further 
investigation such as tryptic peptide analysis would be necessary to confirm which 
variant is present.  
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3.3.8 Analysis of clinical samples 
 
3.3.8.1 Screening for clinically significant variants. 
 
The script selects regions of interest for the four previously characterised clinically 
significant variants and publishes m/z windows into a portable document format 
(pdf) report. An example of the 2 page report produced can be found in Appendix 4.  
 
Figure 3.49 shows part of the generated report from the analysis of a clinical sample 
from a healthy individual. The shaded areas highlight the positions where additional 
peaks are expected in the mass spectrum if a variant were present.  
 
 
 
Figure 3.49. Example of the variant diagnostic section of the generated report for a 
control sample  
 
Figure 3.50 shows the presence of reporter ions for HbC and HbS mutations 
confirming the sample as compound heterozygote for the two mutations. As for the 
HbC singly charged peak at m/z 950.6, the isotope envelope demonstrates that it 
corresponds to only one singly charged ion species, and with the presence of the HbS 
reporter ions it is confirmed that there is no normal β-chain present in the sample. In 
cases of homozygous HbS samples the expected peak at this position for the normal 
β-chain (m/z 951.6 for normal β-chain) is completely absent from the ETD spectrum. 
This observation has been used for distinguishing between heterozygous or 
HbC window
HbS window
HbE window
HbD window
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homozygous HbS carriers. In cases where the sample had been classified as SS by 
the hospital lab but fragment ions for the normal β-chain were observed, findings 
were in agreement with results from the other MS methods shown in previous 
chapter, indicating the sample was a heterozygous HbS carrier.  
 
 
 
Figure 3.50. Example of the variant diagnostic section of the generated report for a 
sample compound heterozygous of HbS and HbC 
 
For variants HbE and HbD-Punjab confirmation is not as straightforward. The 
analysed sample set contained only one sample with HbE variants and the whole 
ETD spectrum, rather than just selected regions, was analysed using the Data 
Analysis software. The peak intensity of the monitored reporter ion was too small to 
be diagnostically useful in the monitored m/z window. After carefully investigation 
of the ETD spectrum the c26
2+
 at m/z 1381.8 was suggested to be a more suitable 
reporter ion instead of the previously chosen c29
3+
 ion at m/z 1001.95.  
For the HbD-Punjab mutation a larger number of samples were analysed. The 
monitored reporter ion at m/z 974.5 was observed for 9 samples out of the 10 
analysed samples. The reporter ion was not present in sample E143, which was not 
confirmed by other MS methods either (discussed in the previous Chapter). This 
shows good agreement within the different MS experimental approaches, confirming 
that this is not a measurement error, or an inability of the ETD approach to detect 
this mutation. After investigating the whole ETD spectra for all samples with HbD-
HbC
HbS
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Punjab variant, the reporter ion for this mutation was suggested to be changed for 
(z+1)28
3+ 
ion (m/z 993.2), since it was present in all investigated ETD spectra, and 
was absent in the mass spectra of samples from healthy patients.  
The one sample with HbO-Arab variant showed the same fragment ions which were 
observed for the HbD-Punjab mutation, as expected.  
For HbS variant the chosen reporter ion proved to be reliable. The reporter ion for 
the HbC variant could be changed for c7
+ 
 at m/z 822.5 from the c8
+ 
 at m/z 950.6, 
since the presence of the c7
+ 
 ion peak was clearly observed in cases of all samples 
with this variant. The chosen reporter ion, however, was a good indicator of the 
presence of HbC variant, and its replacement may not be necessary.  
A summary of the number of analysed samples with different conditions and the 
number of detected samples by the ETD approach can be found in Table 3.20. In a 
small number of cases the ETD approach did not confirm the presence of a variant. 
This was caused by poor data quality due to the sample introduction issues discussed 
earlier.  
 
Mutation Number of 
analysed samples 
Detected Comment 
SS 18 7+9* 
1 not confirmed due to technical problems 
*not SS, only AS indicated 
Transfused SS 4 1 
Not confirmed mutations are due to technical 
issue not problems with ETD approach 
AS 47 43 
Not confirmed mutations are due to technical 
issue not problems with ETD approach 
SC 3 3 
No peaks for normal β-chain 
CC 1 1 
No peaks for normal β-chain 
AC 6 5 
In case of the one not confirmed it is assumed 
human error may have been the reason 
mixing samples 
AE 1 1 
c26
2+
 fragment at m/z 1381.8 confirms 
AD 10 9 
The one not detected was not confirmed by 
other MS methods either 
AO 1 1 
Same fragments as AD 
 
Table 3.20. Summary of analysed samples with different conditions and successful 
confirmation by the ETD approach  
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Analysis of several sample batches with a total number of about 1,000 analysed 
samples highlighted significant issues with the sample introduction method chosen. 
Since an LC flow was used to facilitate the sample introduction from the sample loop 
into the ion source of the mass spectrometer, it was assumed that there would not be 
any significant carry- over of a previous sample to interfere with measurement of the 
following sample. This unfortunately proved to be not the case and therefore data 
obtained for intact globin chain analysis could not be used. Clinical samples are 
assumed to form salt adducts during analysis due to the chemical environment in the 
blood collection tubes (anticoagulant agent K2/K3EDTA). The salt present in the 
samples made the analysis less efficient, and influenced the yield of the ETD 
fragmentation for the ions of interest. The LC pump and sample introduction system 
was not able to perform reliable sample introduction for the analysis of 1,000 
samples and needed constant maintenance, indicating that it was not robust enough 
for clinical laboratory applications.  
 
3.3.8.2 Analysis of rare hemoglobin variants 
 
Samples containing rare variants were also analysed using the top-down MS/MS 
method. Some of these samples required slight changes to the initial isolation 
settings.  
In those cases, where the original isolation settings yielded fragmentation for variant 
and normal chains simultaneously, results obtained support the hypothesis that the 
measurement would be able to provide information regarding rarer abnormalities 
without the need for any additional experiments. Four examples, listed in Table 3.21, 
are presented here which resulted in fragment ions being obtained indicating the 
variant chain sequence. When additional measurements were necessary, the samples 
were analysed in collaboration with Julia Smith at the laboratory of Bruker UK 
Limited.  
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Sample Observed mass shift Mutation  Identified variant 
E61 Beta chain -10 Da β5(Pro→Ser)  Hb Tyne 
E187 Beta chain +58 Da β16(Gly→Asp)  Hb J-Baltimore 
H47 Beta chain +28 Da β10(Ala→Val)  Hb Iraq-Halabja  
M136 Beta chain +14 Da β11(Val→Leu/Ile)  
"Hb Hamilton" 
or a novel variant 
 
Table 3.21. List of rare Hemoglobin variants analysed with the top-down ETD-
method 
 
Sample E61 was presented in the previous Chapter as a carrier of variant Hb Tyne. 
This mutation affects the 5
th
 position of the β-chain sequence; a Pro is substituted 
with Ser, resulting in a -10 Da mass difference of the intact variant globin chain to 
normal β-chain, and also a -10 Da mass shift for the variant fragment ions. 
Additional fragment ions were observed in the ETD spectrum after the analysis of 
the sample with the proposed test method. The c4
+ 
ion (m/z 468.33) was present in 
the ETD spectrum of the patient sample but not in a control sample (Figure 3.51). 
The Pro at position 5 of the normal β-chain prevents the cleavage at position 4, 
generating a c4
+ 
ion. The N-terminal cleavage to Pro residue was not observed in 
ETD spectra, since it would require the cleavage of two bonds. In the mutated chain 
the 5
th
 amino acid is changed to Ser, therefore the cleavage can easily happen, 
resulting in the observed c4
+ 
ion. This supports the hypothesis regarding the 
suggested position and also the nature of the substitution. An additional peak at -10 
Da to the normal c5
+ 
ion was observed at m/z 555.37, although this peak was present 
in the control sample too, as it is an overlapping peak with the doubly charged c10 
 
ion, which is expected at m/z 555.30. The isotope envelope for this peak, however, 
indicates the presence of a singly charged ion species, as shown in Figure 3.51. The 
obtained ETD spectrum was information rich, revealing many fragment ions 
matching the sequence of the variant β-chain of Hb Tyne. Ion peaks up to c15 are 
clearly present. This mutation could be identified, but was more challenging. From 
the ETD spectrum obtained with the original isolation and fragmentation settings, 
the substitution and the variant could be identified with high confidence without 
additional sample preparation involving enzymatic cleavage, or additional MS 
measurements.  
CHAPTER 3 - RESULTS OF THE CLINICAL TRIAL 
218 
 
 
 
Figure 3.51. Additional fragment ions observed for sample E61, carrier of Hb Tyne variant 
βHb Tyne-chain 1VHLTSEEKSAVTALWGKVNVDEVGGEALGR30
91LHCDKLHVDPENFRLLGNVLVCVLAHHFGKEFTPPVQAAYQKVVAGVANALAHKYH146
31LLVVYPWTQRFFESFGDLSTPDAVMGNPKVKAHGKKVLGAFSDGLAHLDNLKGTFATLSE 90
β-chain          1VHLTPEEKSAVTALWGKVNVDEVGGEALGR30
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The analysis of sample M136 also resulted in an information rich ETD spectrum of 
the variant chain. This sample is a carrier of a mutation affecting position 11 of the 
β-chain, with a substitution of Val to either Leu or Ile residue, resulting in a mass 
difference +18 Da to normal β-chain. The fragments observed are shown in Figure 
3.52. The corresponding mass peaks were observed for c11
2+
 with the +18 Da mass-
shift at m/z 611.88 not present in the mass spectrum of the control sample. Other ions 
from the c-series were also observed in the ETD mass spectrum. Doubly charged 
ions matching the expected m/z for c12-c16 and for c18 were also present in the mass 
spectrum of the sample but absent from the control sample. This sample could be 
analysed and the variant chain and mutation site, substitution identified with the 
original measurement settings without the need for additional experiments or 
enzymatic cleavage step.  
 
 
 
Figure 3.52. Additional fragment ions observed for sample M136  
 
In the case of sample H47 there was no normal β-chain present, only a sickle β-chain 
and a variant β-chain. The isolation window clearly covers the targeted ions for the 
sickle β-chain and a fragmentation rich ETD spectrum was recorded with the 
previously described c-ions being observed. The other chain present in this sample 
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was identified as Hb Iraq-Halabja, which occurs as a result of a mutation affecting 
position 10 of the β-chain, in which the Ala residue is substituted with a Val residue 
causing a mass difference of +28 Da. The multiply charged variant β-chain peaks 
are, however, less successfully fragmented. There are some fragments observed that 
were not present in a control sample, which were in agreement with the predicted 
masses for the fragments of the previously identified mutation.  
Figure 3.53 shows the identified fragment peaks. No confirmation regarding the 
mass shift resulting in variant c10
 
ion could be obtained. With careful investigation of 
the mass spectrum around the m/z expected for the variant c11
2+
, the peaks may be 
considered to be present although overlapping with other peaks. Additional peaks at 
the expected m/z for doubly charged ions of c12 to c15 were confidently identified. 
These mass peaks would not be present if the mutation with the +28 Da mass 
difference was not present at position 10. Different isolation settings may give a 
more confident identification due to higher intensity fragment peaks originating 
predominantly from the variant chain and not from the sickle beta-chain.  
 
 
 
Figure 3.53. Additional fragments observed for sample H47  
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difference was +58 Da, which for the 18+ charge state on the intact level was not 
within the isolation window set originally for the test screening method. Additional 
experiments needed to be performed. The isolation window was initially adjusted. 
The first isolation was at m/z 888.0 and the second isolation step at m/z 885.6. The 
ETD and PTR parameters were kept the same as in previous experiments. The 
overall ion intensity was lower in the ETD spectrum than that observed for the 
normal β-chain. Additional fragment ions compared to control sample are shwon in 
Figure 3.54. Observed ions can be matched with predicted doubly charged fragment 
ions for the identified chain for c18, c20, c22, c23, c29 and c30. Although c16 fragment 
ions for the position of the substitution were not observed, the +58 Da may be the 
result of a Gly → Asp substitution. The assigned fragment ions would be absent if 
this mutation had not occurred.  
 
 
 
Figure 3.54. Fragment ions observed for sample E187 variant β-chain  
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3.4 Conclusion  
3.4.1 Clinical trial with previously developed methods 
 
Two mass spectrometry-based approaches utilizing Waters XEVO TQ instrument 
have been used in combination to analyse a total number of 2,017 samples for 
hemoglobinopathy diagnosis.  
The different mass spectrometry based methods used for hemoglobinopathy 
screening have been evaluated for suitability in clinical screening, satisfying the need 
for reliable and fast measurement. The primary aim was to test the methods on 
clinical samples, and assess their robustness on population screening scale with the 
analysis of all samples arriving to a clinical lab in the period of twelve weeks. All 
samples have been analysed using both methods.  
 
The first line testing using intact globin chain analysis was able to detect all samples 
with variants. Determination of the mass error of the β-globin chain indicated 
presence of -1 Da variants when compared to the mass error ranges of the normal 
samples within the same sample batch. Current issues which will need further 
development are the necessity to overcome the requirement for the analysis of 
several normal samples to provide the normal range for the actual measurement 
conditions. A calibration method for normalisation in combination of a statistical 
method to identify normal ranges will be necessary.  
Intact globin chain analysis was able to indicate the presence of HbS variants for 
every analysed sample with this mutation, and also provided an estimation of the 
proportion of the variant chain to normal beta-chain.  
Calculating intensity ratios of the δ-chain mass peak to the β-chain mass peak proved 
to be a reliable quantitation method for elevated HbA2 levels, which quantirtative 
application has not been published and tested on a larger set of clinical samples 
before this study. A calibration which would allow for adjusting values to ce-HPLC 
values would be beneficial before sample measurements to assure the elevated 
values are always assigned the same way, and the reference ranges quoted are 
correct.  
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Nine samples have been identified with rare abnormal mutations, seven of these only 
detectable using mass spectrometry. Five out of seven of these samples have been 
characterised. One sample needs further mass spectrometric investigation with 
techniques such as high energy CID fragmentation or ECD to clarify what 
substitution has taken place. Two remaining samples need to be further 
characterised.  
Intact globin chain analysis was able to give estimation regarding glycated beta-
chain levels, which can be used for monitoring long-term diabetic conditions. 
Reliable estimation of HbF levels was also possible, which is desirable based on 
NHS screening requirements. Elevated HbF levels can indicate the presence of some 
thalassemic conditions and also HPFH disease.  
The direct infusion approach satisfies most of the requirements and so is regarded as 
currently the best choice for a rapid diagnostic screen. It enables the most 
information to be obtained in the shortest time frame for a relatively low cost. 
Currently this method needs expert staff to interpret the measured data. This could be 
alleviated by use of automated data interpretation software.  
 
An MRM-method was used to confirm the presence of clinically significant variants 
such as HbS, HbE and HbC. It is also able to detect the Hb G-Philadelphia mutation 
presented in Chapter 2. The method confirmed all samples with the mentioned 
mutations, except one sample with HbS. The βSICKLE-chain was only present in a low 
proportion (according to intact globin chain analysis 6.5%) and did not result in a 
MRM peak for the monitored βSICKLE-chain peptide. The calculated proportions of 
βSICKLE-chain based on peptide ratios differed significantly from the levels 
determined using the intact globin chain analysis. This observed occasional 
difference highlighted potential problems with the method. These are thought to be 
caused by incomplete enzymatic cleavage which may have affected the different 
globin-chains and the proportion of the resulted peptides differently. 
By monitoring three pairs of peptides in the β- and δ-chains quantitation of HbA2 
levels was performed. The T2 and T3 peptide ratios did not provide as high a 
correlation to the reference ce-HPLC values as the novel T5 peptide ratios, therefore 
the T5 peptide ratios are proposed to be most appropriate for HbA2 quantitation 
purposes. The use of the T5 peptides and the obtained well correlating results to 
current methods are also important because Daniel et al. presented MRM transitions 
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only for T2 and T3 peptides (Daniel et al. 2007), but the T5 peptide ratios have not 
previously been reported for the purpose of HbA2 quantitation. Monitoring T5 
peptide ratios provided values which allowed clear differentiation between normal 
and elevated values. The ranges observed for the normal values, however, did show 
some variation from batch to batch. The distribution of the normal levels did not 
prove to be as consistent as had been observed for intact globin chain analysis. The 
measurement of a calibration series with known HbA2 levels would be beneficial for 
adjustment of the values and obtain the necessary consistency. It needs to be 
assessed whether this variation originated from measurement issues, or the 
previously mentioned potential problems with enzymatic cleavage. It is suggested 
that high quality sequencing grade trypsin for the sample preparation is evaluated to 
verify or exclude this hypothesis.  
Other factors such as sample age and its influence on the resulted values also need to 
be evaluated.  
 
It can be concluded that the combined use of the two MS methods was able to detect 
all clinically significant variants. MS methods were also able to detect rarer 
hemoglobin variants which were not detected using hospital methods. Both MS 
methods can be used for the quantitation of HbA2. Intact globin chain analysis is also 
able to provide estimated values of glycated hemoglobin and HbF levels. For 
confirmation of HbD-Punjab mutation mass spectrometry analysis of the tryptic 
peptide mixture by a Q-ToF instrument was still required.  
Intact globin chain analysis is not confirmative only indicative, while the MRM-
method only confirms known and monitored variants, but cannot detect other 
abnormalities. A combination of the two methods could provide a solution for 
population screening. The two type of analysis can be performed on the same triple 
quadrupole instrument reducing the number of techniques necessary, since in the 
current clinical setting confirmative diagnosis is achieved using different techniques.  
 
3.4.2  Pilot study using the top-down ETD method 
 
The top-down ETD approach has also demonstrated a high potential for screening 
applications of hemoglobinopathies.   
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The developed method contains different measurement segments for different 
purposes. The initial analysis of denatured intact globin chains allows detection of 
mass shift in case of rare variants, has the potential for HbA2, HbA1c quantitation and 
for detecting abnormally elevated HbF levels. 
The top down ETD method targets normal and unresolved β-chain variants within a 
3 Da window on the multiply charged ion level. The β-chain and all clinically 
significant variant β-chains are simultaneously fragmented producing sequence 
information and characteristic fragment ions. The characteristic fragment ions are 
monitored for HbS, HbC, HbE, HbD-Punjab. Since HbO-Arab affects the same 
position of the β-chain as HbD-Punjab with both resulting in a -1 Da mass shift, 
these variants may be monitored using the same reporter fragment ion. The method 
developed for the preliminary clinical testing on a subset of the samples from the 
clinical trial identified all variants correctly, and confirmed the mutations based on 
the obtained fragments.  
After a simple dilution step the method was capable of providing absolute 
confirmation of the monitored mutations. The structural information obtained is 
highly valuable information, which cannot be obtained by the use of current clinical 
screening techniques. The script developed for batch data processing is extremely 
useful for high-throughput applications to allow automation of data analysis. The 
generated pdf report is easy to use and its interpretation does not require expert staff 
which is also desirable for clinical laboratory applications. 
The sample introduction method with a modified HPLC was not able to satisfy the 
high-throughput requirements. Samples were only not identified with the ETD-MS 
method due to the technical problems of the sample introduction.  
 
The following issues need to be addressed to fulfil all the requirements against a 
screening method which would be acceptable by the NHS: 
 
• Method optimisation and testing are required to assure the method is suitable 
for quantitation of δ-chain to allow detection of β-thalassemia 
• Consistent measurement of glycated Hb needs to be established 
• HbF levels need to be monitored to detect samples with elevated levels 
• Method optimisation, or the development of an alternative approach, is 
required to enable discrimination between HbD-Punjab and HbO-Arab.  
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• An improved sample introduction is required (which is currently under 
development) 
• Further automation of data processing, including the possibility of 
synchronisation with data acquisition for automated further investigation of 
cases with abnormal mass shifts would be beneficial 
 
For identification of unknown variants a higher sequence coverage would be 
desirable, which may be obtained by combining CID and ETD fragmentation of the 
intact globin chains (Zubarev et al. 2008). MS
3
 experiments derived from b- or y-
type ions as intermediate product ions from a first fragmentation step with CID 
would generate sequence information regarding sections of the protein which are 
otherwise not covered by a simple one-step fragmentation experiment (Syka et al. 
2004).  
 
The application of top-down ETD technology for screening of structural hemoglobin 
variants have been tested, and the results are promising. Obtaining sequence 
information of the globin chains without the additional enzymatic cleavage step is a 
major advantage of this approach. The ETD based method is the method of choice 
for future developmental work.  
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The work presented in this thesis has illustrated the use of mass spectrometry 
approaches in hemoglobinopathy diagnosis.  
 
Mass spectrometry plays an important role in the analysis of biological molecules 
today. Human diseases may be diagnosed from the analysis of certain biomolecules 
which are responsible for the clinical condition (eg. mutant DNA and modified 
proteins) or molecules which are involved in disease related biochemical processes 
during the development of the disease. The speed, specificity and sensitivity of mass 
spectrometry make this technique attractive for clinical applications where rapid 
identification and characterization of proteins is necessary (Reid and McLuckey 
2002).  
Mass spectrometry has the potential to become a leading technique in the field of 
hemoglobinopathy diagnosis, but it is important to clarify that it will never provide 
the gold standard. DNA analysis is the only way of identifying with certainty what 
exact genetic mutation has taken place, from that the manifestations of the genetic 
mutations, either affecting the structure or the level of production of certain globin 
chains, can be determined.  
The primary aim of developing MS-based approaches is to avoid difficult and 
expensive DNA analysis in most cases marking it possible to support current 
antenatal screening programs. The application of mass spectrometry-based methods 
has been shown to provide this. With the definitive diagnosis of unknown variants, 
which can be obtained by using mass spectrometry, the number of samples that 
require DNA analysis has been very significantly decreased.  
Despite several publications regarding the use of MS in this field, it has not yet been 
implemented as a routine technique in hematology labs. The current techniques 
(HPLC and IEF) provide satisfactory diagnosis of clinically significant variants. At 
the moment MS is primarily used for the identification of abnormal structural 
hemoglobin variants following the protocol from Wild et al. (Wild et al. 2001).  
There have been several attempts to develop MS-based screening methods, with the 
highest potential provided by an MRM-based approach by Daniel et al. (Daniel et al. 
2005, Daniel et al. 2007) Thousands of samples have been analysed and it has been 
shown that targeted peptide monitoring could provide an automated high-throughput 
method for screening of the clinically significant hemoglobin variants.  
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4.1 Evaluation of the combination of two MS-based approaches using a 
triple quadrupole mass spectrometer 
 
It has been shown that a triple quadrupole system can be used to obtain diagnosis of 
several hemoglobin disorders. Two methods employed in combination were able to 
provide confirmation of the presence of all clinically significant mutations.  
 
Intact globin chain analysis provided information regarding the presence of 
additional variant globin chains, and with mass error calculations were able to 
provide indication of -1 Da variants. It also provided estimation of HbA2 and 
glycated hemoglobin levels, and detected elevated HbF levels. During the clinical 
trial the method detected seven hemoglobin variants which were 
chromatographically not detectable. In preliminary testing it also highlighted 
problems with current clinical methods, such as when a sample classed, as HbD-
Punjab, was identified with certainty by MS as HbG-Philadelphia. This kind of 
misdiagnosis, when a sample is falsely diagnosed as HbD-Punjab, one of the 
clinically significant variants, is unacceptable and highlights that even the use of two 
different techniques can confirm a condition incorrectly.  
Targeted peptide analysis as a necessary second line method using the same triple 
quadrupole instrument provided confirmation of known variants HbS, HbE and HbC 
and an estimation of of HbA2 levels. New MRM method and transitions for the use 
of the T5 peptide ratios in the normal β- and minor δ-chain is a novel result , 
previously not presented in the literature. The reliable monitoring of this specific 
peptide pair is a promising achievement of the work conducted to provide a 
competitive method for future clinical application.  
 
Both methods were capable of providing an estimation of HbA2 levels, and were able 
to distinguish between normal and elevated levels. Despite an obvious correlation 
between HbA2 values obtained using the ce-HPLC method and the different mass 
spectrometry based methods, values differ as shown in the statistical analysis. All 
three methods measure different chemical entities. The ce-HPLC method measures 
the quantity of αδ dimers, a building block of protein HbA2, and reports based on 
UV response. The intact globin-chain analysis determines the ratio between the β- 
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and δ- globin chains. The MRM method measures the peptide ratios by monitoring 
fragmentation routes. All three analyses are performed using different chemical 
properties. An important fact which needs to be emphasised is that both MS-based 
methods were in agreement with HPLC and provided confirmation regarding the 
HbA2 level of a sample being in a normal or abnormal range. It is important to 
emphasize that neither the intact globin chain analysis nor the T5 peptide ratio 
monitoring have been previously tested on a large number of antenatal samples, and 
both show good correlation and promise to compete against current quantitative 
chromatographic techniques. 
 
Future work 
 
Based on observations resulting from the clinical trial the following method 
optimisation issues need to be addressed:  
 Intact globin chain analysis is the suggested method for HbA2 quantitation 
and further developments and evaluation of this method is targeted. A 
calibration method needs to be developed to eliminate batch to batch 
variations and to provide an absolute range for normal samples to ensure that 
elevated levels are detected at any time under any instrumental conditions 
with high confidence.  
 The development of an automated screening method for HbD-Punjab 
mutation would be beneficial.  
 The MRM-method may be extended to monitor the presence of peptides of 
rare variants identified during the clinical trial for further screening purposes.  
 The remaining two samples with α- and β- chain variants will be 
characterised.  
 Issues encountered regarding the efficiency of the enzymatic cleavage need 
to be investigated and the problem eliminated to confident diagnostic value 
and also reliable quantitation which is required for HbC and HbE variant 
level determination.  
 
As part of more fundamental research ion mobility studies can be carried out to 
better characterise different clinically significant variants. HbS showed different 
collisional cross sections in a previously presented publication (Scarff et al. 2009). 
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Ion mobility analysis of other clinically significant variants may reveal certain 
similarities or differences in the shape of the globin-chain dimers to provide insight 
into structure-function relationships. Ion mobility mass spectrometry have also been 
successfully employed in challenging cases before (Williams et al. 2008), additional 
potential future applications may be considered when this technique becomes 
available on a less expensive bench top mass spectrometer, which would also be 
more likely to be employed in a clinical laboratory.   
 
4.2 Evaluation of top-down ETD-based MS approach on an iontrap 
system 
 
In collaboration with Bruker Daltonics the developed top-down ETD method has 
shown great potential for automated hemoglobinopathy screening. Monitoring the 
presence of characteristic fragment ions of the intact globin chain provided 
confirmation of clinically significant variants and additional fragmentation 
information of rare hemoglobin variants. A significant advantage of the method is 
that it provides sequence information without the need for enzymatic cleavage. No 
expert staff are required to interpret the results using the automatically generated 
report. Confident diagnosis of HbD-Punjab and HbO-Arab mutation in an automated 
manner can be achieved, which proved to be challenging with the other MS methods 
and required full scan tryptic peptide analysis on a Q-ToF instrument.  
 
Future work 
 
The developed method, to realise its full potential, needs further optimisation and 
technical improvements. A reliable low cost sample introduction system would allow 
intact globin chain analysis section to be optimised and evaluated for HbA2, HbA1c 
and HbF level estimations similarly as achieved using the triple quadrupole 
instrument with NanoMate sample introduction.  
As has been pointed out by Graca et al. even complete MS-based sequence analysis 
will not be able to give definitive answers in case of rare variants like Hb Machida, 
which result in the same mass shift at the exact same position on the β-chain as HbC 
(Graca et al. 2012). Differentiation also needs to be achieved for Hb D-Punjab and 
Hb O-Arab mutations. This needs to be addressed in further development of the top-
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down ETD method to be able to distinguish between these two clinically significant 
variants.  
It also needs to be investigated whether quantitation of the different -1 Da variants 
could be achieved based on ratio calculations between normal and variant fragment 
ions.  
 
Concluding remarks 
 
When comparing the methods to decide which one has the higher potential to 
become an applied technique in the clinical laboroartory, it has to be considered 
which method can offer the most information at the lowest cost. The aim is to fulfil 
the NHS requirements set in the Sickle cell and thalassemia screening Programme 
(NHS 2012b). The MRM method may have potential for screening for specific 
known variants, but intact protein mass can provide additional information not 
available from targeted peptide analysis. To maximise the obtained information the 
two methods may need to be used in combination. This adds complication and 
makes the screening process long and since it requires more analytical steps that 
introduce greater variability.  
 
The ETD method has a significant chance of acceptance in the clinical lab, since it 
only requires a simple dilution sample preparation step, which could be automated in 
the future. The overall data acquisition time (15 minutes) is not shorter than the sum 
of the other two MS approaches, but turn-around time is significantly less due to the 
absence of the need for lengthy enzymatic cleavage.  
As proposed extension of the clinical trial to other regional laboratories would 
generate at least as much data as the initial trial giving further confidence in the 
approach. 
 
Clinicians remain sceptical, since mass spectrometry has not yet shown the ability to 
detect all existing variants, but databases and extended methods are constantly 
improving to provide the highest level of information possible using this technique. 
Since mass spectrometry is one of the fastest developing fields in science and recent 
developments target clinical applications, the technique will no doubt become a 
leading routine technique in medical diagnosis in the near future.  
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Appendix 1 
Figures for Batch B 
 
 
 
  
  
7
6
5
4
3
2
1
%
 H
b
A
2
ce-HPLC Intact MS           T2 peptides         T3 peptides       T5 peptides
Batch B
y = 0.9428x + 1.625
R² = 0.5815
0
1
2
3
4
5
6
7
8
0 1 2 3 4 5 6 7 8
H
b
A
2
%
-I
n
ta
ct
 M
S
 
HbA2% - ce-HPLC
Batch B - Intact MS
y = 0.7155x + 0.0944
R² = 0.4168
0
1
2
3
4
5
6
7
8
0 1 2 3 4 5 6 7 8
H
b
A
2
%
-T
2
 -
M
R
M
HbA2% - ce-HPLC
Batch B-T2-peptide
y = 0.5793x + 0.0995
R² = 0.4851
0
1
2
3
4
5
6
7
8
0 1 2 3 4 5 6 7 8
H
b
A
2
%
 -
T
3
-M
R
M
HbA2% - ce-HPLC
Batch B - T3-peptide
y = 0.9857x + 0.2417
R² = 0.813
0
1
2
3
4
5
6
7
8
0 1 2 3 4 5 6 7 8
H
b
A
2
%
-T
5
 -
M
R
M
HbA2% - ce-HPLC
Batch B - T5-peptide
APPENDICES 
 
253 
 
 
 
 
 
Bathc B mass error box plots
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Figures for Batch C 
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Batch C error boxplots
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Figures for Batch D 
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Batch D error boxplots
1.0
0.5
0.0
-0.5
-1.0
-1.5
HBB_HBA_Mass_Error_DaAve_HBB_Mass_Error_DaAve_HBA_Mass_Error_Da
 
 
-1.7
-1.5
-1.3
-1.1
-0.9
-0.7
-0.5
-0.3
-0.1
0.1
0.3
0.5
0.7
0.9
1.1
1.3
H
b
B
-H
b
A
 M
a
ss
 E
rr
o
r 
(D
a
)
HbB-HbA Mass Error - Batch D
-1.7
-1.5
-1.3
-1.1
-0.9
-0.7
-0.5
-0.3
-0.1
0.1
0.3
0.5
0.7
0.9
1.1
1.3
H
b
A
 M
a
ss
 E
rr
o
r 
(D
a
)
HbA Mass Error - Batch D
-1.7
-1.5
-1.3
-1.1
-0.9
-0.7
-0.5
-0.3
-0.1
0.1
0.3
0.5
0.7
0.9
1.1
1.3
H
b
B
 M
a
ss
 E
rr
o
r 
(D
a
)
HbB Mass Error - Batch D
APPENDICES 
 
260 
 
-0.5
0
0.5
1
1.5
2
2.5
3
3.5
1 3 5 7 9
D
if
fe
re
n
ce
 (
In
ta
ct
 M
S
 -
 H
P
L
C
) 
Mean of HbA2% by two methods  
Batch D - Intact MS - Difference Plot 
Identity
Bias (1.77)
95% Limits of
agreement
(1.02 to 2.51)
1
2
3
4
5
6
7
8
9
10
1 3 5 7 9
H
b
d
%
 -
 M
S
 
HbA2%-HPLC 
Batch D - Intact MS - Scatter Plot with Passing & Bablok Fit 
Identity
Passing &
Bablok (I) fit
(0.69 + 1.38x)
95% CI bands
-0.5
0
0.5
1
1.5
2
2.5
1 3 5 7 9
D
if
fe
re
n
ce
 (
M
R
M
-T
5
- 
- 
H
P
L
C
) 
Mean of HbA2% by two methods 
Batch D - MRM-T5 peptides - Difference Plot 
Identity
Bias (0.99)
95% Limits of
agreement
(0.27 to 1.70)
1
2
3
4
5
6
7
8
9
1 3 5 7 9
H
b
A
2
%
-M
R
M
-T
5
 
HbA2% - HPLC 
Batch D - MRM-T5 peptides - Scatter Plot with Passing & 
Bablok Fit 
Identity
Passing &
Bablok (I) fit
(0.03 + 1.33x)
95% CI bands
APPENDICES 
 
261 
 
y = 0.8303x + 0.1894
R² = 0.7532
0
1
2
3
4
5
6
7
8
9
0 1 2 3 4 5 6 7 8 9
H
b
A
2
%
 -
T
5
-M
R
M
HbA2% - ce-HPLC
Batch E - T5-peptide
Figures for Batch E 
 
 
 
 
 
8
6
4
2
0
%
 H
b
A
2
ce-HPLC Intact MS           T2 peptides         T3 peptides       T5 peptides
Batch E
y = 1.0775x + 1.8338
R² = 0.7288
0
1
2
3
4
5
6
7
8
9
0 1 2 3 4 5 6 7 8 9
H
b
A
2
%
 -
In
ta
ct
M
S
HbA2% - ce-HPLC
Batch E - Intact MS
y = 0.7306x + 0.6626
R² = 0.4112
0
1
2
3
4
5
6
7
8
9
0 1 2 3 4 5 6 7 8 9
H
b
A
2
%
 -
T
2
-M
R
M
HbA2% - ce-HPLC
Batch E T2-peptide
y = 0.7146x + 0.2601
R² = 0.8105
0
1
2
3
4
5
6
7
8
9
0 1 2 3 4 5 6 7 8 9
H
b
A
2
%
 -
T
3
-M
R
M
HbA2% - ce-HPLC
Batch E - T3-peptide
APPENDICES 
 
262 
 
 
 
 
 
 
 
1.0
0.8
0.6
0.4
0.2
-0.0
-0.2
-0.4
-0.6
HBB_HBA_Mass_Error_DaAve_HBB_Mass_Error_DaAve_HBA_Mass_Error_Da
 
Batch E error boxplots
-1.7
-1.5
-1.3
-1.1
-0.9
-0.7
-0.5
-0.3
-0.1
0.1
0.3
0.5
0.7
0.9
1.1
1.3
H
b
B
-H
b
A
 M
a
ss
 E
rr
o
r 
(D
a
)
HbB-HbA Mass Error - Batch E
-1.7
-1.5
-1.3
-1.1
-0.9
-0.7
-0.5
-0.3
-0.1
0.1
0.3
0.5
0.7
0.9
1.1
1.3
H
b
A
 M
a
ss
 E
rr
o
r 
(D
a
)
HbA Mass Error - Batch E
-1.7
-1.5
-1.3
-1.1
-0.9
-0.7
-0.5
-0.3
-0.1
0.1
0.3
0.5
0.7
0.9
1.1
1.3
H
b
B
 M
a
ss
 E
rr
o
r 
(D
a
)
HbB Mass Error - Batch E
APPENDICES 
 
263 
 
-0.5
0
0.5
1
1.5
2
2.5
3
3.5
1 3 5 7 9D
if
fe
re
n
ce
 (
In
ta
ct
 M
S
 -
 H
P
L
C
) 
Mean of HbA2%-by two methods 
Batch E - Intact MS - Difference Plot 
Identity
Bias (2.04)
95% Limits of
agreement
(1.26 to 2.83)
1
2
3
4
5
6
7
8
9
1 3 5 7 9
H
b
A
2
%
 -
 I
n
ta
ct
 M
S
 
HbA2% - HPLC 
Batch E - Intact MS - Scatter Plot with Passing & Bablok Fit 
Identity
Passing &
Bablok (I) fit
(0.33 +
1.62x)
95% CI bands
-1.5
-1
-0.5
0
0.5
1
1.5
1 2 3 4 5 6
D
if
fe
re
n
ce
 M
R
M
-T
5
 -
 H
P
L
C
) 
Mean of HbA2% by two methods 
Batch E - MRM-T5 peptides - Difference Plot 
Identity
Bias (-0.27)
95% Limits of
agreement
(-0.87 to 0.33)
1
2
3
4
5
6
7
1 2 3 4 5 6 7
H
b
A
2
%
- 
M
R
M
-T
5
  
 
HbA2%-HPLC 
Batch E - MRM-T5 peptides - Scatter Plot with Passing & 
Bablok Fit 
Identity
Passing &
Bablok (I) fit
(-0.04 +
0.90x)
95% CI bands
APPENDICES 
 
264 
 
Figures for Batch F 
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Batch F error boxplots
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Figures for Batch G 
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Batch G error boxplots
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Figures for Batch H 
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Batch H error boxplots
1.00
0.75
0.50
0.25
0.00
-0.25
-0.50
-0.75
HBB_HBA_Mass_Error_DaAve_HBB_Mass_Error_DaAve_HBA_Mass_Error_Da
 
 
-1.7
-1.5
-1.3
-1.1
-0.9
-0.7
-0.5
-0.3
-0.1
0.1
0.3
0.5
0.7
0.9
1.1
1.3
H
b
B
-H
b
A
 M
a
ss
 E
r
r
o
r
 (
D
a
)
HbB-HbA Mass Error - Batch H
-1.7
-1.5
-1.3
-1.1
-0.9
-0.7
-0.5
-0.3
-0.1
0.1
0.3
0.5
0.7
0.9
1.1
1.3
H
b
A
 M
a
ss
 E
rr
o
r 
(D
a
)
HbA Mass Error - Batch H
-1.7
-1.5
-1.3
-1.1
-0.9
-0.7
-0.5
-0.3
-0.1
0.1
0.3
0.5
0.7
0.9
1.1
1.3
H
b
B
 M
a
ss
 E
rr
o
r 
(D
a
)
HbB Mass Error - Batch H
APPENDICES 
 
272 
 
-0.5
0
0.5
1
1.5
2
2.5
3
3.5
1 3 5 7 9
D
if
fe
re
n
ce
 (
In
ta
ct
 M
S
 -
 H
P
L
C
) 
Mean of HbA2% by two methods 
Batch H - Intact MS - Difference Plot 
Identity
Bias (1.84)
95% Limits of
agreement
(0.80 to 2.89)
1
2
3
4
5
6
7
8
9
10
1 3 5 7 9
H
b
A
2
%
- 
In
ta
ct
 M
S
 
HbA2% - HPLC 
Batch H - Intact MS - Scatter Plot with Passing & Bablok Fit 
Identity
Passing &
Bablok (I) fit
(-0.46 + 1.85x)
95% CI bands
-0.5
0
0.5
1
1.5
2
1 3 5 7 9
D
if
fe
re
n
ce
 (
M
R
M
-T
5
-H
P
L
C
) 
Mean of HbA2% by two methods 
Batch H - MRM-T5 peptides - Difference Plot 
Identity
Bias (0.41)
95% Limits of
agreement
(-0.37 to 1.19)
1
2
3
4
5
6
7
8
9
1 3 5 7 9
H
b
A
2
%
 -
 M
R
M
-T
5
 
HbA2%-HPLC 
Batch H - MRM-T5 peptides - Scatter Plot with Passing & 
Bablok Fit 
Identity
Passing &
Bablok (I) fit
(-1.75 +
1.81x)
95% CI bands
APPENDICES 
 
273 
 
Figures for Batch I 
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Batch I error boxplots
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Figures for Batch J 
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Batch J error boxplots
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Figures for Batch K 
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Batch K error boxplots
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Figures for Batch L 
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Batch L error boxplots
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Figures for Batch M 
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Batch M error boxplots
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Appendix 2  
 
  
Hospital 
number 
Hospital 
comment 
Our 
number 
δ-chain 
% Sickle β % Comment 
1 18626847 AS B/2 6.5 33.8   
2 18636282 AS B/7 5.4 40   
3 18942346 AS C/01 5.8 40.2   
4 18968368 AS C/103 7.6 34.3   
5 18987758 AS C/154 6.6 40.4   
6 19000645 AS D/86 6.6 34.0   
7 18997141 AS D/87 7.7 36.6   
8 18965398 AS D/90 7.4 34.4   
9 19026666 AS D/96 6.9 34.4   
10 18984306 AS D/108 6.9 22.4   
11 19023812 AS E/20 8.6 40.7   
12 19088085 AS E/197 6.4 32.5   
13 19104439 AS E/240 7.4 35.3   
14 19063471 AS E/257 8.1 29.0   
15 19143309 AS F/50 6.72 41.3   
16 19190287 AS F/116 6.35 38.9   
17 19236403 AS G/32 5.7 42.7   
18 19243173 AS G/33 7.2 41.1   
19 19256132 AS G/93 7.9 44.0   
20 19160116 AS H/41 7.1 32.9   
21 19167290 AS H/42 8.3 37.8   
22 19177623 AS H/43 7.1 27.8   
23 19210745 AS H/44 8.3 40.8   
24 19243309 AS H/47 - 99.3   
25 19294788 AS H/70 7.2 40.4   
26 19335077 AS I/07 6.9 41.0   
27 19349335 AS I/09 6.7 40.4   
28 19366797 AS I/39 6.6 34.7   
29 19370399 AS I/53 6.5 40.4   
30 19401960 AS J/16 6.2 40.7   
31 19353426 AS J/41 5.8 35.9   
32 19329213 AS J/42 5.2 40.6   
33 19335932 AS J/43 6.0 36.4   
34 19429327 AS J/45 5.9 42.7   
35 19442432 AS J/66 6.4 40.0   
36 19529354 AS K/42 7.0 41.5   
37 19452101 AS K/43 6.6 41.3   
38 19531007 AS K/45 6.8 44.0   
39 19455394 AS K/46 5.7 32.3   
40 19550500 AS K/50 6.4 31.0   
41 19551541 AS K/57 6.4 30.0   
42 19554540 AS K/78 6.8 40.9   
43 19606434 AS L/49 7.6 42.6   
44 19644581 AS L/130 7 37.8   
45 19675732 AS M/50 6.49 40.4   
46 19681412 AS M/51 7.5 39.6   
47 19702509 AS M/122 6.5 34.3   
48 19100576 F+S F/128 - 27.1 Calculated to HbF 
Table A.1. Calculated sickle β-chain percentages for the samples classed as 
heterozygous sickle carriers.   
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Hospital 
number 
Hospital comment 
Our 
number 
δ-chain 
% 
Sickle β % Comment 
1 18963649 SC C/99 7.7 48.3 
 
2 18925552 SC D/95 9.3 52.9 
 
3 19395725 SC J/40 9.7 52.9 
 
4 18680594 SS B/127 19.8 84.8 high, but not 100% 
5 19051166 SS D/92 4.4 9.5 
low, potentially  
transfused 
6 19052015 SS E/34 - 100 
 
7 19089366 SS E/146 19.2 80.7 high, but not 100% 
8 19099276 SS E/180 - 94.8 high, but not 100% 
9 19104272 SS E/239 7.0 46.4 
Potentially 
heterozygous 
10 19217134 SS F/229 - 100 
 
11 19271790 SS H/39 - 100 
 
12 19272934 SS H/40 - 100 
 
13 19162734 SS H/143 - 100 
 
14 19348189 SS I/01 - 100 
 
15 19364122 SS I/74 - 100 
 
16 19444782 SS J/48 7.3 55.1 
Potentially 
heterozygous 
17 19504631 SS J/87 - 100 
 
18 19513031 SS J/106 6.4 43.3 
Potentially 
heterozygous 
19 19516260 SS J/116 4.1 6.5 
low, potentially 
transfused 
20 19669274 SS M/42 6.4 33.9 
 
21 19729121 SS M/154 5.4 37.7 
 
22 19063417 TRANSFUSED SS F/129 5.2 32.6 
 
23 19217967 TRANSFUSED SS F/230 6.5 41.9 
 
24 19218036 TRANSFUSED SS F/231 4.1 3.3 very low 
25 19249866 TRANSFUSED SS G/92 6.2 44.4 
 
 
Table A.2. Calculated sickle β-chain percentages for the samples classed as 
heterozygous sickle carriers.   
 
 
 
 
 
  
APPENDICES 
 
290 
 
 
 
  
Hospital 
number 
Hospital 
comment Our number T2 T3 T5 
HbS 
% 
Hb
C Comment 
1 18626847 AS B/2 2.4 2.1 3.7 20.7     
2 18636282 AS B/7 2.1 1.6 3.1 27.0     
3 18942346 AS C/01 3.5 2.4 3.2 38.9     
4 18968368 AS C/103 - 2.8 2.9 19.9     
5 18987758 AS C/154 - 2.4 2.5 27.2     
6 19000645 AS D/86 87.7 1.1 4.2 11.5     
7 18997141 AS D/87 40.4 1.3 4.8 13.1     
8 18965398 AS D/90 52.6 1.4 4.7 15.1     
9 19026666 AS D/96 18.8 1.4 4.5 12.9     
10 18984306 AS D/108 77.5 1.4 5.3 5.0     
11 19023812 AS E/20 3.3 2.9 3.4 52.7     
12 19088085 AS E/197 2.5 2.1 2.9 18.8     
13 19104439 AS E/240 3.7 2.8 3.0 27.8     
14 19063471 AS E/257 4.0 3.3 3.8 16.5 -   
15 19143309 AS F/50 1.0 2.4 4.1 15.7     
16 19190287 AS F/116 1.1 1.6 3.0 20.4     
17 19236403 AS G/32 1.4 2.2 3.3 19.4     
18 19243173 AS G/33 1.5 2.3 3.8 17.7     
19 19256132 AS G/93 0.9 1.8 3.1 22.4     
20 19160116 AS H/41 1.1 2.3 4.7 5.6     
21 19167290 AS H/42 0.8 2.5 4.8 14.6     
22 19177623 AS H/43 1.3 2.3 5.2 3.7     
23 19210745 AS H/44 1.4 2.6 5.0 21.0     
24 19243309 AS H/47 5.5 2.4 5.2 17.1     
25 19294788 AS H/70 1.1 2.0 3.9 12.9     
26 19335077 AS I/07 3.9 2.9 2.6 41.6     
27 19349335 AS I/09 3.9 3.1 2.7 42.0     
28 19366797 AS I/39 3.8 2.9 2.7 31.8     
29 19370399 AS I/53 3.9 2.6 2.7 39.7     
30 19401960 AS J/16 0.2 1.9 3.4 8.9     
31 19353426 AS J/41 0.6 1.9 4.2 9.2 0.0   
32 19329213 AS J/42 0.3 1.7 3.3 12.4 0.1   
33 19335932 AS J/43 0.3 2.1 4.0 5.5 0.0   
34 19429327 AS J/45 0.7 1.9 4.5 19.4 0.0   
35 19442432 AS J/66 0.9 2.2 4.3 12.2     
36 19529354 AS K/42 1.2 1.1 5.1 8.3 - 
Sickle values are really 
low 
37 19452101 AS K/43 1.1 1.1 4.1 5.0 - 
peptides are present, but 
quantitation is not 
satisfying 
38 19531007 AS K/45 1.5 1.0 4.3 8.7 -   
39 19455394 AS K/46 0.6 0.3 3.7 1.3 -   
40 19550500 AS K/50 1.3 1.1 4.4 1.6 -   
41 19551541 AS K/57 1.2 1.1 4.5 1.4 -   
42 19554540 AS K/78 1.6 1.2 4.8 1.7 -   
43 19606434 AS L/49 1.2 1.3 4.2 0.2   Problem with digestion 
44 19644581 AS L/130 2.4 1.7 3.3 14.3     
45 19675732 AS M/50 1.8 1.6 2.8 29.0     
46 19681412 AS M/51 1.5 1.2 2.8 24.8     
47 19702509 AS M/122 2.5 1.6 4.7 13.2     
48 19100576 F+S F/128 8.9 2.7 8.9 100   baby 
 
Table A.3. Calculated sickle β-chain percentages for the samples classed as 
heterozygous sickle carriers based on MRM method results.   
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Hospital 
number 
Hospital 
comment 
Our 
number 
MRM δ-chain 
peptide ratios % Varian
t Sickle 
% 
Hb
C Comment T2 T3 T5 
1 18963649 SC C/99 - 1.9 2.4 99.3 99.4 * MRM recalculated 41.1 
2 18925552 SC D/95 76.9 1.0 4.7 99.6 100 
*MRM recalcalculated 
10.9 
3 19395725 SC J/40 1.1 2.3 5.3 99.1 99.9 
* MRM recalculated 
12.7% Sickle and 87.3% 
HbC 
4 18680594 SS B/127 3.0 1.6 3.7 97.9     
5 19051166 SS D/92 77.7 0.5 3.9 0.2     
6 19052015 SS E/34 3.9 3.2 5.3 99.9     
7 19089366 SS E/146 3.6 2.3 3.0 89.8     
8 19099276 SS E/180 4.4 2.8 3.9 99.8     
9 19104272 SS E/239 2.8 2.0 2.4 39.1     
10 19217134 SS F/229 3.3 2.1 4.0 100.0     
11 19271790 SS H/39 2.3 2.0 5.1 100.0     
12 19272934 SS H/40 1.9 2.1 4.5 100.0     
13 19162734 SS H/143 3.8 2.1 4.0 100.0     
14 19348189 SS I/01 3.8 2.8 2.4 99.7     
15 19364122 SS I/74 3.8 2.6 3.1 99.8     
16 19444782 SS J/48 0.6 1.8 3.5 44.5     
17 19504631 SS J/87 2.0 3.4 6.7 99.8     
18 19513031 SS J/106 1.8 1.6 3.9 17.3 0.0   
19 19516260 SS J/116 1.8 1.6 3.8 0.0 0.0 
no peaks at all for sickle 
peptide 
20 19669274 SS M/42 2.3 1.0 2.8 0.8   Low intensity peak 
21 19729121 SS M/154 1.9 1.0 3.2 13.8     
22 19063417 
TRANSFUSED 
SS F/129 1.8 1.5 3.1 13.6     
23 19217967 
TRANSFUSED 
SS F/230 2.0 1.8 3.7 20.8     
24 19218036 
TRANSFUSED 
SS F/231 1.8 1.7 3.0 0.0     
25 19249866 
TRANSFUSED 
SS G/92 2.4 1.5 2.7 13.7     
 
Table A.4. Calculated sickle β-chain percentages for the samples classed as 
heterozygous sickle carriers.   
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Appendix 3 
 
 
Figure A.1. Predicted fragments for the HbJ Baltimore βT2-T3 peptide 
 
 
Figure A.2. MS/MS spectrum of the HbJ Baltimore βT2-T3 peptide m/z 100-670 
 
 
 
Figure A.3. MS/MS spectrum of the HbJ Baltimore βT2-T3 peptide m/z 710-1240 
 
Hb J Baltimore T2-T3 peptide   
Average Mass = 2286.5276,  Monoisotopic Mass = 2285.1651
Residues: 1-22
N-Terminus = H,  C-Terminus = OH
Fragment ions: Monoisotopic/Average (1750) m/z ratios with 1 positive charge(s).
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Figure A.4. MS/MS spectrum of the HbJ Baltimore βT2-T3 peptide m/z 1260-1640 
 
 
 
 
Figure A.5. MS/MS spectrum of the HbJ Baltimore βT2-T3 peptide m/z 1620-1870 
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